UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|
SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2015
OR
¨ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|
SECURITIES EXCHANGE ACT OF 1934 |
For the transition period
from to
Commission File Number 000-30929
KERYX
BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
13-4087132 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
750 Lexington Avenue
New York, New York 10022
(Address including zip code of principal executive offices)
(212) 531-5965
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See definition of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
x |
|
Accelerated filer |
|
¨ |
|
|
|
|
Non-accelerated filer |
|
¨ (Do not check if smaller reporting company) |
|
Smaller reporting company |
|
¨ |
Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes ¨ No x
There were 103,596,271 shares of the registrants common stock, $0.001 par value, outstanding as of April 20, 2015.
KERYX BIOPHARMACEUTICALS, INC.
FORM 10-Q
FOR THE
QUARTER ENDED MARCH 31, 2015
TABLE OF CONTENTS
SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Certain matters discussed in this report, including matters discussed under the caption Managements Discussion and
Analysis of Financial Condition and Results of Operations, may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the
Exchange Act, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by
such forward-looking statements. The words anticipate, believe, estimate, may, expect, project and similar expressions are generally intended to identify forward-looking
statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed under the captions Risk Factors,
Managements Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report, as well as other factors which may be identified from time to time in our other filings with the Securities and
Exchange Commission, or the SEC, or in the documents where such forward-looking statements appear. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements. Such
forward-looking statements include, but are not limited to, statements about our:
|
|
|
estimates regarding market size and projected growth, as well as our expectation of market acceptance of AuryxiaTM (ferric citrate); |
|
|
|
expectations for increases or decreases in expenses; |
|
|
|
expectations for pre-clinical and clinical development and regulatory progress, including our pending Marketing Authorization Application with the European Medicines Agency, manufacturing, regulatory approval, and
commercialization (including market acceptance) of Auryxia or any other products that we may acquire or in-license; |
|
|
|
expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities; |
|
|
|
expectations regarding our ability to successfully market Riona® through our Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd.;
|
|
|
|
expectations regarding our ability to successfully develop Auryxia for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients; |
|
|
|
expectations that the European Medicines Agency will concur with our interpretation of our registration studies in End Stage Renal Disease and non-dialysis dependent chronic kidney disease, supportive data, conduct of
such studies, or any other part of our Marketing Authorization Application submission; |
|
|
|
expectations for generating revenue or becoming profitable on a sustained basis; |
|
|
|
expectations of the scope of patent protection with respect to Auryxia; |
|
|
|
expectations or ability to enter into marketing and other partnership agreements; |
|
|
|
expectations or ability to enter into product acquisition and in-licensing transactions; |
|
|
|
estimates of the sufficiency of our existing cash and cash equivalents to finance our operating requirements, including expectations regarding the value and liquidity of our investments; |
|
|
|
expectations for future capital requirements. |
The forward-looking statements contained in
this report reflect our views and assumptions only as of the date that this report is signed. Except as required by law, we assume no responsibility for updating any forward-looking statements.
We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking
statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
1
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Keryx Biopharmaceuticals, Inc.
Consolidated Balance Sheets as of March 31, 2015 and December 31, 2014
(in thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
March 31, 2015 |
|
|
December 31, 2014 |
|
|
|
(Unaudited) |
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
168,836 |
|
|
$ |
74,284 |
|
Short-term investment securities |
|
|
|
|
|
|
11,508 |
|
Interest receivable |
|
|
|
|
|
|
48 |
|
Inventory |
|
|
27,242 |
|
|
|
7,830 |
|
Accounts receivable, net |
|
|
1,283 |
|
|
|
834 |
|
Other current assets |
|
|
3,388 |
|
|
|
4,092 |
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
200,749 |
|
|
|
98,596 |
|
Property, plant and equipment, net |
|
|
1,455 |
|
|
|
1,532 |
|
Goodwill |
|
|
3,208 |
|
|
|
3,208 |
|
Other assets, net |
|
|
307 |
|
|
|
292 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
205,719 |
|
|
$ |
103,628 |
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
|
$ |
33,069 |
|
|
$ |
24,146 |
|
Accrued compensation and related liabilities |
|
|
2,573 |
|
|
|
4,751 |
|
Deferred revenue |
|
|
714 |
|
|
|
414 |
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
36,356 |
|
|
|
29,311 |
|
Deferred tax liability |
|
|
722 |
|
|
|
700 |
|
Other liabilities |
|
|
99 |
|
|
|
133 |
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
37,177 |
|
|
|
30,144 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
Stockholders equity: |
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value per share (5,000,000 shares authorized, no shares issued and outstanding) |
|
|
|
|
|
|
|
|
Common stock, $0.001 par value per share (130,000,000 shares authorized, 103,700,385 and 92,758,789 shares issued, 103,620,437 and
92,678,841 shares outstanding at March 31, 2015 and December 31, 2014, respectively) |
|
|
104 |
|
|
|
93 |
|
Additional paid-in capital |
|
|
747,392 |
|
|
|
624,606 |
|
Treasury stock, at cost, 79,948 shares at March 31, 2015 and December 31, 2014, respectively |
|
|
(357 |
) |
|
|
(357 |
) |
Accumulated deficit |
|
|
(578,597 |
) |
|
|
(550,858 |
) |
|
|
|
|
|
|
|
|
|
Total stockholders equity |
|
|
168,542 |
|
|
|
73,484 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
205,719 |
|
|
$ |
103,628 |
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the consolidated financial statements.
2
Keryx Biopharmaceuticals, Inc.
Consolidated Statements of Operations
for the three months ended March 31, 2015 and 2014 (Unaudited)
(in thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, |
|
|
|
2015 |
|
|
2014 |
|
Revenues: |
|
|
|
|
|
|
|
|
Product revenue, net |
|
$ |
422 |
|
|
$ |
|
|
License revenue |
|
|
753 |
|
|
|
10,000 |
|
|
|
|
|
|
|
|
|
|
Total Revenues |
|
|
1,175 |
|
|
|
10,000 |
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Cost of goods sold |
|
|
76 |
|
|
|
|
|
License expenses |
|
|
452 |
|
|
|
|
|
Research and development |
|
|
9,591 |
|
|
|
16,359 |
|
Selling, general and administrative |
|
|
18,880 |
|
|
|
7,292 |
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
28,999 |
|
|
|
23,651 |
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
|
(27,824 |
) |
|
|
(13,651 |
) |
|
|
|
Interest and other income, net |
|
|
107 |
|
|
|
121 |
|
|
|
|
|
|
|
|
|
|
Loss before income taxes |
|
|
(27,717 |
) |
|
|
(13,530 |
) |
|
|
|
Income taxes |
|
|
22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(27,739 |
) |
|
$ |
(13,530 |
) |
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per common share |
|
$ |
(0.28 |
) |
|
$ |
(0.15 |
) |
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing basic and diluted net loss per common share |
|
|
100,553,490 |
|
|
|
88,517,437 |
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the consolidated financial statements.
3
Keryx Biopharmaceuticals, Inc.
Consolidated Statement of Stockholders Equity
for the three months ended March 31, 2015 (Unaudited)
(in thousands, except share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock |
|
|
Additional paid-in Capital |
|
|
Treasury stock |
|
|
Accumulated deficit |
|
|
Total |
|
|
|
Shares |
|
|
Amount |
|
|
|
Shares |
|
|
Amount |
|
|
|
Balance at December 31, 2014 |
|
|
92,758,789 |
|
|
$ |
93 |
|
|
$ |
624,606 |
|
|
|
79,948 |
|
|
$ |
(357 |
) |
|
$ |
(550,858 |
) |
|
$ |
73,484 |
|
Changes during the period: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock in public offering (net of offering costs of $8,216) |
|
|
10,541,667 |
|
|
|
11 |
|
|
|
118,273 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
118,284 |
|
Issuance of restricted stock |
|
|
399,000 |
|
|
|
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* |
Forfeiture of restricted stock |
|
|
(17,696 |
) |
|
|
( |
)* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
)* |
Issuance of common stock in connection with exercise of options |
|
|
18,625 |
|
|
|
|
* |
|
|
97 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97 |
|
Compensation in respect of options and restricted stock granted to employees, directors and third-parties |
|
|
|
|
|
|
|
|
|
|
4,416 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,416 |
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(27,739 |
) |
|
|
(27,739 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 31, 2015 |
|
|
103,700,385 |
|
|
$ |
104 |
|
|
$ |
747,392 |
|
|
|
79,948 |
|
|
$ |
(357 |
) |
|
$ |
(578,597 |
) |
|
$ |
168,542 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* |
Amount less than one thousand dollars. |
The accompanying notes are an integral part of the
consolidated financial statements.
4
Keryx Biopharmaceuticals, Inc.
Consolidated Statements of Cash Flows
for the three months ended March 31, 2015 and 2014 (Unaudited)
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, |
|
|
|
2015 |
|
|
2014 |
|
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(27,739 |
) |
|
$ |
(13,530 |
) |
Adjustments to reconcile net loss to cash flows used in operating activities: |
|
|
|
|
|
|
|
|
Stock compensation expense |
|
|
4,321 |
|
|
|
2,552 |
|
Depreciation and amortization |
|
|
138 |
|
|
|
32 |
|
Deferred income taxes |
|
|
22 |
|
|
|
|
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Decrease (increase) in other current assets |
|
|
704 |
|
|
|
(13 |
) |
Increase in accounts receivable, net |
|
|
(449 |
) |
|
|
|
|
Decrease (increase) in accrued interest receivable |
|
|
48 |
|
|
|
(195 |
) |
Increase in inventory |
|
|
(19,317 |
) |
|
|
|
|
(Increase) decrease in other assets |
|
|
(15 |
) |
|
|
64 |
|
Increase in accounts payable and accrued expenses |
|
|
8,923 |
|
|
|
1,951 |
|
Decrease in accrued compensation and related liabilities |
|
|
(2,178 |
) |
|
|
(910 |
) |
Increase in deferred revenue |
|
|
300 |
|
|
|
|
|
(Decrease) increase in other liabilities |
|
|
(34 |
) |
|
|
3 |
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities |
|
|
(35,276 |
) |
|
|
(10,046 |
) |
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
Purchases of property, plant and equipment |
|
|
(61 |
) |
|
|
(221 |
) |
Investment in held-to-maturity short-term securities |
|
|
|
|
|
|
(49,772 |
) |
Proceeds from maturity of held-to-maturity short-term securities |
|
|
11,508 |
|
|
|
107 |
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities |
|
|
11,447 |
|
|
|
(49,886 |
) |
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds from public offerings |
|
|
126,500 |
|
|
|
115,057 |
|
Offering costs related to public offerings |
|
|
(8,216 |
) |
|
|
(7,460 |
) |
Proceeds from exercise of options |
|
|
97 |
|
|
|
1,896 |
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities |
|
|
118,381 |
|
|
|
109,493 |
|
|
|
|
|
|
|
|
|
|
NET INCREASE IN CASH AND CASH EQUIVALENTS |
|
|
94,552 |
|
|
|
49,561 |
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of period |
|
|
74,284 |
|
|
|
55,696 |
|
|
|
|
|
|
|
|
|
|
CASH AND CASH EQUIVALENTS AT END OF PERIOD |
|
$ |
168,836 |
|
|
$ |
105,257 |
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the consolidated financial statements.
5
Keryx Biopharmaceuticals, Inc.
Notes to Consolidated Financial Statements (unaudited)
Unless the context requires otherwise, references in this report to Keryx, Company, we, us and
our refer to Keryx Biopharmaceuticals, Inc. and our subsidiaries.
NOTE 1 GENERAL
Basis of Presentation
We are a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease. Most of our
biopharmaceutical development and substantially all of our administrative operations during the three months ended March 31, 2015 and 2014 were conducted in the United States of America.
The accompanying unaudited consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles
(GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial
statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the consolidated financial statements have been included. Nevertheless, these unaudited consolidated
financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2014. The results of operations for the three months ended
March 31, 2015, are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.
Certain prior period amounts in the condensed consolidated financial statements have been altered to conform to the current quarter
presentation. As of September 30, 2014, we removed the non-cash compensation disclosures from our consolidated statements of operations and, instead, present the amounts of non-cash compensation included in cost of goods sold, selling, general
and administrative expenses and research and development expenses in the accompanying notes to the consolidated financial statements. See Note 4 Stockholders Equity.
Except for 2009, we have incurred substantial operating losses since our inception, and expect to continue to incur operating losses for the
foreseeable future and may never become profitable. As of March 31, 2015, we have an accumulated deficit of $578.6 million.
Our
first product, AuryxiaTM (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the U.S. Food and Drug Administration (FDA), in September 2014 for
the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia, which was launched in late December 2014, is being marketed in the U.S. through our specialty salesforce and commercial
infrastructure. We currently have approximately 60 sales representatives in the field calling on approximately 5,000 target nephrologists.
Our Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co. Ltd. (Torii), received manufacturing and
marketing approval of ferric citrate in January 2014 from the Japanese Ministry of Health, Labour and Welfare as an oral treatment for the improvement of hyperphosphatemia in patients with CKD, including dialysis and non-dialysis dependent CKD
(NDD-CKD). JTs subsidiary, Torii, launched the product under the brand name Riona® in May 2014. Under the license agreement with JT and Torii, we received a non-refundable
payment of $10.0 million in February 2014 for the achievement of the marketing approval milestone. We also receive royalty payments based on a tiered double-digit percentage of net sales of Riona in Japan escalating up to the mid-teens, as
well as up to an additional $55.0 million upon the achievement of certain annual net sales milestones. We owe a mid-single digit percentage of net sales royalty to the licensor of ferric citrate associated with net sales of Riona in Japan. See Note
5 for additional information.
We have also submitted, in March 2014, a Marketing Authorization Application (MAA) with the
European Medicines Agency (EMA) for the approval of Auryxia in patients with CKD, including dialysis and NDD-CKD. Also in March 2014, the EMA validated our MAA, confirming that the submission is sufficiently complete to begin the formal
review process. The regulatory review of our MAA submission is ongoing.
6
In September 2014, we announced the initiation of a pivotal Phase 3 study of Auryxia for the
treatment of iron deficiency anemia (IDA) in patients with Stage 3-5 NDD-CKD. This studys primary endpoint is the between group comparison of the proportion of patients achieving a 1 g/dL or greater increase in hemoglobin at any
point during the 16-week randomized period.
Currently, our only product is Auryxia. In January 2015, we began to recognize product
revenue based on prescription sales of Auryxia in the U.S. We may engage in business development activities that include seeking strategic relationships for Auryxia, as well as evaluating other compounds and companies for in-licensing or
acquisition. In addition, we have generated, and expect to continue to generate, revenue from the sublicensing of rights to Auryxia in Japan to our Japanese partner, JT and Torii.
Our major sources of cash have been proceeds from various public and private offerings of our common stock, option and warrant exercises,
interest income, and from the upfront and milestone payments from our Sublicense Agreement with JT and Torii and miscellaneous payments from our other prior licensing activities. Prior to the launch of Auryxia in late December 2014, we have not
commercialized any drug, and we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to complete our development efforts, obtain additional regulatory approvals for our drug,
successfully complete any post-approval regulatory obligations and successfully manufacture and commercialize our drug alone or in partnership. We may continue to incur substantial operating losses even after we begin to generate meaningful revenues
from Auryxia.
In January 2015, we raised approximately $118.3 million, net of underwriting discounts and offering expenses of
approximately $8.2 million, in an underwritten public offering. The shares were sold under Registration Statements (Nos. 333-201605 and 333-201639) on Form S-3 and Form S-3MEF, respectively, filed by us with the Securities and Exchange Commission.
See Note 4 for additional information.
We currently expect that our existing capital resources combined with future anticipated cash
flows will be sufficient to execute our business plan. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing and expenditures associated with commercial activities related to
Auryxia and the magnitude of cash received from product sales, the timing and expenditures associated with the build-up of inventory and capacity expansion, the timing and expenditures associated with the regulatory review process for our EU MAA
filing, and the timing, design and conduct of clinical trials for Auryxia. As a result of these factors, we may need to seek additional financings to provide the cash necessary to execute our current operations, including beyond the initial
commercialization of Auryxia, and to develop any drug candidates we may in-license or acquire.
Our common stock is listed on the Nasdaq
Capital Market and trades under the symbol KERX.
Corporate
In January 2015, we announced the transitioning of the role of Chief Executive Officer from Ron Bentsur to Greg Madison. Mr. Madison
joined Keryx in February 2014 as Executive Vice President and Chief Operating Officer to transition Keryx from a development-stage organization into a fully integrated commercial entity, bringing to Keryx a wealth of relevant expertise in both the
phosphate binder and iron deficiency anemia markets. In March 2015, Mr. Madison was appointed to our Board of Directors. Mr. Madison assumed the Chief Executive Officer role following the resignation of Mr. Bentsur on April 30,
2015.
In February 2015, we announced a planned consolidation of our finance and accounting function into our Boston office and that our
Chief Financial Officer, James Oliviero, will be leaving Keryx by October 2015. Mr. Oliviero has been with Keryx for twelve years and has served as the Chief Financial Officer since 2009. We have commenced a search for a new Chief Financial
Officer who will be based in our Boston office. Mr. Oliviero will continue to manage our finance and accounting team during the remainder of his tenure and will assist in the transition of his duties to the new Chief Financial Officer.
In April 2015, we announced the appointment of John F. Neylan, M.D., as our Chief Medical Officer.
In April 2015, we signed a new lease agreement for approximately 27,300 square feet in Boston, Massachusetts, for a 94 month term commencing
May 1, 2015, at an average rent of approximately $123,600 per month. The new lease will replace our current subleased space in the same building, which term expires on December 31, 2015.
7
Recently Issued Accounting Standards
In August 2014, the Financial Accounting Standards Board issued a new standard, Accounting Standards Update No. 2014-15, Disclosure of
Uncertainties about an Entitys Ability to Continue as a Going Concern. This new standard will explicitly require management to assess an entitys ability to continue as a going concern and to provide footnote disclosures in certain cases.
Currently there is no guidance in GAAP about managements responsibility to evaluate whether there is substantial doubt about an entitys ability to continue as a going concern. The new standard applies to all entities and provides an
explicit requirement that management assesses and discloses going concern uncertainties. Previous guidance in auditing standards required auditors to evaluate going concern. The new standard will be effective for all entities in the first annual
period ending after December 15, 2016, which is December 31, 2016 for calendar year-end entities. Earlier application is permitted.
In May 2014, the Financial Accounting Standards Board issued a comprehensive new standard which amends revenue recognition principles and
provides a single set of criteria for revenue recognition among all industries. The new standard provides a five step framework whereby revenue is recognized when promised goods or services are transferred to a customer at an amount that reflects
the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosures pertaining to revenue recognition in both interim and annual periods. The standard is effective for
interim and annual periods beginning after December 15, 2016 and allows for adoption using a full retrospective method, or a modified retrospective method. We are currently assessing the method of adoption and the expected impact the new
standard will have on our financial position and results of operations.
Cash and Cash Equivalents
We treat liquid investments with original maturities of three months or less when purchased as cash and cash equivalents.
Investment Securities
We classify
our short-term debt securities as held-to-maturity. Held-to-maturity securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted
for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method. Available-for-sale
investment securities are recorded at fair value (see Note 2 Fair Value Measurements). Other-than-temporary impairment charges are included in interest and other income, net, and unrealized gains (losses), if determined to be temporary, are
included in accumulated other comprehensive income (loss) in stockholders equity.
The following table summarizes our investment
securities at March 31, 2015, and December 31, 2014:
|
|
|
|
|
|
|
|
|
(in thousands) |
|
March 31, 2015 |
|
|
December 31, 2014 |
|
Short-term investments (held to maturity): |
|
|
|
|
|
|
|
|
Obligations of domestic governmental agencies |
|
$ |
|
|
|
$ |
11,508 |
|
|
|
|
|
|
|
|
|
|
Total short-term investment securities |
|
$ |
|
|
|
$ |
11,508 |
|
|
|
|
|
|
|
|
|
|
Inventory
Inventories are stated at the lower of cost or estimated realizable value. We determine the cost of our inventories, which include amounts
related to materials, third-party contract manufacturing and packaging services, and manufacturing overhead, on a first-in, first-out basis. We capitalize inventory costs at our suppliers when, based on managements judgment, the realization of
future economic benefit is probable at each given supplier. We received FDA approval for Auryxia on September 5, 2014, and on that date began capitalizing inventory purchases of saleable product from certain suppliers. Prior to FDA approval,
all saleable product purchased from such suppliers were included as a component of research and development expense.
8
Accounts Receivable, net
We extend credit to our customers for product sales resulting in accounts receivable. Customer accounts are monitored for past due amounts.
Past due accounts receivable, determined to be uncollectible, are written off against the allowance for doubtful accounts. Allowances for doubtful accounts are estimated based upon past due amounts, historical losses and existing economic factors,
and are adjusted periodically. We offer cash discounts to our customers, generally 2% of the sales price, as an incentive for prompt payment. The estimate of cash discounts is recorded at the time of sale. We account for the cash discounts by
reducing revenue and accounts receivable by the amount of the discounts we expect our customers to take. The accounts receivable are reported in the consolidated balance sheets, net of the allowances for doubtful accounts and cash discounts. There
was no allowance for doubtful accounts at March 31, 2015 and December 31, 2014.
Revenue Recognition
Our commercial launch of Auryxia occurred in late December 2014. We sell product to a limited number of major wholesalers, our
Distributors, as well as certain pharmacies, or collectively, our Customers. Our Distributors resell the product to retail pharmacies for purposes of their reselling the product to fill patient prescriptions. In accordance with GAAP, our revenue
recognition policy requires that: (i) there is persuasive evidence that an arrangement exists between us and the Customer, (ii) delivery has occurred, (iii) collectability is reasonably assured and (iv) the price is fixed or
determinable. Until we have the ability to reliably estimate returns of Auryxia from our Customers, revenue will be recognized based on the resale of Auryxia for the purposes of filling patient prescriptions, and not based on sales from us to such
Customers. Consistent with industry practice, once we achieve sufficient history such that we can reliably estimate returns based on sales to our Customers, we anticipate that our revenues will be recognized based on sales to our Customers. We
currently defer Auryxia revenue recognition until the earlier of the product being resold for purposes of filling patient prescriptions and the expiration of the right of return (twelve months after the expiration date of the product). The
deferred revenue is recorded net of discounts, rebates, and chargebacks. We also defer the related cost of product sales and record such amounts as finished goods inventory held by others, which is included in inventory on our consolidated balance
sheet, until revenue related to such product sales is recognized.
We have written contracts with our Customers and delivery occurs when a
Customer receives Auryxia. We evaluate the creditworthiness of each of our Customers to determine whether revenues can be recognized upon delivery, subject to satisfaction of the other requirements, or whether recognition is required to be delayed
until receipt of payment. In order to conclude that the price is fixed or determinable, we must be able to (i) calculate our gross product revenues from the sales to Customers and (ii) reasonably estimate our net product revenues. We
calculate gross product revenues based on the wholesale acquisition cost that we charge our Customers for Auryxia. We estimate our net product revenues by deducting from our gross product revenues (a) trade allowances, such as invoice discounts
for prompt payment and distributor fees, (b) estimated government and private payor rebates, chargebacks and discounts, such as Medicaid reimbursements, (c) reserves for expected product returns and (d) estimated costs of incentives
offered to certain indirect customers, including patients.
Trade Allowances: We generally provide invoice discounts on Auryxia
sales to our Distributors for prompt payment and pay fees for distribution services, such as fees for certain data that Distributors provide to us. The payment terms for sales to Distributors generally include a prompt-pay discount for payment
within 30 days. Based on our judgment and industry experience, we expect our Distributors to earn these discounts and fees, and deduct the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time
such revenues are recognized.
Rebates, Chargebacks and Discounts: We contract with Medicaid, other government agencies and various
commercial and Medicare Part D private insurance providers, or collectively, our Third-party Payors, so that Auryxia will be eligible for partial or full reimbursement from such Third-party Payors. We also contract with certain specialty pharmacies
directly so that Auryxia will be eligible for purchase by these specialty pharmacies. We estimate the rebates, chargebacks and discounts we will provide to Third-party Payors and specialty pharmacies, and deduct these estimated amounts from our
gross product revenues at the time the revenues are recognized. We estimate the rebates, chargebacks and discounts that we will provide to Third-party Payors and specialty pharmacies based upon (i) our contracts with these Third-party Payors
and specialty pharmacies, (ii) the government-mandated discounts applicable to government-funded programs and (iii) information obtained from our Customers and other third parties regarding the payor mix for Auryxia.
9
Product Returns: During the three months ended March 31, 2015, the first full period
in which we began selling Auryxia, we were not able to reasonably estimate product returns for all product sold to Customers due to insufficient historical returns data. Once sufficient data exists, we will estimate the amount of Auryxia that will
be returned and deduct these estimated amounts from our gross revenues at the time that revenues are recognized. Our Customers have the right to return Auryxia during the 18-month period beginning six months prior to the labeled expiration date and
ending twelve months after the labeled expiration date. Currently the expiration date for Auryxia is eighteen months after it has been converted into tablet form, which is the last step in the manufacturing process for Auryxia and generally occurs
within a few months before Auryxia is delivered to Customers. As of March 31, 2015, we have experienced no product returns.
Other
Incentives: Other incentives that we offer to indirect customers include co-pay mitigation rebates provided by us to commercially insured patients who have coverage for Auryxia and who reside in states that permit co-pay mitigation programs, and
vouchers for a month supply of Auryxia at no patient cost. Our co-pay mitigation program is intended to reduce each participating patients portion of the financial responsibility for Auryxias purchase price to a specified dollar amount.
Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, we estimate the average co-pay mitigation amounts and the percentage of patients that we expect to participate in the
program in order to establish our accruals for co-pay mitigation rebates and deduct these estimated amounts from our gross product revenues at the time the revenues are recognized. Our vouchers offered to date will expire on December 31, 2015.
We adjust our accruals for co-pay mitigation and voucher rebates based on our estimates regarding the portion of issued rebates that we estimate will not be redeemed.
The following table summarizes activity in each of the product revenue allowance and reserve categories described above for the three months
ended March 31, 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands) |
|
Trade allowances |
|
|
Rebates, chargebacks and discounts |
|
|
Product returns |
|
|
Other incentives (1) |
|
|
Total |
|
Balance at January 1, 2015 |
|
$ |
136 |
|
|
$ |
48 |
|
|
$ |
|
|
|
$ |
275 |
|
|
$ |
459 |
|
Provision related to current period and deferred sales |
|
|
347 |
|
|
|
221 |
|
|
|
|
|
|
|
858 |
|
|
|
1,426 |
|
Credits/payments made for current period and deferred sales |
|
|
(63 |
) |
|
|
(2 |
) |
|
|
|
|
|
|
(280 |
) |
|
|
(345 |
) |
Credits/payments made for prior period and deferred sales |
|
|
(136 |
) |
|
|
(4 |
) |
|
|
|
|
|
|
(275 |
) |
|
|
(415 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 31, 2015 |
|
$ |
284 |
|
|
$ |
263 |
|
|
$ |
|
|
|
$ |
578 |
|
|
$ |
1,125 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Includes co-pay mitigation and voucher rebates. |
The following table summarizes product
revenue recognized and deferred during the three months ended March 31, 2015, and the year ended December 31, 2014:
|
|
|
|
|
|
|
|
|
(in thousands) |
|
March 31, 2015 |
|
|
December 31, 2014 |
|
Product revenue recognized |
|
$ |
422 |
|
|
$ |
|
|
Deferred product revenue |
|
|
714 |
|
|
|
414 |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1,136 |
|
|
$ |
414 |
|
|
|
|
|
|
|
|
|
|
In conjunction with our recognition and deferral of product revenues, we expensed and capitalized the
associated cost of goods, as follows, during the three months ended March 31, 2015, and the year ended December 31, 2014:
|
|
|
|
|
|
|
|
|
(in thousands) |
|
March 31, 2015 |
|
|
December 31, 2014 |
|
Cost of goods sold expensed |
|
$ |
76 |
|
|
$ |
|
|
Finished goods inventory held by others |
|
|
107 |
|
|
|
47 |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
183 |
|
|
$ |
47 |
|
|
|
|
|
|
|
|
|
|
10
We recognize license revenue in accordance with the revenue recognition guidance of the
Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified
objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered
that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone
payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and
(4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.
For arrangements for which royalty revenue information becomes available and collectability is reasonably assured, we recognize revenue during
the applicable period earned. When collectability is reasonably assured but a reasonable estimate of royalty revenue cannot be made, the royalty revenue is recognized in the quarter that the licensee provides the written report and related
information to us.
Cost of Goods Sold
Cost of goods sold includes the cost of active pharmaceutical ingredient (API) for Auryxia on which product revenue was recognized
during the period, as well as the associated costs for tableting, packaging, shipment, insurance and quality assurance. Cost of goods sold also includes the royalty expense due the licensor of Auryxia related to the product revenue recognized during
the period.
License Expenses
License expenses include royalty and other expenses due to the licensor of Auryxia related to our license agreement with JT and Torii. With
regard to royalty expense, such expense is directly related to the royalty revenue received from JT and Torii and is recognized in the same period as the revenue is recorded. Other expenses are recognized in the period they are incurred.
Stock-Based Compensation
We
recognize all share-based payments to employees and to non-employee directors for service on our board of directors as compensation expense in the consolidated financial statements based on the grant date fair values of such payments. Stock-based
compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.
For share-based payments to consultants and other third-parties,
compensation expense is determined at the measurement date. The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record
compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent
reporting date.
Income Taxes
As of March 31, 2015, we have U.S. net operating loss carryforwards of approximately $545.4 million which expire from 2019 through 2035.
We have established a 100% valuation allowance against our net deferred tax assets due to our history of pre-tax losses and the likelihood that the deferred tax assets will not be realizable. Due to our historical equity transactions, the
utilization of certain tax loss carryforwards may be subject to annual limitations imposed by Internal Revenue Code Section 382 relating to the change of control provisions.
For the three months ended March 31, 2015, we recognized $22,000 in income tax expense related to the recording of a deferred tax
liability associated with capitalized goodwill, an indefinite-lived intangible asset that is being amortized for tax purposes. Indefinite-lived intangibles are non-monetary assets which are not amortized for book purposes since there is no
foreseeable limit to the cash flows provided by them. The total deferred tax liability recognized on the balance sheet as of March 31, 2015 is $722,000.
11
Our lack of earnings history and the uncertainty surrounding our ability to generate taxable
income prior to the reversal or expiration of such deferred tax liability were the primary factors considered by management when recording the deferred tax liability.
We are not aware of any unrecorded tax liabilities which would materially impact our financial position or our results of operations.
Net Loss Per Share
Basic net loss
per share is computed by dividing the losses allocable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share does not reflect the effect of shares of common stock to be
issued upon the exercise of stock options, as their inclusion would be anti-dilutive for all periods presented. The options outstanding as of March 31, 2015 and 2014, which are not included in the computation of net loss per share amounts, were
6,257,851 and 4,360,925, respectively.
Comprehensive Loss
Comprehensive loss is the same as net loss for all periods presented.
Segment Reporting
We operate in
only one reportable segment: the Products segment.
Impairment of Goodwill
Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill
impairment using a two-step process. The first step compares the fair value of the reporting unit with the units carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the units
goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting units goodwill is compared with the carrying amount of
the units goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. As of December 31, 2014, management concluded that there was no
impairment of our goodwill. For the period ending March 31, 2015, management determined that there were no impairment indicators that would trigger a goodwill impairment analysis.
NOTE 2 FAIR VALUE MEASUREMENTS
We measure certain financial assets and liabilities at fair value on a recurring basis in the consolidated financial
statements. The hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following
three categories:
|
|
|
Level 1 quoted prices in active markets for identical assets and liabilities; |
|
|
|
Level 2 inputs other than Level 1 quoted prices that are directly or indirectly observable; and |
|
|
|
Level 3 unobservable inputs that are not corroborated by market data. |
We review
investment securities for impairment and to determine the classification of the impairment as temporary or other-than-temporary. We review our investments on an ongoing basis for indications of possible impairment. Once identified, the determination
of whether the impairment is temporary or other-than-temporary requires significant judgment.
12
The following table provides the fair value measurements of applicable financial assets as of
March 31, 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial assets at fair value as of March 31, 2015 |
|
(in thousands) |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
Money market funds (1) |
|
$ |
162,471 |
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
162,471 |
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Included in cash and cash equivalents on our consolidated balance sheet. The carrying amount of money market funds approximates fair value. |
NOTE 3 INVENTORY
Upon approval of Auryxia on September 5, 2014 by the FDA, we began capitalizing our purchases of saleable inventory of
Auryxia from suppliers. Inventories consist of the following at March 31, 2015 and December 31, 2014 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31, 2015 |
|
|
December 31, 2014 |
|
Raw materials |
|
$ |
111 |
|
|
$ |
111 |
|
Work in process |
|
|
26,360 |
|
|
|
7,263 |
|
Finished goods |
|
|
664 |
|
|
|
409 |
|
Finished goods inventory held by others |
|
|
107 |
|
|
|
47 |
|
|
|
|
|
|
|
|
|
|
Total inventory |
|
$ |
27,242 |
|
|
$ |
7,830 |
|
|
|
|
|
|
|
|
|
|
NOTE 4 STOCKHOLDERS EQUITY
Common Stock
On
January 21, 2015, we announced the pricing of an underwritten public offering in which we sold 10,541,667 shares of our common stock at a price of $12.00 per share for gross proceeds of approximately $126.5 million. Net proceeds from this
offering were approximately $118.3 million, net of underwriting discounts and offering expenses of approximately $8.2 million. The shares were sold under Registration Statements (Nos. 333-201605 and 333-201639) on Form S-3 and Form S-3MEF,
respectively, filed by us with the Securities and Exchange Commission.
Equity Incentive Plans
Total shares available for the issuance of stock options or other stock-based awards under our stock option and incentive plans were 3,973,425
shares at March 31, 2015.
Stock Options
The following table summarizes stock option activity for the three months ended March 31, 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares |
|
|
Weighted- average exercise price |
|
|
Weighted- average contractual term |
|
|
Aggregate intrinsic value |
|
|
|
|
|
|
|
|
|
(in years) |
|
|
|
|
Outstanding at December 31, 2014 |
|
|
5,132,426 |
|
|
$ |
9.32 |
|
|
|
7.0 |
|
|
$ |
26,916,823 |
|
Granted |
|
|
1,189,150 |
|
|
|
14.42 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
(18,625 |
) |
|
|
5.19 |
|
|
|
|
|
|
$ |
143,765 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited |
|
|
(24,017 |
) |
|
|
11.93 |
|
|
|
|
|
|
|
|
|
Expired |
|
|
(21,083 |
) |
|
|
11.33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at March 31, 2015 |
|
|
6,257,851 |
|
|
$ |
10.29 |
|
|
|
7.3 |
|
|
$ |
22,306,663 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested and expected to vest at March 31, 2015 |
|
|
6,142,322 |
|
|
$ |
10.22 |
|
|
|
7.3 |
|
|
$ |
22,233,401 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at March 31, 2015 |
|
|
2,809,216 |
|
|
$ |
5.87 |
|
|
|
5.0 |
|
|
$ |
20,119,734 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Upon the exercise of stock options, we issue new shares of our common stock. As of March 31, 2015,
125,000 options issued to employees are unvested, milestone-based options.
13
Restricted Stock
Certain employees, directors and consultants have been awarded restricted stock under our incentive plans. The time-vesting restricted stock
grants vest primarily over a period of three years. The following table summarizes restricted share activity for the three months ended March 31, 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares |
|
|
Weighted average grant date fair value |
|
|
Aggregate intrinsic value |
|
Outstanding at December 31, 2014 |
|
|
926,947 |
|
|
$ |
12.22 |
|
|
$ |
13,116,300 |
|
Granted |
|
|
399,000 |
|
|
|
14.28 |
|
|
|
|
|
Vested |
|
|
(138,489 |
) |
|
|
12.01 |
|
|
$ |
1,821,032 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited |
|
|
(17,696 |
) |
|
|
8.59 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at March 31, 2015 |
|
|
1,169,762 |
|
|
$ |
13.00 |
|
|
$ |
14,891,070 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2015, 80,000 shares of restricted stock issued to employees are unvested, milestone-based
shares.
On September 14, 2009, we entered in an employment agreement with Ron Bentsur, our previous Chief Executive Officer, which
was amended on January 13, 2012, and further amended on each of September 11, 2013 and April 30, 2015. The agreement, as amended, terminated on April 30, 2015. As of March 31, 2015, Mr. Bentsur had been granted a
total of 1,250,000 shares of restricted stock based on the achievement of certain milestone awards described in his employment agreement. In accordance with the termination of Mr. Bentsurs employment, until July 30, 2015,
Mr. Bentsur has the opportunity to earn milestone awards of 100,000 shares of restricted stock, vesting upon grant, upon each event of our outlicensing Auryxia in a foreign market, other than Japan, resulting in a greater than $10 million
non-refundable cash payment to us with a gross deal value to us of at least $50 million.
Stock-Based Compensation
We incurred $4.3 million and $2.6 million of non-cash compensation expense related to equity incentive grants during the three months ended
March 31, 2015 and 2014, respectively. The following table reflects stock-based compensation expense for the three month period ended March 31, 2015 and 2014:
|
|
|
|
|
|
|
|
|
Stock-Based Compensation |
|
Three months ended March 31, |
|
(in thousands) |
|
2015 |
|
|
2014 |
|
Cost of goods sold |
|
$ |
1 |
|
|
$ |
|
|
Research and development |
|
|
921 |
|
|
|
804 |
|
Selling, general and administrative |
|
|
3,399 |
|
|
|
1,748 |
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation expense |
|
$ |
4,321 |
|
|
$ |
2,552 |
|
|
|
|
|
|
|
|
|
|
Stock-based compensation costs capitalized as part of inventory were immaterial for the three months ended
March 31, 2015.
The fair value of stock options granted is estimated at the date of grant using the Black-Scholes pricing model. The
expected term of options granted is derived from historical data, the expected vesting period and the full contractual term. Expected volatility is based on the historical volatility of our common stock. The risk-free interest rate is based on the
U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for
the foreseeable future.
|
|
|
|
|
|
|
|
|
Black-Scholes Option Valuation Assumptions |
|
Three months ended March 31, |
|
|
|
2015 |
|
|
2014 |
|
Risk-free interest rates |
|
|
1.7 |
% |
|
|
2.0 |
% |
Dividend yield |
|
|
|
|
|
|
|
|
Volatility |
|
|
91.6 |
% |
|
|
104.9 |
% |
Weighted-average expected term |
|
|
6.0 years |
|
|
|
6.0 years |
|
14
The weighted average grant date fair value of options granted for the three months ended
March 31, 2015 and 2014 was $10.83 and $11.28 per option, respectively. We used historical information to estimate forfeitures within the valuation model. As of March 31, 2015, there was $30.1 million and $12.4 million of total
unrecognized compensation cost related to non-vested stock options and restricted stock, respectively, which is expected to be recognized over weighted-average periods of 2.4 years and 2.3 years, respectively. These amounts do not include, as of
March 31, 2015, 125,000 options outstanding and 80,000 shares of restricted stock outstanding which are milestone-based and vest upon certain corporate milestones, such as change in control. Stock-based compensation will be measured and
recorded if and when it is probable that the milestone will occur.
NOTE 5 LICENSE AGREEMENTS
In November 2005, we entered into a license agreement with Panion & BF Biotech, Inc. (Panion). Under
the license agreement, we acquired the exclusive worldwide rights, excluding certain Asian-Pacific countries, for the development and marketing of Auryxia. To date, we have paid an aggregate of $9.6 million of milestone payments to Panion, and
Panion is eligible to receive one additional milestone payment of $2.0 million upon our successful achievement of European marketing approval, in addition to royalty payments based on a mid-single digit percentage of net sales of Auryxia. For the
three months ended March 31, 2015, we recorded approximately $24,000 in cost of goods sold related to royalties payments due Panion relating to sales of Auryxia in the U.S.
In September 2007, we entered into a Sublicense Agreement with JT and Torii, JTs pharmaceutical business subsidiary, under which JT and
Torii obtained the exclusive sublicense rights for the development and commercialization of ferric citrate in Japan, which is being marketed in the U.S. under the trade name Auryxia. JT and Torii are responsible for the future development and
commercialization costs in Japan. Effective as of June 8, 2009, we entered into an Amended and Restated Sublicense Agreement (the Revised Agreement) with JT and Torii, which, among other things, provided for the elimination of all
significant on-going obligations under the sublicense agreement.
In January 2014, JT and Torii received manufacturing and marketing
approval of ferric citrate from the Japanese Ministry of Health, Labour and Welfare. Ferric citrate, launched in May 2014 and being marketed in Japan by JTs subsidiary, Torii Pharmaceutical Co., Ltd., under the brand name Riona®, is indicated as an oral treatment for the improvement of hyperphosphatemia in patients with CKD. Under the terms of the license agreement with JT and Torii, we received a non-refundable
payment of $10.0 million in February 2014 for the achievement of the marketing approval milestone. As a result, we recorded license revenue of $10.0 million in accordance with our revenue recognition policy, which is included in the three months
ended March 31, 2014. We also receive royalty payments based on a tiered double-digit percentage of net sales of Riona® in Japan escalating up to the mid-teens, as well as up to
an additional $55.0 million upon the achievement of certain annual net sales milestones. In accordance with our revenue recognition policy, royalty revenues are recognized in the quarter that JT and Torii provide their written report and related
information to us regarding sales of Riona®, which generally will be one quarter following the quarter in which the underlying sales by JT and Torii occurred. For the three months ended
March 31, 2015, we recorded $0.8 million in license revenue related to royalties earned on net sales of Riona® in Japan. We record the associated mid-single digit percentage of net sales
royalty expense due Panion, the licensor of Auryxia, as license expenses in the same period as the royalty revenue from JT and Torii is recorded. For the three months ended March 31, 2015, we recorded $0.5 million in license expenses related to
royalties due Panion relating to sales of Riona® in Japan.
NOTE 6 LEGAL PROCEEDINGS
We, and our subsidiaries, are not a party to, and our property is not the subject of, any material pending legal
proceedings.
15
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Unless the context requires otherwise, references in this report to Keryx, the
Company, we, us and our refer to Keryx Biopharmaceuticals, Inc. and our subsidiaries.
The following discussion and analysis contains forward-looking statements about our plans and expectations of what may happen in the future.
Forward-looking statements are based on a number of assumptions and estimates that are inherently subject to significant risks and uncertainties, and our results could differ materially from the results anticipated by our forward-looking statements
as a result of many known or unknown factors, including, but not limited to, those factors discussed in Risk Factors. See also the Special Cautionary Notice Regarding Forward-Looking Statements set forth at the beginning of
this report.
You should read the following discussion and analysis in conjunction with the unaudited consolidated financial statements,
and the related footnotes thereto, appearing elsewhere in this report, and in conjunction with managements discussion and analysis and the audited consolidated financial statements included in our annual report on Form 10-K for the year ended
December 31, 2014.
OVERVIEW
We
are a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease. Our first product, Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the U.S.
Food and Drug Administration, or FDA, in September 2014 for the control of serum phosphorus levels in patients with chronic kidney disease, or CKD, on dialysis. The U.S. approval of Auryxia was based on data from our Phase 3 registration program, in
which Auryxia effectively reduced serum phosphorus levels to well within the KDOQI guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin,
iron and transferrin saturation, or TSAT, whereas these parameters remained relatively constant in patients treated with active control (Renvela® and/or PhosLo®). The most common adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough.
We launched Auryxia in the U.S. in late December 2014. Auryxia is being marketed in the U.S. through our specialty salesforce and commercial
infrastructure. We currently have approximately 60 sales representatives in the field calling on approximately 5,000 target nephrologists.
Our Japanese partner, Japan Tobacco Inc., or JT, and Torii Pharmaceutical Co. Ltd., or Torii, received manufacturing and marketing approval of
ferric citrate in January 2014 from the Japanese Ministry of Health, Labour and Welfare as an oral treatment for the improvement of hyperphosphatemia in patients with CKD, including dialysis and NDD-CKD. JTs subsidiary, Torii, launched the
product under the brand name Riona® in May 2014. Under the license agreement with JT and Torii, we received a non-refundable payment of $10.0 million in February 2014 for the achievement of
the marketing approval milestone. We also receive royalty payments based on a tiered double-digit percentage of net sales of Riona® in Japan escalating up to the mid-teens, as well as up to an
additional $55.0 million upon the achievement of certain annual net sales milestones.
We have also submitted, in March 2014, a Marketing
Authorization Application, or MAA, with the European Medicines Agency, or EMA, for the approval of Auryxia in patients with CKD, including dialysis and NDD-CKD. Also in March 2014, the EMA validated our MAA, confirming that the submission is
sufficiently complete to begin the formal review process. The regulatory review of our MAA submission is ongoing.
In September 2014, we
announced the initiation of a pivotal Phase 3 study of Auryxia for the treatment of iron deficiency anemia, or IDA, in patients with Stage 3-5 NDD-CKD. This studys primary endpoint is the between group comparison of the proportion of patients
achieving a 1 g/dL or greater increase in hemoglobin at any point during the 16-week randomized period. In our completed 12-week Phase 2 study of Auryxia for the management of elevated serum phosphorus levels and iron deficiency in subjects with
Stage 3 to 5 NDD-CKD, a post-hoc analysis of this endpoint demonstrated that the proportion of patients achieving a 1 g/dL or greater increase in hemoglobin at any time point during the study was 40% in the Auryxia arm vs. 15% in the placebo arm
(p-value <0.001). Secondary endpoints in the Phase 3 study include change from baseline to the end of the randomized period for hemoglobin, ferritin, TSAT and serum phosphorus.
Currently, our only product is Auryxia. We may engage in business development activities that include seeking strategic relationships for
Auryxia, as well as evaluating other compounds and companies for in-licensing or acquisition. We have also generated, and expect to continue to generate, revenue from the sublicensing of rights to Auryxia in Japan to JT and Torii.
16
RECENT DEVELOPMENTS
In January 2015, we announced the transitioning of the role of Chief Executive Officer from Ron Bentsur to Greg Madison. Mr. Madison
joined Keryx in February 2014 as Executive Vice President and Chief Operating Officer to transition Keryx from a development-stage organization into a fully integrated commercial entity, bringing to Keryx a wealth of relevant expertise in both the
phosphate binder and iron deficiency anemia markets. In March 2015, Mr. Madison was appointed to our Board of Directors. Mr. Madison assumed the Chief Executive Officer role following the resignation of Mr. Bentsur on April 30,
2015.
In February 2015, we announced a planned consolidation of our finance and accounting function into our Boston office and that our
Chief Financial Officer, James Oliviero, will be leaving Keryx by October 2015. Mr. Oliviero has been with Keryx for twelve years and has served as the Chief Financial Officer since 2009. We have commenced a search for a new Chief Financial
Officer who will be based in our Boston office. Mr. Oliviero will continue to manage our finance and accounting team during the remainder of his tenure and will assist in the transition of his duties to the new Chief Financial Officer.
In April 2015, we announced the appointment of John F. Neylan, M.D., as our Chief Medical Officer.
In April 2015, we signed a new lease agreement for approximately 27,300 square feet in Boston, Massachusetts, for a 94 month term commencing
May 1, 2015, at an average rent of approximately $123,600 per month. The new lease will replace our current subleased space in the same building, which term expires on December 31, 2015.
GENERAL CORPORATE
We have devoted
substantially all of our efforts to the identification, in-licensing, development and partnering of drug candidates, as well as pre-commercial/commercial activities related to Auryxia, and have incurred negative cash flow from operations each year
since our inception. We have spent, and expect to continue to spend, substantial amounts in connection with implementing our business strategy, including our product development efforts, our clinical trials, commercial, partnership and licensing
activities. Prior to the launch of Auryxia in late December 2014, we have not commercialized any drug, and we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to complete our
development efforts, obtain additional regulatory approvals for our drug, successfully complete any post-approval regulatory obligations and successfully manufacture and commercialize our drug. We may continue to incur substantial operating losses
even after we begin to generate meaningful revenues from our drug.
CRITICAL ACCOUNTING POLICIES
The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which
have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets
and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions.
We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially
result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates.
These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following:
Revenue Recognition
Our commercial launch of Auryxia occurred in late December 2014. We sell product to a limited number of major wholesalers,
our Distributors, as well as certain pharmacies, or collectively, our Customers. Our Distributors resell the product to retail pharmacies for purposes of their reselling the product to fill patient prescriptions. In accordance with GAAP, our revenue
recognition policy requires that: (i) there is persuasive evidence that an arrangement exists between us and the Customer, (ii) delivery has occurred, (iii) collectability is reasonably assured and (iv) the price is fixed or
determinable. Until we have the ability to reliably estimate returns of Auryxia from our Customers, revenue will be recognized based on the resale of Auryxia for the purposes of filling patient prescriptions, and not based on sales from us to such
Customers. Consistent with industry practice, once we achieve sufficient history such that we can reliably estimate returns based on sales to our Customers, we anticipate that our revenues will be recognized based on sales to our Customers. We
currently defer Auryxia revenue recognition until the earlier of the
17
product being resold for purposes of filling patient prescriptions and the expiration of the right of return (twelve months after the expiration date of the product). The deferred revenue is
recorded net of discounts, rebates, and chargebacks. We also defer the related cost of product sales and record such amounts as finished goods inventory held by others, which is included in inventory on our consolidated balance sheet, until revenue
related to such product sales is recognized.
We have written contracts with our Customers and delivery occurs when a Customer receives
Auryxia. We evaluate the creditworthiness of each of our Customers to determine whether revenues can be recognized upon delivery, subject to satisfaction of the other requirements, or whether recognition is required to be delayed until receipt of
payment. In order to conclude that the price is fixed or determinable, we must be able to (i) calculate our gross product revenues from the sales to Customers and (ii) reasonably estimate our net product revenues. We calculate gross
product revenues based on the wholesale acquisition cost that we charge our Customers for Auryxia. We estimate our net product revenues by deducting from our gross product revenues (a) trade allowances, such as invoice discounts for prompt
payment and distributor fees, (b) estimated government and private payor rebates, chargebacks and discounts, such as Medicaid reimbursements, (c) reserves for expected product returns and (d) estimated costs of incentives offered to
certain indirect customers, including patients.
Trade Allowances: We generally provide invoice discounts on Auryxia sales to our
Distributors for prompt payment and pay fees for distribution services, such as fees for certain data that Distributors provide to us. The payment terms for sales to Distributors generally include a prompt-pay discount for payment within 30 days.
Based on our judgment and industry experience, we expect our Distributors to earn these discounts and fees, and deduct the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time such revenues are
recognized.
Rebates, Chargebacks and Discounts: We contract with Medicaid, other government agencies and various commercial and
Medicare Part D private insurance providers, or collectively, our Third-party Payors, so that Auryxia will be eligible for partial or full reimbursement from such Third-party Payors. We also contract with certain specialty pharmacies directly so
that Auryxia will be eligible for purchase by these specialty pharmacies. We estimate the rebates, chargebacks and discounts we will provide to Third-party Payors and specialty pharmacies, and deduct these estimated amounts from our gross product
revenues at the time the revenues are recognized. We estimate the rebates, chargebacks and discounts that we will provide to Third-party Payors and specialty pharmacies based upon (i) our contracts with these Third-party Payors and specialty
pharmacies, (ii) the government-mandated discounts applicable to government-funded programs and (iii) information obtained from our Customers and other third parties regarding the payor mix for Auryxia.
Product Returns: During the three months ended March 31, 2015, the first full period in which we began selling Auryxia, we were
not able to reasonably estimate product returns for all product sold to Customers due to insufficient historical returns data. Once sufficient data exists, we will estimate the amount of Auryxia that will be returned and deduct these estimated
amounts from our gross revenues at the time that revenues are recognized. Our Customers have the right to return Auryxia during the 18-month period beginning six months prior to the labeled expiration date and ending twelve months after the labeled
expiration date. Currently the expiration date for Auryxia is eighteen months after it has been converted into tablet form, which is the last step in the manufacturing process for Auryxia and generally occurs within a few months before Auryxia is
delivered to Customers. As of March 31, 2015, we have experienced no product returns.
Other Incentives: Other incentives that
we offer to indirect customers include co-pay mitigation rebates provided by us to commercially insured patients who have coverage for Auryxia and who reside in states that permit co-pay mitigation programs, and vouchers for a month supply of
Auryxia at no patient cost. Our co-pay mitigation program is intended to reduce each participating patients portion of the financial responsibility for Auryxias purchase price to a specified dollar amount. Based upon the terms of the
program and information regarding programs provided for similar specialty pharmaceutical products, we estimate the average co-pay mitigation amounts and the percentage of patients that we expect to participate in the program in order to establish
our accruals for co-pay mitigation rebates and deduct these estimated amounts from our gross product revenues at the time the revenues are recognized. Our vouchers offered to date will expire on December 31, 2015. We adjust our accruals for
co-pay mitigation and voucher rebates based on our estimates regarding the portion of issued rebates that we estimate will not be redeemed.
18
The following table summarizes activity in each of the product revenue allowance and reserve
categories described above for the three months ended March 31, 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands) |
|
Trade allowances |
|
|
Rebates, chargebacks and discounts |
|
|
Product returns |
|
|
Other incentives (1) |
|
|
Total |
|
Balance at January 1, 2015 |
|
$ |
136 |
|
|
$ |
48 |
|
|
$ |
|
|
|
$ |
275 |
|
|
$ |
459 |
|
Provision related to current period and deferred sales |
|
|
347 |
|
|
|
221 |
|
|
|
|
|
|
|
858 |
|
|
|
1,426 |
|
Credits/payments made for current period and deferred sales |
|
|
(63 |
) |
|
|
(2 |
) |
|
|
|
|
|
|
(280 |
) |
|
|
(345 |
) |
Credits/payments made for prior period and deferred sales |
|
|
(136 |
) |
|
|
(4 |
) |
|
|
|
|
|
|
(275 |
) |
|
|
(415 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 31, 2015 |
|
$ |
284 |
|
|
$ |
263 |
|
|
$ |
|
|
|
$ |
578 |
|
|
$ |
1,125 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Includes co-pay mitigation and voucher rebates. |
The following table summarizes product
revenue recognized and deferred during the three months ended March 31, 2015, and the year ended December 31, 2014:
|
|
|
|
|
|
|
|
|
(in thousands) |
|
March 31, 2015 |
|
|
December 31, 2014 |
|
Product revenue recognized |
|
$ |
422 |
|
|
$ |
|
|
Deferred product revenue |
|
|
714 |
|
|
|
414 |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1,136 |
|
|
$ |
414 |
|
|
|
|
|
|
|
|
|
|
In conjunction with our recognition and deferral of product revenues, we expensed and capitalized the
associated cost of goods, as follows, during the three months ended March 31, 2015, and the year ended December 31, 2014:
|
|
|
|
|
|
|
|
|
(in thousands) |
|
March 31, 2015 |
|
|
December 31, 2014 |
|
Cost of goods sold expensed |
|
$ |
76 |
|
|
$ |
|
|
Finished goods inventory held by others |
|
|
107 |
|
|
|
47 |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
183 |
|
|
$ |
47 |
|
|
|
|
|
|
|
|
|
|
We recognize license revenue in accordance with the revenue recognition guidance of the Codification. We
analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified objectives are
achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent
the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is
non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the
milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.
For arrangements for which royalty revenue information becomes available and collectability is reasonably assured, we recognize revenue during
the applicable period earned. When collectability is reasonably assured but a reasonable estimate of royalty revenue cannot be made, the royalty revenue is recognized in the quarter that the licensee provides the written report and related
information to us.
Stock Compensation
We have granted stock options and restricted stock to employees, directors and consultants, as well as warrants to other third parties. For
employee and director grants, the value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model takes into account volatility in the price of our stock, the risk-free interest
rate, the estimated life of the option, the closing market price of our stock and the exercise price. We base our estimates of our stock price volatility on the historical volatility of our common
19
stock and our assessment of future volatility; however, these estimates are neither predictive nor indicative of the future performance of our stock. For purposes of the calculation, we assumed
that no dividends would be paid during the life of the options and warrants. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. In addition, we are required to estimate
the expected forfeiture rate and only recognize expense for those equity awards expected to vest. As a result, if other assumptions had been used, our recorded stock-based compensation expense could have been materially different from that reported.
In addition, because some of the options and warrants issued to employees, consultants and other third-parties vest upon the achievement of certain milestones, the total expense is uncertain.
Total compensation expense for options and restricted stock issued to consultants is determined at the measurement date. The
expense is recognized over the vesting period for the options and restricted stock. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record stock-based compensation expense based on the fair value
of the equity awards at the reporting date. These equity awards are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date. This results in a change to the amount previously
recorded in respect of the equity award grant, and additional expense or a reversal of expense may be recorded in subsequent periods based on changes in the assumptions used to calculate fair value, such as changes in market price, until the
measurement date is reached and the compensation expense is finalized.
Accruals for Clinical Research Organization and Clinical Site Costs
We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We
analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments
and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs
applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With
respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the
successful recruitment of patients, and the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts
expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.
Inventory
Inventories are stated
at the lower of cost or estimated realizable value. We determine the cost of our inventories, which include amounts related to materials, third-party contract manufacturing and packaging services, and manufacturing overhead, on a first-in, first-out
basis. We capitalize inventory costs at our suppliers when, based on managements judgment, the realization of future economic benefit is probable at each given supplier. We received FDA approval for Auryxia on September 5, 2014, and on
that date began capitalizing inventory purchases of saleable product from certain suppliers. Prior to FDA approval, all saleable product purchased from such suppliers were included as a component of research and development expense.
Accounts Receivable, Allowances for Doubtful Accounts and Cash Discounts
We extend credit to our customers for product sales resulting in accounts receivable. Customer accounts are monitored for past due amounts.
Past due accounts receivable, determined to be uncollectible, are written off against the allowance for doubtful accounts. Allowances for doubtful accounts are estimated based upon past due amounts, historical losses and existing economic factors,
and are adjusted periodically. We offer cash discounts to our customers, generally 2% of the sales price, as an incentive for prompt payment. The estimate of cash discounts is recorded at the time of sale. We account for the cash discounts by
reducing revenue and accounts receivable by the amount of the discounts we expect our customers to take. The accounts receivable are reported in the consolidated balance sheets, net of the allowances for doubtful accounts and cash discounts. There
was no allowance for doubtful accounts at March 31, 2015 and December 31, 2014.
20
Accounting Related to Goodwill
As of March 31, 2015, there was approximately $3.2 million of goodwill on our consolidated balance sheet. Goodwill is reviewed for
impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the units carrying value,
including goodwill. When the carrying value of the reporting unit is greater than fair value, the units goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the
second step, the implied fair value of the reporting units goodwill is compared with the carrying amount of the units goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be
written down to its implied fair value.
We are required to perform impairment tests annually, at December 31, and whenever events or
changes in circumstances suggest that the carrying value of an asset may not be recoverable. For all of our acquisitions, various analyses, assumptions and estimates were made at the time of each acquisition that were used to determine the valuation
of goodwill and intangibles. In future years, the possibility exists that changes in forecasts and estimates from those used at the acquisition date could result in impairment indicators.
Accounting For Income Taxes
In
preparing our consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process involves management estimation of our actual current tax exposure and assessment of
temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities. We must then assess the likelihood that our deferred tax assets will be recovered
from future taxable income and, to the extent we believe that recovery is not likely, we must establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we must include an expense within
the tax provision in the consolidated statement of operations. Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net
deferred tax assets. We have fully offset our deferred tax assets with a valuation allowance. Our lack of earnings history and the uncertainty surrounding our ability to generate taxable income prior to the reversal or expiration of such deferred
tax assets were the primary factors considered by management in maintaining the valuation allowance.
For the three months ended
March 31, 2015, we recognized $22,000 in income tax expense related to the recording of a deferred tax liability associated with capitalized goodwill, an indefinite-lived intangible asset that is being amortized for tax purposes.
Indefinite-lived intangibles are non-monetary assets which are not amortized for book purposes since there is no foreseeable limit to the cash flows provided by them. Our lack of earnings history and the uncertainty surrounding our ability to
generate taxable income prior to the reversal or expiration of such deferred tax liability were the primary factors considered by management when recording the deferred tax liability.
RECENTLY ISSUED ACCOUNTING STANDARDS
In
August 2014, the Financial Accounting Standards Board issued a new standard, Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entitys Ability to Continue as a Going Concern. This new standard will explicitly
require management to assess an entitys ability to continue as a going concern and to provide footnote disclosures in certain cases. Currently there is no guidance in GAAP about managements responsibility to evaluate whether there is
substantial doubt about an entitys ability to continue as a going concern. The new standard applies to all entities and provides an explicit requirement that management assesses and discloses going concern uncertainties. Previous guidance in
auditing standards required auditors to evaluate going concern. The new standard will be effective for all entities in the first annual period ending after December 15, 2016, which is December 31, 2016 for calendar year-end entities.
Earlier application is permitted.
In May 2014, the Financial Accounting Standards Board issued a comprehensive new standard which amends
revenue recognition principles and provides a single set of criteria for revenue recognition among all industries. The new standard provides a five step framework whereby revenue is recognized when promised goods or services are transferred to a
customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosures pertaining to revenue
21
recognition in both interim and annual periods. The standard is effective for interim and annual periods beginning after December 15, 2016 and allows for adoption using a full retrospective
method, or a modified retrospective method. We are currently assessing the method of adoption and the expected impact the new standard will have on our financial position and results of operations.
RESULTS OF OPERATIONS
Three months ended
March 31, 2015 and March 31, 2014
Product Revenue, Net. For the three months ended March 31, 2015, we recognized
$0.4 million in product revenue from sales of Auryxia, net of allowances, discounts, incentives, rebates and chargebacks. Our commercial launch of Auryxia occurred in late December 2014. There was no product revenue for three months ended
March 31, 2014.
|
|
|
|
|
|
|
|
|
(in thousands) |
|
Three months ended March 31, 2015 |
|
|
Percent of gross Auryxia product sales |
|
Gross Auryxia product sales |
|
$ |
964 |
|
|
|
|
|
Less provision for product sales allowances and accruals |
|
|
|
|
|
|
|
|
Trade allowances |
|
|
100 |
|
|
|
10 |
% |
Rebates, chargebacks and discounts |
|
|
30 |
|
|
|
3 |
% |
Product returns |
|
|
|
|
|
|
|
|
Other incentives (1) |
|
|
412 |
|
|
|
43 |
% |
|
|
|
|
|
|
|
|
|
Total |
|
|
542 |
|
|
|
56 |
% |
|
|
|
|
|
|
|
|
|
Net Auryxia product sales |
|
$ |
422 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Includes co-pay mitigation and voucher rebates. |
We sell product to a limited number of major
wholesalers, our Distributors, as well as certain pharmacies, or collectively, our Customers. Our Distributors resell the product to retail pharmacies for purposes of their reselling the product to fill patient prescriptions. In accordance with our
revenue recognition policy, until we have the ability to reliably estimate returns of Auryxia from our Customers, revenue recognition is deferred until the earlier of the product being resold for purposes of filling patient prescriptions and the
expiration of the right of return (twelve months after the expiration date of the product), and not based on sales from us to our Customers. At March 31, 2015, we have deferred revenue of $0.7 million, which represents Auryxia product shipped
to our Customers, but not yet resold to fill patient prescriptions, net of applicable discounts and rebates. We expect Auryxia product revenue and patient prescriptions to increase in 2015 as we continue the commercialization of Auryxia.
Other incentives, which is currently our largest deduction from gross product revenues, includes costs associated with patient services
programs, including a voucher program that provides a free month of drug to patients as we work to build formulary access for Auryxia. Going forward, we expect that voucher redemptions will represent a continuously decreasing percentage of our
business. This will result in less impact to our gross to net deduction over time, but it will be partially offset by increases in rebates as more of our business will be contracted with Third-party Payors.
License Revenue. For the three months ended March 31, 2015, we recognized $0.8 million in license revenue on royalty payments from
sales of Riona® in Japan. JTs subsidiary, Torii, launched Riona® in May 2014. License revenue for the three months ended
March 31, 2014 was $10.0 million due to the recognition of a $10.0 million non-refundable milestone payment in January 2014 related to JT and Toriis achievement of marketing approval in Japan. We receive royalty payments based on a tiered
double-digit percentage of net sales of Riona® in Japan escalating up to the mid-teens for sales made by Torii. We may also receive up to an additional $55 million of milestone payments
upon the achievement of certain annual net sales milestones.
Cost of Goods Sold. For the three months ended March 31, 2015,
we recognized $0.1 million in cost of goods sold related to product sales of Auryxia. Our commercial launch of Auryxia occurred in late December 2014. There was no cost of goods sold expense recorded for the three months ended March 31,
2014. Cost of goods sold includes the cost of API for Auryxia on which product revenue was recognized during the period, as well as the associated costs for tableting, packaging, shipment, insurance and quality assurance. Cost of goods sold also
includes the royalty expense due the licensor of Auryxia related to the product revenue recognized during the period.
22
License Expenses. For the three months ended March 31, 2015, we recognized $0.5
million in license expenses related to royalties due to the licensor of Auryxia relating to sales of Riona® in Japan. There were no license expenses for the three months ended
March 31, 2014. We owe a mid-single digit percentage of net sales royalty to the licensor of Auryxia associated with net sales of Riona® in Japan.
Research and Development Expenses. Research and development expenses decreased by $6.8 million to $9.6 million for the three months
ended March 31, 2015, as compared to $16.4 million for the three months ended March 31, 2014. The decrease in research and development expenses was due to a $2.9 million decrease in regulatory and clinical study expenses related to Auryxia
and a $3.8 million decrease in expenses related to the manufacturing of Auryxia, which were expensed in the comparable period in 2014 and primarily capitalized as inventory following the approval of Auryxia in September 2014. The three months ended
March 31, 2015 included $2.0 million of expenses for medical affairs activities, as the medical affairs group will increasingly be supporting additional research and development of Auryxia in the post-approval setting and, therefore, the
associated costs are included in research and development expenses as of January 2015. The three months ended March 31, 2014, included a $2.0 million one-time milestone payment to the licensor of Auryxia for JT and Toriis achievement of
the Japanese marketing approval milestone in January 2014. We expect our quarterly research and development expenses to remain at a comparable level for the remainder of 2015.
Selling, General and Administrative Expenses. Selling, general and administrative expenses increased by $11.6 million to $18.9 million
for the three months ended March 31, 2015, as compared to $7.3 million for the three months ended March 31, 2014. The increase was primarily related to a $10.2 million increase in commercial activities and associated personnel costs
related to the commercialization of Auryxia, which included a $1.7 million increase in associated stock-based compensation expense related to the recording of the fair value of equity awards granted, which are expensed over the vesting periods of
the individual awards. We expect our quarterly selling, general and administrative costs for the remainder of 2015 to increase modestly as we continue the commercialization of Auryxia.
Interest and Other Income, Net. Interest and other income, net, decreased by $14,000 to $107,000 for the three months ended
March 31, 2015, as compared to $121,000 for the three months ended March 31, 2014.
Income Taxes. For the three months
ended March 31, 2015, we recognized $22,000 in income tax expense related to the recording of a deferred tax liability associated with capitalized goodwill, an indefinite-lived intangible asset that is being amortized for tax purposes.
Indefinite-lived intangibles are non-monetary assets which are not amortized under GAAP since there is no foreseeable limit to the cash flows provided by them. Our lack of earnings history and the uncertainty surrounding our ability to generate
taxable income prior to the reversal or expiration of such deferred tax liability were the primary factors considered by management when recording the deferred tax liability. There was no income tax expense for the three months ended March 31,
2014. We continue to maintain a full valuation allowance against our net deferred tax assets.
LIQUIDITY AND CAPITAL RESOURCES
Our major sources of cash have been proceeds from various public and private offerings of our common stock, option and warrant exercises,
interest income, and from the upfront and milestone payments from our Sublicense Agreement with JT and Torii and miscellaneous payments from our other prior licensing activities. The commercial launch of our first product, Auryxia, occurred in late
December 2014. Even though we are commercializing Auryxia, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to complete our development efforts, obtain additional regulatory
approvals for our drug, successfully complete any post-approval regulatory obligations and successfully manufacture and commercialize our drug alone or in partnership. We may continue to incur substantial operating losses even after we begin to
generate meaningful revenues from our drug.
On January 21, 2015, we announced the pricing of an underwritten public offering in
which we sold 10,541,667 shares of our common stock at a price of $12.00 per share for gross proceeds of approximately $126.5 million. Net proceeds from this offering were approximately $118.3 million, net of underwriting discounts and offering
expenses of approximately $8.2 million. The shares were sold under Registration Statements (Nos. 333-201605 and 333-201639) on Form S-3 and Form S-3MEF, respectively, filed by us with the Securities and Exchange Commission.
23
In January 2014, our Japanese partner, JT and Torii, received manufacturing and marketing
approval of ferric citrate from the Japanese Ministry of Health, Labour and Welfare. Ferric citrate, launched in May 2014 and being marketed in Japan by JTs subsidiary, Torii, under the brand name Riona®, is indicated as an oral treatment for the improvement of hyperphosphatemia in patients with CKD, including dialysis and NDD-CKD. Under the license agreement with JT and Torii, we received a
non-refundable payment of $10.0 million in February 2014 for the achievement of the marketing approval milestone. We also receive royalty payments based on a tiered double-digit percentage of net sales of Riona® in Japan escalating up to the mid-teens, as well as up to an additional $55.0 million upon the achievement of certain annual net sales milestones. We owe a mid-single digit percentage of net
sales royalty to the licensor of Auryxia associated with net sales of Riona® in Japan.
As of March 31, 2015, we had $168.8 million in cash and cash equivalents, as compared to $85.8 million in cash, cash equivalents,
short-term investments and interest receivable at December 31, 2014, representing an increase of $83.0 million. We currently expect that our existing capital resources combined with future anticipated cash flows will be sufficient to execute
our business plan. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing and expenditures associated with commercial activities related to Auryxia and the magnitude of cash
received from product sales, the timing and expenditures associated with the build-up of inventory and capacity expansion, the timing and expenditures associated with the regulatory review process for our EU MAA filing, and the timing, design and
conduct of clinical trials for Auryxia. As a result of these factors, we may need to seek additional financings to provide the cash necessary to execute our current operations, including beyond the initial commercialization of Auryxia, and to
develop any drug candidates we may in-license or acquire.
Net cash used in operating activities for the three months ended March 31,
2015 was $35.3 million, as compared to $10.0 million for the three months ended March 31, 1014. This increase in net cash used in operating activities was primarily related to Auryxia commercial expenditures to support the launch, including the
manufacturing of inventory.
For the three months ended March 31, 2015, net cash provided by investing activities was $11.4 million,
primarily due to the maturity of held-to-maturity short-term securities, as compared to $49.9 million of net cash used in investing activities for the three months ended March 31, 2014, primarily related to the investment in held-to-maturity
short-term securities.
For the three months ended March 31, 2015, net cash provided by financing activities was $118.4 million as
compared to $109.5 million for the three months ended March 31, 2014. The increase was primarily related to $118.3 million of net proceeds received from our public offering of common stock in January 2015, as compared to $107.5 million of net
proceeds received from our public offering of common stock in January 2014.
OFF-BALANCE SHEET ARRANGEMENTS
We have not entered into any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests,
derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity,
market risk or credit risk support, or engages in leasing, hedging, or research and development services on our behalf.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The primary objective of our investment activities is to preserve principal while maximizing our income from investments and minimizing our
market risk. We currently invest in government and investment-grade corporate debt in accordance with our investment policy, which we may change from time to time. The securities in which we invest have market risk. This means that a change in
prevailing interest rates, and/or credit risk, may cause the fair value of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the prevailing interest rate later
rises, the fair value of our investment will probably decline. As of March 31, 2015, our portfolio of financial instruments consists of cash equivalents, including money market funds. Due to the short-term nature of these financial instruments,
we believe there is no material exposure to interest rate risk, and/or credit risk, arising from our portfolio of financial instruments.
24
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
As of March 31, 2015, management carried out, under the supervision and with the participation of our Chief Executive Officer and Chief
Financial Officer, an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our disclosure controls and procedures are designed to
provide reasonable assurance that information we are required to disclose in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in applicable rules and forms.
Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2015, our disclosure controls and procedures were effective.
Changes in Internal Controls Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended March 31, 2015, that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and
procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control
system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems,
no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We, and our subsidiaries, are not a party to, and our property is not the subject of, any material pending legal proceedings.
ITEM 1A. RISK FACTORS
You should carefully consider the following risks and uncertainties. If any of the following occurs, our business, financial condition and/or
operating results could be materially harmed. These factors could cause the trading price of our common stock to decline, and you could lose all or part of your investment.
Risks related to our business and industry
We have a limited operating history and have incurred substantial operating losses since our inception. We expect to continue to incur losses in the
future and may never become profitable.
We have a limited operating history. You should consider our prospects in light of the
risks and difficulties frequently encountered by early stage companies. In addition, we have incurred substantial operating losses since our inception and expect to continue to incur operating losses for the foreseeable future and may never become
profitable. As of March 31, 2015, we had an accumulated deficit of $578.6 million. As we continue our research and development and initial commercial efforts, we will incur increasing losses. We may continue to incur substantial operating
losses even after we begin to generate meaningful revenues from our drug, Auryxia. Our ability to achieve profitability depends on a number of factors, including our ability to complete our development efforts, obtain additional regulatory approvals
for our drug, successfully complete any post approval regulatory obligations and successfully manufacture and commercialize our drug.
25
We are highly dependent on the commercial success of Auryxia in the U.S. for the foreseeable future; we may
be unable to attain profitability and positive cash flow from operations.
In September 2014, the FDA approved Auryxia
(formerly known as Zerenex) for the control of serum phosphorus levels in patients with CKD on dialysis. The commercial success of Auryxia will depend on a number of factors, including:
|
|
|
the effectiveness of Auryxia as a treatment for adult patients with CKD on dialysis; |
|
|
|
the size of the treatable patient population; |
|
|
|
the effectiveness of the sales, managed markets and marketing efforts by us and our competitors; |
|
|
|
the adoption of Auryxia by physicians, which depends on whether physicians view it as a safe and effective treatment to lower serum phosphorus levels in patients with CKD on dialysis; |
|
|
|
our ability to both secure and maintain adequate reimbursement for, and optimize patient access to, Auryxia by providing third party payers with a strong value proposition based on the existing burden of illness
associated with CKD patients on dialysis and the benefits of Auryxia; |
|
|
|
the occurrence of any side effects, adverse reactions or misuse, or any unfavorable publicity in these areas, associated with Auryxia; |
|
|
|
our ability to obtain and maintain strong intellectual property protection for Auryxia; |
|
|
|
the development or commercialization of competing products or therapies for the control of serum phosphorus levels in patients with CKD on dialysis; and |
|
|
|
our ability to identify reliable suppliers and successfully manufacture Auryxia. |
Our revenues
from the commercialization of Auryxia are subject to these and other factors, and therefore may be unpredictable from quarter-to-quarter. Ultimately, we may never generate sufficient revenues from Auryxia to reach or maintain profitability or
sustain our anticipated levels of operations.
Auryxia may cause undesirable side effects or have other properties that could limit its commercial
potential.
The most commonly reported adverse reactions in the clinical trials that supported the approval of Auryxia in the U.S.
were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%). Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia (14%) in clinical trials. If we or others identify previously
unknown side effects, if known side effects are more frequent or severe than in the past, if we or others detect unexpected safety signals for Auryxia or any products perceived to be similar to Auryxia, or if any of the foregoing are perceived to
have occurred, then in any of these circumstances:
|
|
|
sales of Auryxia may be impaired; |
|
|
|
regulatory approvals for Auryxia may be restricted or withdrawn; |
|
|
|
we may decide to, or be required to, send drug warnings or safety alerts to physicians, pharmacists and hospitals, or may decide to conduct a product recall; |
|
|
|
reformulation of the product, additional nonclinical or clinical studies, changes in labeling or changes to or reapprovals of manufacturing facilities may be required; |
26
|
|
|
we may be precluded from pursuing additional development opportunities to enhance the clinical profile of Auryxia within its indicated populations, as well as be precluded from studying Auryxia in additional indications
and populations and in new formulations; and |
|
|
|
government investigations or lawsuits, including class action suits, may be brought against us. |
Any of the above occurrences would harm or prevent sales of Auryxia, likely increase our expenses and impair our ability to successfully
commercialize Auryxia.
Furthermore, as we explore development opportunities to enhance the clinical profile of Auryxia, any clinical
trials conducted, if successful, may expand the patient populations treated with Auryxia within or outside of its current indications or patient populations, which could result in the identification of previously unknown side effects, increased
frequency or severity of known side effects, or detection of unexpected safety signals. In addition, now that Auryxia is commercially available, it will be used in a wider population and in less rigorously controlled environments than in
clinical studies. As a result, regulatory authorities, healthcare practitioners, third party payers or patients may perceive or conclude that the use of Auryxia is associated with serious adverse effects, undermining our commercialization
efforts.
We rely on third parties to manufacture and analytically test our drug. If these third parties do not successfully manufacture and test
our drug, our business will be harmed.
We have limited experience in manufacturing products for clinical or commercial purposes.
We intend to continue, in whole or in part, to use third parties to manufacture and analytically test our drug for commercial distribution and use in clinical trials and. We may not be able to enter into future contract agreements with these
third-parties on terms acceptable to us, if at all.
Our ability to conduct clinical trials, manufacture and commercialize our drug will
depend on the ability of such third parties to manufacture our drug on a large scale at a competitive cost and in accordance with current Good Manufacturing Practice regulations, (or cGMPs), and other regulatory requirements, including requirements
from federal, state and local environmental and safety regulatory agencies and foreign regulatory requirements, if applicable. Significant scale-up of manufacturing may result in unanticipated technical challenges and will require validation studies
that are subject to FDA inspection. Scale-up/technology transfer activities can be complex, and insufficient process knowledge can result in a poorly scaled up process with inadequate process control. A lack of process control can lead to increased
deviations during the manufacturing process, out of specification test results, batch rejection and the possible distribution of drug products that do not conform to predetermined specifications. In addition, a variety of factors can affect a
contract manufacturers qualifications to produce acceptable product, including deficiencies in the contractors quality unit, lack of training, a shortage of qualified personnel, capacity constraints and changes in the contractors
commercial or quality related priorities. Any of these difficulties, if they occur, and are not overcome to the satisfaction of the FDA or other regulatory agency, could lead to significant delays and possibly the termination of the development
program for our drug, particularly given that some of the third parties we intend to employ in the manufacturing process are single source providers. These risks become more acute as we scale up for commercial quantities, where a reliable source of
active pharmaceutical ingredient (or API) and a qualified contract manufacturer become critical to commercial success. For example, given the large quantity of materials required for Auryxia production and the large quantities of Auryxia that will
be required for commercial success, the commercial viability of Auryxia will also depend on adequate supply of starting materials that meet quality, quantity and cost standards and the ability of our contract manufacturers to produce the API and
finished drug product on a commercial scale. Failure to achieve this level of supply can jeopardize and prevent the successful commercialization of the product. Moreover, issues that may arise in our scale-up/technology transfer of Auryxia can lead
to significant delays in our development and commercial timelines.
Our third-party manufacturers may not perform as required under the
terms of our supply agreement or quality agreement, or may not remain in the contract manufacturing business for the time required by us to successfully manufacture and distribute our drug. In addition, our contract manufacturers will be subject to
ongoing periodic and unannounced inspections by the FDA and corresponding foreign governmental agencies to ensure strict compliance with cGMPs, as well as other governmental regulations and corresponding foreign standards. While we periodically
audit our contractors for adherence to regulatory requirements, and are ultimately held responsible for their regulatory compliance, we cannot assure you that unforeseen changes at these contractors will not occur that could change their regulatory
standing. The same issues apply to contract analytical services which we use for quality, impurity and
27
release testing of our drug. We are required by law to establish adequate oversight and control over raw materials, components and finished products furnished by our third-party manufacturers,
which we establish by contract, supplier qualification and periodic audits, but unforeseen circumstances could affect our third-party manufacturers compliance with applicable regulations and standards. As we continue to scale up production, we
continue to develop analytical tools for Auryxia drug substance and drug product testing. Failure to develop effective analytical tools could result in regulatory or technical delay or could jeopardize our ability to obtain FDA approval. Moreover,
even with effective analytical methods available, there is no assurance that we will be able to analyze all the raw materials and qualify all impurities to the satisfaction of the FDA, possibly requiring additional analytical studies, analytical
method development, or preclinical studies, which could significantly delay our ability to receive regulatory approvals for our drug. Additionally, changes in the analytical specifications required by the FDA or other regulatory authority, such as
United States Pharmacopeial Convention standards, from time to time, could delay our ability to receive regulatory approvals for our drug or our commercial efforts. Switching or engaging multiple third-party contractors to produce our drug substance
or drug product may be difficult and time consuming because the number of potential manufacturers may be limited and the process by which multiple manufacturers make the drug substance or drug product must meet established specifications at each
manufacturing facility. It may be difficult and time consuming for us to find and engage replacement or multiple manufacturers quickly and on terms acceptable to us, if at all. For Auryxia, the loss of any of our drug substance or drug product
manufacturers would result in significant additional costs and delays in our development program. Moreover, if we need to add or change manufacturers after commercialization, the FDA and corresponding foreign regulatory agencies must approve any new
manufacturers in advance, which will involve additional inspections to ensure compliance with FDA and foreign regulations and standards.
If we do
not establish or maintain manufacturing, drug development and marketing arrangements with third parties, we may be unable to commercialize our products.
We do not possess all of the capabilities to fully commercialize our product on our own. From time to time, we may need to contract with
additional third parties, or renew or revise contracts with existing third parties, to:
|
|
|
assist us in developing, testing and obtaining regulatory approval for and commercializing our compound and technologies; and |
|
|
|
market and distribute our drug. |
We can provide no assurance that we will be able to
successfully enter into agreements with such third parties on terms that are acceptable to us, if at all. If we are unable to successfully contract with third parties for these services when needed, or if existing arrangements for these services are
terminated, whether or not through our actions, or if such third parties do not fully perform under these arrangements, we may have to delay, scale back or end one or more of our drug development programs or seek to develop or commercialize our
product independently, which could result in significant delays. Furthermore, such failure could result in the termination of license rights to our product. If these manufacturing, development or marketing agreements take the form of a partnership
or strategic alliance, such arrangements may provide our collaborators with significant discretion in determining the efforts and resources that they will apply to the development and commercialization of our product. We cannot predict the form or
scope that any such collaboration might take, and we may pursue other strategic alternatives if terms or proposed collaborations are not attractive. To the extent that we rely on third parties to research, develop or commercialize our product, we
are unable to control whether such product will be scientifically or commercially successful. Additionally, if these third parties fail to perform their obligations under our agreements with them or fail to perform their work in a satisfactory
manner, in spite of our efforts to monitor and ensure the quality of such work, we may face delays in achieving the business or regulatory milestones required for commercialization of our current drug and any future drug candidate.
We will incur significant liability if it is determined that we are promoting any off-label use of Auryxia.
Physicians are permitted to prescribe drug products for uses that are not described in the products labeling and that differ from those
approved by the FDA or other applicable regulatory agencies. Such off-label uses are common across medical specialties. Although the FDA and other regulatory agencies do not regulate a physicians choice of treatments, the FDA and
other regulatory agencies do restrict communications on the subject of off-label use. Companies are not permitted to promote drugs for off-label uses or promote drugs using marketing claims that are not otherwise consistent with the FDA-approved
labeling, including comparative or superiority claims that are not consistent with the FDA-approved labeling or supported by substantial evidence. Accordingly, we may not promote
28
Auryxia in the U.S. for use in any indications other than for the control of serum phosphorus levels in patients with CKD on dialysis and all promotional claims must be consistent with the
FDA-approved labeling for Auryxia. The FDA and other regulatory and enforcement authorities actively enforce laws and regulations prohibiting promotion of off-label uses and the promotion of products for which marketing approval has not been
obtained as well as the false advertising or misleading promotion of drugs. A company that is found to have improperly promoted off-label uses or to have otherwise engaged in false or misleading promotion of drugs will be subject to significant
liability, including civil and administrative remedies as well as criminal sanctions.
Notwithstanding the regulatory restrictions on
off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading, and non-promotional scientific exchange concerning their products in certain circumstances. We intend to engage in medical education
activities and communicate with healthcare providers in compliance with all applicable laws, regulatory guidance and industry best practices. Although we believe we have put in place a robust compliance program designed to ensure that all such
activities are performed in a legal and compliant manner, Auryxia is our first commercial product, so our implementation of our compliance program in connection with commercialization activities is still relatively new.
If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be
adversely affected.
As a manufacturer of pharmaceuticals, even though we do not (and do not expect in the future to) control
referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payers, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients rights are and will be applicable to our
business. We are subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business. The regulations include:
|
|
|
federal healthcare program anti-kickback laws, which prohibit, among other things, persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual,
for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid; |
|
|
|
federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that
are false or fraudulent, and which may apply to entities like us which provide coding and billing advice to customers; |
|
|
|
the federal Health Insurance Portability and Accountability Act of 1996, which prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which
also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; |
|
|
|
the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of
drug samples; |
|
|
|
state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state
laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts; |
|
|
|
the federal Foreign Corrupt Practices Act which prohibits corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff
member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity; and |
|
|
|
the federal Physician Payments Sunshine Act, which was passed as part of the Patient Protection and Affordable Care Act of 2010, and similar state laws in certain states, that require pharmaceutical and medical device
companies to monitor and report certain payments and transfers of value made to physicians and teaching hospitals. |
29
If our operations are found to be in violation of any of the laws described above or any other
laws, rules or regulations that apply to us, we will be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or
restructuring of our operations could adversely affect our ability to operate our business and our financial results.
In preparation for
the commercial launch of Auryxia, we assembled an experienced compliance team who compiled a program based on industry best practices that is designed to ensure that our commercialization of Auryxia complies with all applicable laws, regulations and
industry standards. We also hire, manage and incentivize our employees around a culture of compliance, trust, respect and ownership. Because our program is relatively new and the requirements in this area are constantly evolving, we cannot be
certain that our program will eliminate all areas of potential exposure. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us
for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our managements attention from the operation of our business, as well as damage our business or reputation.
Moreover, achieving and sustaining compliance with applicable federal and state privacy, security, fraud and reporting laws may prove costly.
If
our competitors develop and market products that are less expensive, more effective or safer than our drug product, or our drug product does not achieve market acceptance vis-à-vis existing treatments, our commercial opportunities may be
reduced or eliminated.
The pharmaceutical industry is highly competitive. Our competitors include pharmaceutical companies and
biotechnology companies, as well as universities and public and private research institutions. In addition, companies that are active in different but related fields represent substantial competition for us. Many of our competitors have
significantly greater capital resources, larger research and development staffs and facilities and greater experience in drug development, regulation, manufacturing and marketing than we do. These organizations also compete with us to recruit
qualified personnel, attract partners for joint ventures or other collaborations, and license technologies that are competitive with ours. As a result, our competitors may be able to more easily develop technologies and products that could render
our drug product obsolete or noncompetitive. To compete successfully in this industry we must identify novel and unique drugs or methods of treatment and then complete the development of those drugs as treatments in advance of our competitors.
Auryxia is competing in the U.S. with other FDA approved phosphate binders such as
Renagel® (sevelamer hydrochloride) and Renvela® (sevelamer carbonate), both marketed by Genzyme Corporation (a wholly-owned subsidiary
of Sanofi), or Genzyme, PhosLo® (calcium acetate), marketed by Fresenius Medical Care, Fosrenol® (lanthanum carbonate), marketed by
Shire Pharmaceuticals Group plc, and Velphoro® (sucroferric oxyhydroxide), marketed by Fresenius Medical Care North America, as well as over-the-counter calcium carbonate products such as TUMS® and metal-based options such as aluminum and magnesium. Our strategy to compete against these existing treatments depends in part on physicians and patients accepting that Auryxia is
differentiated in the marketplace versus these FDA approved phosphate binders. In addition, we may have to compete against existing treatments on price, which becomes more challenging as generic versions of these existing treatments come to market.
For example, an authorized generic of Renvela® was launched in the U.S. in April 2014 by Impax Laboratories, Inc., or Impax, under a settlement agreement with Genzyme whereby Genzyme agreed to
grant Impax a license to sell a one-time allotment of a specified number of bottles of an authorized generic version of Renvela® tablets. Impax is also pursuing approval of its pending
Abbreviated New Drug Application, or ANDA, for generic Renvela® with the FDA. In addition, a generic formulation of PhosLo®
manufactured by Roxane Laboratories, Inc. was launched in the U.S. in October 2008. In addition, upon the expiration of its core patents, generic formulations of Fosrenol® may be launched.
These generic formulations could have a further material effect on the pricing of phosphate binders.
Furthermore, our commercial
opportunities may be reduced or eliminated if our competitors develop and market products that are less expensive, more effective or safer than our drug product. Other companies have drug candidates in various stages of pre-clinical or clinical
development to treat diseases for which we are also seeking to acquire and develop drug products. Even if we are successful in developing effective drugs, our product(s) may not compete successfully with products produced by our competitors.
30
If we lose our key personnel or are unable to attract and retain additional personnel, our operations could
be disrupted and our business could be harmed.
As of April 20, 2015, we had 156 full and part-time employees. To successfully
develop and commercialize our drug and any drug candidates we may in-license or acquire, we must be able to attract and retain highly skilled personnel. Our limited resources may hinder our efforts to attract and retain highly skilled personnel. In
addition, if we lose the services of our current personnel our ability to continue to execute on our business plan could be materially impaired. Although we have employment agreements with Greg Madison, James Oliviero, Brian Adams and John Neylan,
M.D., these agreements do not prevent them from terminating their employment with us.
In January 2015, we announced the transitioning of
the role of Chief Executive Officer from Ron Bentsur to Greg Madison. Mr. Madison joined Keryx in February 2014 as Executive Vice President and Chief Operating Officer to transition Keryx from a development-stage organization into a fully
integrated commercial entity, bringing to Keryx a wealth of relevant expertise in both the phosphate binder and iron deficiency anemia markets. In March 2015, Mr. Madison was appointed to our Board of Directors. Mr. Madison assumed the
Chief Executive Officer role following the resignation of Mr. Bentsur on April 30, 2015.
In February 2015, we announced a
planned consolidation of our finance and accounting function into our Boston office and that our Chief Financial Officer, James Oliviero, will be leaving Keryx by October 2015. Mr. Oliviero has been with Keryx for twelve years and has served as
the Chief Financial Officer since 2009. We have commenced a search for a new Chief Financial Officer who will be based in our Boston office. Mr. Oliviero will continue to manage our finance and accounting team during the remainder of his tenure
and will assist in the transition of his duties to the new Chief Financial Officer.
Risks associated with our product development efforts
If we do not receive regulatory approvals to market our drug product in a timely manner, or at all, our business will be materially harmed and
our stock price may be adversely affected.
We are commercializing and continuing to develop Auryxia, an oral, absorbable
iron-based compound. In May 2011, we announced positive Scientific Advice from the EMA for the development of Auryxia for the management and control of serum phosphorus in CKD patients undergoing dialysis, and in NDD-CKD patients. The Scientific
Advice from the EMA indicates that our successful Phase 3 program in dialysis in the U.S., in conjunction with safety data generated from other clinical studies with Auryxia, will be considered sufficient to support a MAA to the EMA for the
indication in CKD patients on dialysis. The Scientific Advice also provided us with a regulatory path forward in the NDD-CKD setting in Europe. As a result, we believe that since our Phase 3 program in dialysis, and Phase 2 study in NDD-CKD, in the
U.S. were successful, we will not need to conduct any additional clinical trials to assess the safety or efficacy of Auryxia in order to obtain European approval in CKD, including the dialysis and NDD-CKD settings. Accordingly, in March 2014, we
submitted a MAA with the EMA for both dialysis and NDD-CKD, which was validated by the EMA in March 2014. Scientific Advice is legally non-binding and is based on the current scientific knowledge, which may be subject to future changes. Many
companies which have been provided with positive Scientific Advice by the EMA have ultimately failed to obtain approval of an MAA for their drugs. Additionally, even if the primary endpoint in a Phase 3, or other pivotal, clinical trial is achieved,
the Scientific Advice does not guarantee approval. The EMA may raise issues of safety, study conduct, bias, deviation from the protocol, statistical power and analyses, patient demographics, patient completion rates, changes in scientific or medical
parameters or internal inconsistencies in the data prior to making its final decision, which may delay or prevent EMA approval of Auryxia.
Obtaining approval of an MAA by the EMA is highly uncertain and like many product candidates, we may fail to obtain the approval even though
our MAA has been validated by the EMA. The MAA review processes are extensive, lengthy, expensive and uncertain, and the EMA may delay, limit or deny approval of Auryxia for many reasons, including:
31
|
|
|
we may not be able to demonstrate to the satisfaction of the regulatory authority that Auryxia is safe and effective for any indication; |
|
|
|
the data arising from the clinical trials, including the Phase 3 results for dialysis patients and our Phase 2 results for NDD-CKD, the development program or the MAA for Auryxia may not be satisfactory to the EMA;
|
|
|
|
the EMA may disagree with the number, design, size, conduct or implementation of our clinical trials or conclude that the data fails to meet statistical or clinical significance; |
|
|
|
the EMA may not find the data from preclinical and clinical studies sufficient to demonstrate that Auryxias clinical and other benefits outweigh its safety risks; |
|
|
|
the EMA may disagree with our interpretation of data from preclinical studies or clinical trials, and may reject conclusions from preclinical studies or clinical trials, or determine that primary or secondary endpoints
from clinical trials were not met, or reject safety conclusions from such studies; |
|
|
|
the EMA may not accept data generated at one or more of our clinical trial sites; |
|
|
|
the EMA may determine that we did not properly oversee our clinical trials or follow the regulatory authoritys advice or recommendations in conducting our clinical trials; |
|
|
|
an advisory committee, if convened by the EMA, may recommend against approval of our application or may recommend that the respective regulatory authority require, as a condition of approval, additional preclinical
studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the respective regulatory authority may still not approve Auryxia;
|
|
|
|
data and analyses submitted to the EMA in response to questions raised during the review processes may not be satisfactory to the regulatory authority, and this may lead to significant delays in the approval of Auryxia
or to the rejection of the Auryxia MAA; and |
|
|
|
the EMA may identify deficiencies in the chemistry, manufacturing and controls, or CMC, sections of our MAA, our manufacturing processes, facilities or analytical methods or those of our third party contract
manufacturers, and this may lead to significant delays in the approval of Auryxia or to the rejection of the Auryxia MAA. |
Additionally, our March 2014 MAA submission to the EMA was our first MAA filing in Europe. During the regulatory review process, regulatory
agencies will typically ask questions of drug sponsors, such as the Day 120 questions which we received from the EMA for which we submitted our responses in January 2015. We will endeavor to answer all such questions in a timely and complete
fashion; however, we cannot assure you that our answers to such questions will be complete and to the satisfaction of the regulatory agencies. If certain questions asked have not been fully and satisfactorily answered by us, approval of our filings
may be delayed, or the filings may be rejected.
Accordingly, we may not receive the regulatory approvals needed to market Auryxia. Any
failure or delay in completion of the development program or the EMA review processes would delay or foreclose commercialization of Auryxia and severely harm our business and financial condition.
If we are unable to successfully complete our clinical trial programs, or if such clinical trials take longer to complete than we project, our ability
to execute our current business strategy will be adversely affected.
Whether or not and how quickly we complete our clinical
trials is dependent in part upon the rate at which we are able to engage clinical trial sites and, thereafter, the rate of enrollment of patients, and the rate we collect, clean, lock and analyze the clinical trial database. Patient enrollment is a
function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the study, the existence of competitive clinical trials, and whether existing or new drugs are approved
for the indication we are studying. We are aware that other companies are currently conducting or planning clinical trials that seek to enroll patients with the same disease that we are studying. If we experience delays in identifying and
contracting with sites and/or in patient enrollment in our clinical trial programs, we may incur additional costs and delays in our development programs, and may not be able to complete our clinical trials in a cost-effective or timely manner or at
all. In addition, conducting multi-national studies adds another level of complexity and risk. As a result, we may be subject to events affecting countries outside the U.S.
32
Negative or inconclusive results from the clinical trials we conduct, such as the ongoing Phase 3
study of Auryxia for the treatment of iron deficiency anemia in patients with NDD-CKD, or unanticipated adverse medical events could cause us to have to repeat or terminate the clinical trials. For example, in May 2012, we abandoned our development
efforts and terminated our license for KRX-0401 (perifosine) following negative results from the Phase 3 trial. We may also opt to change the delivery method, formulation or dosage which could affect efficacy results for the drug. Accordingly, we
may not be able to complete our current or future clinical trials within an acceptable time frame, if at all.
Pre-clinical testing and clinical
development are long, expensive and uncertain processes. If our drug does not receive the necessary regulatory approvals, we will be unable to commercialize our drug, Auryxia, in Europe.
We have not received, and may never receive, regulatory approval for the commercial sale of Auryxia by the EMA. We may need to conduct
significant additional research and human testing before we receive product approval with the EMA or with regulatory authorities of other countries. Pre-clinical testing and clinical development are long, expensive and uncertain processes.
Satisfaction of regulatory requirements typically depends on the nature, complexity and novelty of the product. It requires the expenditure of substantial resources. Data obtained from pre-clinical and clinical tests can be interpreted in different
ways, which could delay, limit or prevent regulatory approval. The EMA or a regulatory authority of another country, as applicable, may pose additional questions or request further toxicological, drug-drug interaction, pre-clinical or clinical data
or substantiation. For example, while Auryxia is a Generally Recognized as Safe, or GRAS, substance in the U.S., and the EMA has not requested that we conduct a two-year carcinogenicity study in animals, there is no assurance that the EMA or some
other regulatory authority will not ask us to conduct such a study in order to obtain regulatory approval. In addition, the EMA has not requested us to conduct reproductive toxicity, genotoxicity and single-dose toxicity studies and we are
referencing such studies from the published scientific literature in our regulatory submissions. However, we can provide no assurance that the EMA will not ask us to conduct additional studies. We provided our responses to the EMAs Day 120
questions in January 2015 and in April 2015 we requested a 2-month extension to provide adequate time to respond to the final questions from the EMA; however, we cannot assure you that we have answered, or will continue to answer, these questions to
the EMAs satisfaction or that the EMA will not have additional questions as part of the MAA review. Consequently, it may take us many years to complete the testing of our drug and failure can occur at any stage of this process. Negative,
inconclusive, or insufficient results or medical events during a pre-clinical or clinical trial could cause us to delay or terminate our development efforts. Furthermore, interim results of preclinical or clinical studies do not necessarily predict
their final results, and acceptable results in early studies might not be obtained in later studies.
Safety signals detected during
clinical studies and pre-clinical animal studies, such as the gastrointestinal bleeding and liver toxicities that have been seen in some high-dose Auryxia canine studies, may require us to perform additional safety studies or analyses, which could
delay the development of the drug or lead to a decision to discontinue development of the drug. We have submitted to the EMA data from our short-term and long-term rat and canine pre-clinical studies for Auryxia. While the EMA has reviewed the data
from these studies and we have conducted our Phase 3 clinical program for CKD patients on dialysis, and Phase 2 study in NDD CKD patients, we can provide no assurance that the EMA will not raise any safety concerns in the future from these studies.
Drug candidates in the later stages of clinical development may fail to show the desired traits of safety and efficacy despite positive results in earlier clinical testing. Moreover, the risk remains that the safety and efficacy data from our
pivotal Phase 3 program for dialysis dependent CKD patients may be insufficiently persuasive for the approval of the drug, or may raise safety concerns that may prevent approval of the drug, for the indication sought. The risk also remains that a
clinical program conducted by one of our partners may raise efficacy or safety concerns that may prevent approval of the drug. In addition, qualitative, quantitative and statistical interpretation of any of the prior pre-clinical and clinical safety
and efficacy data of our drug may be viewed as flawed by the EMA or any other regulatory agency. In addition, there can be no assurance that safety and/or efficacy concerns from the prior data were not overlooked or misinterpreted by us or our
consultants, which in subsequent, larger studies might appear and prevent approval of such drug candidate. In addition, top-line results reported on completed clinical trials, such as those from our long-term open label extension, or OLE, study for
Auryxia in dialysis-dependent CKD patients, are based on a preliminary analysis of then available data (both safety and efficacy) and there is the risk that such findings and conclusions could change following a more comprehensive review of the data
by a regulatory authority. For example, in January 2013, we announced successful top-line results from our long-term Phase 3 study of Auryxia for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with ESRD on
dialysis. Updated results from the study were presented in June 2013 at the World Congress of Nephrology. We can provide no assurance that our findings and conclusions from our long-term Phase 3 study of Auryxia or from our long-term OLE study for
Auryxia in dialysis-dependent CKD patients will not change following a more comprehensive review of the data by a regulatory authority.
33
Clinical trials have a high risk of failure. A number of companies in the pharmaceutical
industry, including biotechnology companies, have suffered significant setbacks in advanced clinical trials, even after achieving what appeared to be promising results in earlier trials. We experienced such a setback with our Phase 3 KRX-0401
(perifosine) results in April 2012, and we can provide no assurance that we will not experience such setbacks with Auryxia or any other drug candidate we develop. If we experience delays in the testing or approval process for our existing drug or if
we need to perform more or larger clinical trials than originally planned, our financial results and the commercial prospects for our drug may be materially impaired. In addition, we have limited experience in conducting and managing the clinical
trials necessary to obtain regulatory approval. Accordingly, we may encounter unforeseen problems and delays in the approval process. Although we engage, from time to time, clinical research organizations with experience in conducting regulatory
trials, errors in the conduct, monitoring, data capture and analysis, and/or auditing could potentially invalidate the results.
Because all of our
proprietary technologies are licensed or sublicensed to us by third parties, termination of these license rights would prevent us from developing and commercializing Auryxia.
We do not own our drug, Auryxia. We have licensed and sublicensed the rights, patent or otherwise, to Auryxia from a third party,
Panion & BF Biotech, Inc., or Panion, who in turn licenses certain rights to Auryxia from one of the inventors of Auryxia. The license agreement with Panion requires us to meet development milestones and imposes development and
commercialization due diligence requirements on us. In addition, under the agreement, we must pay royalties based on a mid-single digit percentage of net sales of product resulting from the licensed technologies (including Auryxia) and pay the
patent filing, prosecution and maintenance costs related to the license. If we do not meet our obligations in a timely manner or if we otherwise breach the terms of our license agreement (including upon certain insolvency events), Panion could
terminate the agreement, and we would lose the rights to Auryxia. In addition, if Panion breaches its agreement with the inventor from whom it licenses rights to Auryxia, Panion could lose its license, which could impair or delay our ability to
develop and commercialize Auryxia. From time to time, we may have disagreements with our licensors or collaborators, or they and/or we may have disagreements with the original inventors, regarding the terms of our agreements or ownership of
proprietary rights, which could lead to delays in the research, development and commercialization of our current drug and any future drug candidate, could require or result in litigation or arbitration, which would be time-consuming and expensive,
or could lead to the termination of a license, or force us to negotiate a revised or new license agreement on terms less favorable than the original. In addition, in the event that the owners and/or licensors of the rights we license were to enter
into bankruptcy or similar proceedings, we could potentially lose our rights to our drug or drug candidates or our rights could otherwise be adversely affected, which could prevent us from developing or commercializing our drugs. Finally, our rights
to develop and commercialize Auryxia, whether ourselves or with third parties, are subject to and limited by the terms and conditions of our licenses to Auryxia and the licenses and sublicenses we grant to others.
Our reliance on third parties, such as clinical research organizations, or CROs, may result in delays in completing, or a failure to complete, clinical
trials if such CROs fail to perform under our agreements with them.
In the course of product development, we engage CROs and other
vendors to conduct and manage clinical studies and to assist us in guiding our products through the FDA review and approval process. If the CROs or applicable vendors fail to perform their obligations under our agreements with them or fail to
perform clinical trials in a satisfactory or timely manner, we may face significant delays in completing our clinical trials, submitting our regulatory filings, or approval, as well as the commercialization of one or more drug candidates.
Furthermore, any loss or delay in obtaining contracts with such entities may also delay the completion of our clinical trials and the market approval of drug candidate(s).
Other risks related to our business
Any
acquisitions we make may require a significant amount of our available cash and may not be scientifically or commercially successful.
As part of our business strategy, we may effect acquisitions to obtain additional businesses, products, technologies, capabilities and
personnel. If we make one or more significant acquisitions in which the consideration includes cash, we may be required to use a substantial portion of our available cash.
34
Acquisitions involve a number of operational risks, including:
|
|
|
difficulty and expense of assimilating the operations, technology and personnel of the acquired business; |
|
|
|
our inability to retain the management, key personnel and other employees of the acquired business; |
|
|
|
our inability to maintain the acquired companys relationship with key third parties, such as alliance partners; |
|
|
|
exposure to legal claims for activities of the acquired business prior to the acquisition; |
|
|
|
the diversion of our managements attention from our core business; and |
|
|
|
the potential impairment of goodwill and write-off of in-process research and development costs, adversely affecting our reported results of operations. |
The status of reimbursement from third-party payors for newly approved health care drugs is uncertain and failure to obtain adequate reimbursement could
limit our ability to generate revenue.
Our ability to commercialize pharmaceutical products may depend, in part, on the extent to
which reimbursement for the products will be available from:
|
|
|
government and health administration authorities; |
|
|
|
private health insurers; |
|
|
|
managed care programs; and |
|
|
|
other third-party payors. |
Significant uncertainty exists as to the coverage and reimbursement
status of newly approved health care products, as well as the timing of coverage and reimbursement decisions by third-party payors. Third-party payors, including Medicare and Medicaid, are challenging the prices charged for medical products and
services. Government and other third-party payors increasingly are attempting to contain health care costs by limiting both coverage and the level of reimbursement for new drugs and by refusing, in some cases, to provide coverage for uses of
approved products for disease indications for which the FDA has not granted labeling approval. In 2003, Congress passed the Medicare Prescription Drug, Improvement and Modernization Act of 2003, which for the first time established prescription drug
coverage for Medicare beneficiaries, under Medicare Part D. Under this program, beneficiaries purchase insurance coverage from private insurance companies to cover the cost of their prescription drugs. However, third-party insurance coverage may not
be available to patients for our product. If government and other third-party payors do not provide adequate coverage and reimbursement levels for our product, its market acceptance may be significantly reduced.
Health care reform measures could adversely affect our business.
The business prospects and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and
third-party payors to contain or reduce the costs of health care. In the U.S. and in foreign jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals aimed at changing the health
care system, such as proposals relating to the pricing of healthcare products and services in the U.S. or internationally, the reimportation of drugs into the U.S. from other countries (where they are then sold at a lower price), and the amount of
reimbursement available from governmental agencies or other third party payors. For example, drug manufacturers are required to have a national rebate agreement with the Department of Health and Human Services, or HHS, in order to obtain state
Medicaid coverage, which requires manufacturers to pay a rebate on drugs dispensed to Medicaid patients. On January 27, 2012, the Centers for Medicare and Medicaid Services, or CMS, issued a proposed regulation covering the calculation of
Average Manufacturer Price, or AMP, which is the key variable in the calculation of these rebates.
Furthermore, in the U.S., health care
reform legislation titled the Patient Protection and Affordable Care Act, or PPACA, was signed into law in March 2010. The impact of this legislation on our business is inherently difficult to predict as many of the details regarding the
implementation of this legislation have not been determined. In a decision issued on June 29, 2012, the United States Supreme Court upheld the majority of PPACA. The Courts decision allows implementation of key provisions impacting drug
and device manufacturers to go forward. This includes PPACA changes to the Medicare Part D Program (including closing the donut hole), Medicaid Drug Rebate Program (including the definition of AMP), and expansion of the 340B Drug
Discount Program. The decision also allows the
35
FDA and CMS to continue with implementation efforts, including related to the Biologics Price Competition and Innovation Act and the Physician Payments Sunshine Act, both of which were enacted as
part of the PPACA. Regulations to implement PPACA could result in a decrease in our stock price or limit our ability to raise capital or to obtain strategic partnerships or licenses. Government-financed comparative efficacy research could also
result in new practice guidelines, labeling or reimbursement policies that discourages use of our product.
For example, in July 2010, CMS
released its final rule to implement a bundled prospective payment system for end-stage renal disease facilities as required by the Medicare Improvements for Patients and Providers Act, or MIPPA. The final rule delayed the inclusion of oral
medications without intravenous equivalents, such as phosphate binders, in the bundle until January 1, 2014; however, on January 3, 2013, the United States Congress passed legislation known as the American Taxpayer Relief Act of 2012,
which, among other things, delayed by two years the implementation of oral-only end-stage renal disease related drugs, including phosphate binders, in the bundled ESRD prospective payment system, until January 1, 2016. In April 2014, the United
States Congress passed legislation known as Protecting Access to Medicare Act of 2014, which, among other things, delays by eight years the implementation of oral-only ESRD related drugs, including phosphate binders, in the bundled ESRD prospective
payment system, until January 1, 2025. If phosphate binders are included in the bundle beginning in 2025, or earlier, separate Medicare reimbursement will no longer be available for phosphate binders, as it is today under Medicare Part D. While
it is too early to project the impact bundling may have on the phosphate binder industry, the impact could potentially cause dramatic price reductions for phosphate binders, which could significantly reduce the commercial potential of Auryxia.
On September 27, 2007, the Food and Drug Administration Amendments Act of 2007 was enacted, giving the FDA enhanced post-market
authority, including the authority to require post-marketing studies and post-marketing clinical trials related to serious risks, labeling changes based on new safety information, and compliance with risk evaluation and mitigation strategies
approved by the FDA. The FDAs exercise of this authority may result in delays or increased costs during the period of product development, clinical trials and regulatory review and approval, which may also increase costs related to complying
with new post-approval regulatory requirements, and increase potential FDA restrictions on the sale or distribution of approved products. On July 9, 2012, the Food and Drug Administration Safety and Innovation Act was enacted to, among other
things, renew the drug user fee program, expand the FDAs inspection records access and require manufacturers to establish appropriate oversight and controls over their suppliers and the supply chain, including raw material suppliers and
contract manufacturers, as a part of cGMP compliance. On November 27, 2013, the Drug Quality and Security Act, which includes the Drug Supply Chain Security Act, was signed into law to, among other things, build an electronic, interoperable
system to identify and trace certain prescription drugs as they are distributed in the United States. Requirements for the tracing of products through the pharmaceutical distribution supply chain took effect on January 1, 2015 for manufacturers
and building internal systems to ensure compliance with this law will require dedication of resources. In addition, this law requires engaging in transactions only with authorized trading partners and could limit our pool of available trading
partners.
We face product liability risks and may not be able to obtain adequate insurance.
The use of our drug or future drug candidates in clinical trials, and the future sale of any approved drug and new technology, exposes us to
liability claims. Although we are not aware of any historical or anticipated product liability claims against us, if we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to
cease clinical trials of our drug product or limit commercialization of any approved product.
We have expanded our insurance coverage to
include the commercial sale of Auryxia; however, insurance coverage is becoming increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost. We also may not be able to obtain additional insurance coverage that will
be adequate to cover product liability risks that may arise. Regardless of merit or eventual outcome, product liability claims may result in:
|
|
|
decreased demand for a product; |
|
|
|
injury to our reputation; |
|
|
|
our inability to continue to develop a drug candidate; |
|
|
|
withdrawal of clinical trial volunteers; and |
Consequently, a product liability claim or product recall may result in
losses that could be material to our business.
36
Security breaches and other disruptions could compromise our information and expose us to liability, which
would cause our business and reputation to suffer.
In the ordinary course of our business, we collect and store sensitive data,
including intellectual property, our proprietary business information and that of our suppliers and business partners, as well as personally identifiable information of Auryxia patients, clinical trial participants and employees. We also have
outsourced elements of our information technology structure, and as a result, we are managing independent vendor relationships with third parties who may or could have access to our confidential information. Similarly, our business partners and
other third party providers possess certain of our sensitive data. The secure maintenance of this information is critical to our operations and business strategy. Despite our security measures, our information technology and infrastructure may be
vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. We, our partners, vendors and other third party providers could be susceptible to third party attacks on our, and their, information security
systems, which attacks are of ever increasing levels of sophistication and are made by groups and individuals with a wide range of motives and expertise, including criminal groups. Any such breach could compromise our, and their, networks and the
information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal
information, disrupt our operations, and damage our reputation, any of which could adversely affect our business.
Risks related to our financial
condition
Our existing capital resources may not be adequate to finance our operating cash requirements for the length of time that we have
estimated.
We currently expect that our existing capital resources combined with future anticipated cash flows will be sufficient
to execute our business plan. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing and expenditures associated with commercial activities related to Auryxia and the magnitude of
cash received from product sales, the timing and expenditures associated with the build-up of inventory and capacity expansion, the timing and expenditures associated with the regulatory review process for our EU MAA filing, and the timing, design
and conduct of clinical trials for Auryxia. As a result of these factors, we may need to seek additional financings to provide the cash necessary to execute our current operations, including beyond the initial commercialization of Auryxia, and to
develop any drug candidates we may in-license or acquire.
Our forecast of the period of time through which our existing capital resources
will be adequate to support our current operations is a forward-looking statement that involves risks and uncertainties. The actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control. These
factors include, but are not limited to, the following:
|
|
|
the timing and expenditures associated with commercial activities related to Auryxia and the magnitude of cash received from product sales; |
|
|
|
the timing and expenditures associated with the build-up of inventory and capacity expansion; |
|
|
|
the timing and expenditures associated with the regulatory review process for our EU MAA filing; |
|
|
|
the timing, design and conduct of, and results from, clinical trials for Auryxia; |
|
|
|
the timing of expenses associated with manufacturing and product development of Auryxia and those proprietary drug candidates that may be in-licensed, partnered or acquired; |
|
|
|
the timing of the in-licensing, partnering and acquisition of new product opportunities; |
|
|
|
the progress of the development efforts of parties with whom we have entered, or may enter, into research and development agreements; |
|
|
|
our ability to achieve our milestones under our licensing arrangement; |
|
|
|
the timing and expenses associated with capital expenditures to expand our manufacturing capabilities; |
|
|
|
the timing and expenses associated with building our own commercial infrastructure to manufacture, market and sell our drug and those that may be in-licensed, partnered or acquired; and |
|
|
|
the costs involved in prosecuting and enforcing patent claims and other intellectual property rights or defending against claims of infringement initiated by third parties in respect of their intellectual property
rights. |
37
If our cash is insufficient to meet future operating requirements, we will have to raise
additional funds. If we are unable to obtain additional funds on terms favorable to us or at all, we may be required to cease or reduce our operating activities or sell or license to third parties some or all of our intellectual property. If we
raise additional funds by selling additional shares of our capital stock, the ownership interests of our stockholders will be diluted. If we need to raise additional funds through the sale or license of our intellectual property, we may be unable to
do so on terms favorable to us, if at all.
Risks related to our intellectual property and third-party contracts
If we are unable to adequately protect our intellectual property, third parties may be able to use our intellectual property, which could adversely
affect our ability to compete in the market.
Our commercial success will depend in part on our ability, and the ability of our
licensors, to obtain and maintain patent protection on our drug product and technologies, and to successfully defend these patents against third-party challenges. The patent positions of pharmaceutical and biotechnology companies can be highly
uncertain and involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. Accordingly, the patents we use may not be sufficiently broad to prevent others
from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative drug products or technologies or design around our patented drug product and technologies which may have an
adverse effect on our business. If our competitors prepare and file patent applications in the U.S. that claim technology also claimed by us, we may have to participate in interference or derivation proceedings in front of the U.S. Patent and
Trademark Office to determine priority of invention, which could result in substantial cost, even if the eventual outcome is favorable to us. Because of the extensive time required for development, testing and regulatory review of a potential
product, it is possible that any related patent may expire prior to, or remain in existence for only a short period following, commercialization, thus reducing any advantage of the patent. The patents we use may be challenged or invalidated or may
fail to provide us with any competitive advantage. As many of the patents we use are licensed or sublicensed from third parties, we may not be able to enforce such licensed patents against third party infringers without the cooperation of the patent
owner and the licensor, which may not be forthcoming. In addition, we may not be successful or timely in obtaining any patents for which we submit applications.
Additionally, the laws of foreign countries may not protect our intellectual property rights to the same extent as do the laws of the U.S. In
addition, in jurisdictions outside the U.S. where we own or license patent rights, we may be unable to prevent unlicensed parties from selling or importing products or technologies derived elsewhere using our proprietary technology.
We also rely on trade secrets and know-how to protect our intellectual property where we believe patent protection is not appropriate or
obtainable. Trade secrets are difficult to protect. While we require our employees, licensees, collaborators and consultants to enter into confidentiality agreements, this may not be sufficient to adequately protect our trade secrets or other
proprietary information. In addition, we share ownership and publication rights to data relating to our drug product and technologies with our research collaborators and scientific advisors. If we cannot maintain the confidentiality of this
information, our ability to receive patent protection or protect our trade secrets or other proprietary information will be at risk.
The
intellectual property that we own or have licensed relating to our drug, Auryxia, is limited, which could adversely affect our ability to compete in the market and adversely affect the value of Auryxia.
38
The patent rights that we own or have licensed relating to Auryxia are limited in ways that may
affect our ability to exclude third parties from competing against us. In particular:
|
|
|
Composition of matter patents can provide protection for pharmaceutical products to the extent that the specifically covered compositions are key, non-interchangeable components of the pharmaceutical product. The first
composition of matter and method patent relating to Auryxia in the United States (U.S. Patent No. 5,753,706) expires in February 2017. We licensed additional composition of matter and method of use patents expiring in 2024 with independent
claims covering forms of ferric citrate (the active pharmaceutical ingredient, or API, of Auryxia), pharmaceutical compositions that include the API, pharmaceutical compositions having ferric citrate in an amount effective to reduce serum phosphate
levels, and methods of treating hyperphosphatemia and metabolic acidosis. |
|
|
|
Our method of use patents, including U.S. Patent Nos. 7,767,851, 8,299,298 and 8,338,642 and (which expire in 2024), and U.S. Patent No. 8,093,423 (which expires in 2026) only protect the product when used or sold
for the claimed methods. However, these types of patents do not limit a competitor from making and marketing a product that is identical to our product that is labeled for an indication that is outside of our patented methods. |
|
|
|
We have filed applications under the Patent Term Extension provisions of 35 U.S.C. § 156 on the above mentioned patents for delays caused by FDA regulatory review. If granted we can utilize the patent term
extension on one of these patents, however, we cannot assure you that we can obtain any extension of the term of these patents. If obtained, the maximum term of extension available under 35 U.S.C. § 156 would extend the term of the chosen
patent by no more than five years. Upon expiration of these patents, competitors who obtain the requisite regulatory approval may potentially offer products with the same composition and/or method of use as our product, so long as the competitors do
not infringe any other patents that we may hold. |
|
|
|
Our pending patent applications may not issue as patents and may not issue in all countries in which we develop, manufacture or potentially sell our product(s) or in countries where others develop, manufacture and
potentially sell products using our technologies. Moreover, our pending patent applications, if issued as patents, may not provide additional protection for our product. |
Obtaining proof of direct infringement by a competitor for a method of use patent requires us to demonstrate that the competitors make and
market a product for the patented use(s). Alternatively we can prove that our competitors induce or contribute others in engaging in direct infringement. Proving that a competitor contributes to, or induces, infringement of a patented method by
another has additional proof requirements. For example, proving inducement of infringement requires proof of intent by the competitor. If we are required to defend ourselves against claims or to protect our own proprietary rights against others, it
could result in substantial costs to us and the distraction of our management. An adverse ruling in any litigation or administrative proceeding could prevent us from marketing and selling Auryxia, increase the risk that a generic version of Auryxia
could enter the market to compete with Auryxia, limit our development and commercialization of Auryxia, or otherwise harm our competitive position and result in additional significant costs. In addition, any successful claim of infringement asserted
against us could subject us to monetary damages or injunction, which could prevent us from making or selling Auryxia. We also may be required to obtain licenses to use the relevant technology. Such licenses may not be available on commercially
reasonable terms, if at all.
Moreover, physicians may prescribe a competitive identical product for indications other than the one for
which the product has been approved, or off-label indications, that are covered by the applicable patents. Although such off-label prescriptions may directly infringe or contribute to or induce infringement of method of use patents, such
infringement is difficult to prevent.
In addition, any limitations of our patent protection described above may adversely affect the
value of our drug product and may inhibit our ability to obtain a corporate partner at terms acceptable to us, if at all.
In addition to
patent protection, we may utilize, if granted by the FDA, pediatric exclusivity or other provisions of the Food, Drug and Cosmetic Act of 1938, as amended, or FDCA, such as new chemical entity exclusivity, or NCE, or new formulation exclusivity, to
provide market exclusivity for a drug candidate.
In the U.S., the FDA has the authority to grant additional data protection for approved
drugs where the sponsor conducts specified testing in pediatric or adolescent populations. If granted, this pediatric exclusivity may provide an additional six months which are added to the term of data protection as well as to the term of a
relevant patent, to the extent these protections have not already expired.
39
The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the
first applicant to gain approval of an NDA for a New Chemical Entity, or NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which consists of the molecule(s) or ion(s) responsible for
the action of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of
reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an
NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application (for
example, for new indications, dosages, or strengths of an existing drug). This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing
the original active agent. Five-year and three-year exclusivity will not delay the submission or tentative approval of a full ANDA; however, an applicant submitting a full ANDA would be required to conduct sufficient studies to demonstrate that
their generic product is bioequivalent to Auryxia.
We may also seek to utilize market exclusivities in other territories, such as in the
EU.
We cannot assure that Auryxia or any drug candidates we may acquire or in-license, will obtain such pediatric exclusivity, NCE
exclusivity or any other market exclusivity in the U.S., EU or any other territory, or that we will be the first to receive the respective regulatory approval for such drugs so as to be eligible for any market exclusivity protection. We also cannot
assure that Auryxia or any drug candidates we may acquire or in-license will obtain patent term extension.
Litigation or third-party claims could
require us to spend substantial time and money defending such claims and adversely affect our ability to develop and commercialize our product.
We may be forced to initiate litigation to enforce our contractual and intellectual property rights, or we may be sued by third parties
asserting claims based on contract, tort or intellectual property infringement. In addition, third parties may have or may obtain patents in the future and claim that Auryxia or any other technologies infringe their patents. If we are required to
defend against suits brought by third parties, or if we sue third parties to protect our rights, we may be required to pay substantial litigation costs, and our managements attention may be diverted from operating our business. In addition,
any legal action against our licensor or us that seeks damages or an injunction of our commercial activities relating to Auryxia or other technologies could subject us to monetary liability, a temporary or permanent injunction preventing the
development, marketing and sale of Auryxia or such technologies, and/or require our licensor or us to obtain a license to continue to use Auryxia or other technologies. We cannot predict whether our licensor or we would prevail in any of these types
of actions or that any required license would be made available on commercially acceptable terms, if at all.
Risks Related to Our Common Stock
Future sales or other issuances of our common stock could depress the market for our common stock.
Sales of a substantial number of shares of our common stock, or the perception by the market that those sales could occur, could cause the
market price of our common stock to decline or could make it more difficult for us to raise funds through the sale of equity in the future.
On January 21, 2015, we announced the pricing of an underwritten public offering in which we sold 10,541,667 shares of our common stock
at a price of $12.00 per share for gross proceeds of approximately $126.5 million. Net proceeds from this offering were approximately $118.3 million, net of underwriting discounts and offering expenses of approximately $8.2 million. The shares were
sold under Registration Statements (Nos. 333-201605 and 333-201639) on Form S-3 and Form S-3MEF, respectively, filed by us with the Securities and Exchange Commission.
We may need to seek additional financing to provide cash necessary to execute our current operations, including beyond the initial
commercialization of Auryxia, and to develop any drug candidates we may in-license or acquire. Future issuances of common stock could depress the market for our common stock.
40
If we make one or more significant acquisitions in which the consideration includes stock or
other securities, our stockholders holdings may be significantly diluted. In addition, stockholders holdings may also be diluted if we enter into arrangements with third parties permitting us to issue shares of common stock in lieu of
certain cash payments upon the achievement of milestones.
Our stock price can be volatile, which increases the risk of litigation, and may result
in a significant decline in the value of your investment.
The trading price of our common stock is likely to be highly volatile
and subject to wide fluctuations in price in response to various factors, many of which are beyond our control. These factors include:
|
|
|
announcements of technological innovations by us or our competitors; |
|
|
|
introductions or announcements of new products by us or our competitors; |
|
|
|
announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments involving us or our competitors; |
|
|
|
changes in financial estimates by securities analysts; |
|
|
|
actual or anticipated variations in quarterly or annual operating results; |
|
|
|
developments relating to the marketing, safety and efficacy of our drug product, and regulatory filings and approvals for us or our competitors; |
|
|
|
expectations regarding our financial condition; |
|
|
|
expiration or termination of licenses, research contracts or other collaboration agreements; |
|
|
|
expectations or investor speculation regarding the strength of our intellectual property position, or the availability of other forms of regulatory exclusivity; |
|
|
|
conditions or trends in the regulatory climate and the biotechnology and pharmaceutical industries; |
|
|
|
changes in the market valuations of similar companies; |
|
|
|
negative comments and sentiment in the media; and |
|
|
|
additions or departures of key personnel. |
In addition, equity markets in general, and the
market for biotechnology and life sciences companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies traded in those markets. These
broad market and industry factors may materially affect the market price of our common stock, regardless of our development and operating performance. In the past, following periods of volatility in the market price of a companys securities,
securities class-action litigation has often been instituted against that company. For example, in the past, we have been the subject of a putative stockholders securities class action alleging misstatements or omissions in relation to our clinical
trials for KRX-0401 (perifosine), which we abandoned in May 2012 following negative Phase 3 results. Any litigation instituted against us could cause us to incur substantial costs to defend such claims and divert managements attention and
resources, which could seriously harm our business.
Certain anti-takeover provisions in our charter documents and Delaware law could make a
third-party acquisition of us difficult. This could limit the price investors might be willing to pay in the future for our common stock.
Provisions in our amended and restated certificate of incorporation and bylaws could have the effect of making it more difficult for a third
party to acquire, or of discouraging a third party from attempting to acquire, or control us. These factors could limit the price that certain investors might be willing to pay in the future for shares of our common stock. Our amended and restated
certificate of incorporation allows us to issue preferred stock without the approval of our stockholders. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock
or could adversely affect the rights and powers, including voting rights, of such holders. In certain circumstances, such issuance could have the effect of decreasing the market price of our common stock. Our amended and restated bylaws eliminate
the right of stockholders to call a special meeting of stockholders, which could make it more difficult for stockholders to effect certain corporate actions. Any of these provisions could also have the effect of delaying or preventing a change in
control.
41
ITEM 6. EXHIBITS
The exhibits listed on the Exhibit Index are included with this report.
|
|
|
|
|
3.1 |
|
Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc., as amended, filed as Exhibit 3.1 to the Registrants Annual Report on Form 10-Q for the quarter ended September 30, 2004, filed on
August 12, 2004, and incorporated herein by reference. |
|
|
3.2 |
|
Amended and Restated Bylaws of Keryx Biopharmaceuticals, Inc., filed as Exhibit 3.2 to the Registrants Annual Report on Form 10-K for the year ended December 31, 2001, filed on March 26, 2002, and incorporated herein by
reference. |
|
|
3.3 |
|
Amendment Number 2 to Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc., dated July 24, 2007, filed as Exhibit 3.3 to the Registrants Quarterly Report on Form 10-Q for the quarter ended
September 30, 2007, filed on August 9, 2007 and incorporated herein by reference. |
|
|
3.4 |
|
Amendment Number 3 to Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc. dated June 18, 2013, filed as Exhibit 3.4 to the Registrants Quarterly Report on Form 10-Q for the quarter ended June
30, 2013, filed on August 2, 2013 and incorporated herein by reference. |
|
|
10.1! |
|
Employment Agreement with Gregory P. Madison dated March 10, 2015. |
|
|
10.2 |
|
Employment Agreement with Brian Adams dated April 8, 2014. |
|
|
10.3 |
|
Employment Agreement with John F. Neylan, M.D. dated April 22, 2015. |
|
|
10.4 |
|
Third Amendment to Employment Agreement with Ron Bentsur dated April 30, 2015. |
|
|
31.1 |
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 4, 2015. |
|
|
31.2 |
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 4, 2015. |
|
|
32.1 |
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated May 4, 2015. |
|
|
32.2 |
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated May 4, 2015. |
|
|
101 |
|
Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Stockholders Equity, (iv) Consolidated
Statements of Cash Flows, and (v) the Notes to Consolidated Financial Statements. |
|
Indicates management contract or compensatory plan or arrangement. |
! |
Confidential treatment has been granted with respect to the omitted portions of this exhibit. |
42
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
KERYX BIOPHARMACEUTICALS, INC. |
|
|
|
|
Date: May 4, 2015 |
|
|
|
By: |
|
/s/ James F. Oliviero, CFA |
|
|
|
|
|
|
Chief Financial Officer |
|
|
|
|
|
|
Principal Financial and Accounting Officer |
43
EXHIBIT INDEX
The following exhibits are included as part of this Quarterly Report on Form 10-Q:
|
|
|
|
|
10.1! |
|
Employment Agreement with Gregory P. Madison dated March 10, 2015. |
|
|
10.2 |
|
Employment Agreement with Brian Adams dated April 8, 2014. |
|
|
10.3 |
|
Employment Agreement with John F. Neylan, M.D. dated April 22, 2015. |
|
|
10.4 |
|
Third Amendment to Employment Agreement with Ron Bentsur dated April 30, 2015. |
|
|
31.1 |
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 4, 2015. |
|
|
31.2 |
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 4, 2015. |
|
|
32.1 |
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated May 4, 2015. |
|
|
32.2 |
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated May 4, 2015. |
|
|
101 |
|
Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Stockholders Equity, (iv) Consolidated
Statements of Cash Flows, and (v) the Notes to Consolidated Financial Statements. |
|
Indicates management contract or compensatory plan or arrangement. |
! |
Confidential treatment has been granted with respect to the omitted portions of this exhibit. |
44
Exhibit No. 10.1
CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of this document have been redacted and have been separately filed with the Commission.
EMPLOYMENT AGREEMENT
BETWEEN
GREGORY P.
MADISON
AND
KERYX BIOPHARMACEUTICALS, INC.
EMPLOYMENT AGREEMENT
TABLE OF CONTENTS
|
|
|
|
|
|
|
1. |
|
Effective Date |
|
|
1 |
|
|
|
|
2. |
|
Employment |
|
|
1 |
|
|
|
|
3. |
|
Employment Period |
|
|
1 |
|
|
|
|
4. |
|
Extent of Service |
|
|
2 |
|
|
|
|
5. |
|
Compensation and Benefits |
|
|
2 |
|
|
|
|
6. |
|
Termination of Employment |
|
|
4 |
|
|
|
|
7. |
|
Obligations of the Company upon Termination |
|
|
7 |
|
|
|
|
8. |
|
Change in Control |
|
|
10 |
|
|
|
|
9. |
|
Non-exclusivity of Rights |
|
|
12 |
|
|
|
|
10. |
|
No Mitigation |
|
|
12 |
|
|
|
|
11. |
|
Mandatory Reduction of Payments in Certain Events |
|
|
12 |
|
|
|
|
12. |
|
Restrictions on Conduct of Executive |
|
|
13 |
|
|
|
|
13. |
|
Invention Assignment |
|
|
17 |
|
|
|
|
14. |
|
Return of Materials |
|
|
17 |
|
|
|
|
15. |
|
Successors and Assigns |
|
|
17 |
|
|
|
|
16. |
|
Cooperation |
|
|
17 |
|
|
|
|
17. |
|
Code Section 409A |
|
|
18 |
|
|
|
|
18. |
|
Miscellaneous |
|
|
19 |
|
i
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this Agreement) is made and entered into this 10th day of March, 2015 by and between Keryx
Biopharmaceuticals, Inc., a Delaware corporation (the Company), and Gregory P. Madison (Executive), to be effective as of the Effective Date, as defined in Section 1.
BACKGROUND
WHEREAS, the
Company currently employs Executive as its President and Chief Operating Officer; and
WHEREAS, the Company desires to engage Executive as
President and Chief Executive Officer of the Company in accordance with the terms of this Agreement. Executive is willing to serve as such in accordance with the terms and conditions of this Agreement.
NOW THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Effective
Date. The effective date of this Agreement (the Effective Date) shall be the date first written above.
2.
Employment.
(a) Executive shall be employed as the President and Chief Executive Officer of the Company commencing by no later than
May 20, 2015 (for purposes of this Agreement, the date on which Executive actually is appointed Chief Executive Officer shall be the Start Date). In his capacity as President and Chief Executive Officer, Executive shall have the
duties, responsibilities and authority commensurate with such position and as are typically performed by a President and Chief Executive Officer of a corporation, together with such additional duties, commensurate with Executives position as
President and Chief Executive Officer of the Company that may be assigned to Executive from time to time by the Board of Directors of the Company (the Board). In his capacity as President and Chief Executive Officer, Executive shall
report directly to the Board. The principal location of Executives employment shall be at the Companys offices in Boston, Massachusetts. The Executive understands and agrees that he may be required to travel from time to time for
business reasons, including travel to/from the Companys offices in New York, New York.
3. Employment Period. Unless earlier
terminated herein in accordance with Section 6 hereof, Executives employment shall be for a term beginning on the Start Date and ending on March 9, 2018. The initial and any renewal period during which Executive is employed pursuant
to this Agreement shall be referred to as the Employment Period. The Employment Period shall be automatically renewed for consecutive periods of one (1) year unless either party provides at least sixty (60) days advance
written notice, consistent with Section 18(d) of this Agreement, of its intent not to renew the employment relationship as of the end of the initial or any renewal period. In the case of any such renewal and extension of the Employment Period,
the terms and conditions of this Agreement shall continue to govern unless otherwise agreed to in writing by the parties.
4. Extent of Service. During the Employment Period, Executive agrees to devote his full
business time, attention, energy and best efforts to the business and affairs of the Company and to use Executives reasonable best efforts to perform faithfully and efficiently the responsibilities assigned to Executive hereunder. During the
Employment Period, it shall not be a violation of this Agreement for Executive to (A) manage personal investments, or (B) devote time to charitable and community activities or, with the approval of the Board, industry or professional
activities including service on the board of directors of another corporation, so long as such activities do not interfere or conflict with the performance of Executives responsibilities as an employee of the Company in accordance with this
Agreement.
5. Compensation and Benefits.
(a) Base Salary. Beginning on the Effective Date and during the Employment Period, the Company shall pay to Executive a base salary at
the rate of five hundred twenty five thousand dollars (U.S. $525,000) per year (Base Salary), less normal withholdings, payable in approximately equal bi-weekly or other installments as are or become customary under the Companys
payroll practices for its employees from time to time. On the first regularly scheduled pay date following the Effective Date, the Company shall pay Executive an amount equal to the difference between: (i) the salary paid to Executive between
January 11, 2015 and the Effective Date, and (ii) the Base Salary that would have been paid to Executive between January 11, 2015 and the Effective Date had Executive been earning the Base Salary, subject to normal withholdings and
the related terms described herein. The Compensation Committee of the Board shall review Executives Base Salary annually and, in its sole discretion, may increase Executives Base Salary from year to year. Such adjusted salary then shall
become Executives Base Salary for purposes of this Agreement. In no event shall Executives Base Salary be reduced during the Employment Period unless such reduction is in connection with a proportionate reduction of compensation
applicable to all other executive officers. The annual review of Executives Base Salary by the Board shall consider, among other things, Executives own performance and the Companys performance.
(b) Incentive, Savings and Retirement Plans. During the Employment Period, Executive shall be entitled to participate in all incentive,
savings and retirement plans, practices, policies and programs available to other senior executive officers of the Company (Peer Executives), and on the same basis as such Peer Executives. Without limiting the foregoing, the following
shall apply:
(i) Annual Performance Bonus. For each year during the Employment Period, Executive shall be eligible to receive an
annual performance bonus of up to sixty percent (60%) of his Base Salary (such 60 percent target referred to herein as the Target Annual Bonus, and the actual annual bonus paid referred to herein as the Annual Bonus).
The Compensation Committee, in its sole discretion, shall establish performance goals and objectives from year to year on which the Annual Bonus shall be based, and the Compensation Committee likewise reserves the sole discretion to modify such
goals and objectives, or the final amount of the Annual Bonus, based upon events occurring during the related year or its
2
assessment of the Companys or Executives performance in general. The Compensation Committee shall provide Executive with such goals and objectives and any modifications it may make.
Unless otherwise provided herein, no Annual Bonus shall be deemed to have been earned by Executive for any year in which Executive is not actively employed by the Company on the last day of the fiscal year to which the bonus relates. The Company
shall pay the Annual Bonus no later than two and a half months after the end of the fiscal year to which the applicable bonus relates.
(ii) Equity Grants. Subject to the approval of the Compensation Committee, on the Start Date the Company shall grant to Executive five
hundred fifty thousand (550,000) shares of restricted common stock under the Companys 2013 Incentive Plan (the Plan), subject to the lapsing forfeiture rights set forth below and the terms and conditions of the Companys
standard restricted stock agreement (the Restricted Stock Agreement):
1. Two hundred seventy five thousand
(275,000) shares of restricted stock shall vest and become non-forfeitable if Auryxia is number 1 in market share for the phosphate binder in dialysis market for two (2) consecutive calendar quarters between the Start Date and *, with such market share standing to be determined by exclusive reference to the Companys consolidated market share data which includes physician-level script numbers from IMS National
Prescription Audit Data, DaVita Rx and Fresenius Rx (the Market Share Milestone), provided that Executive is providing services to the Company as an employee or consultant on the date the Market Share Milestone is achieved,
subject to any acceleration upon certain events as may be set forth in the Plan, the Restricted Stock Agreement, or Section 7 below.
2. Twenty five thousand (25,000) shares of restricted stock shall vest and become non-forfeitable if the Company exceeds
$* in net sales for calendar year 2015 (the 2015 Net Sales Milestone), provided that Executive is providing services to the Company as an employee or consultant on the date the 2015 Net Sales Milestone is achieved, subject to any
acceleration upon certain events as may be set forth in the Plan, the Restricted Stock Agreement, or Section 7 below.
3. One hundred twenty five thousand (125,000) shares of restricted stock shall vest and become non-forfeitable if the
Company exceeds $* in net sales for calendar year 2016 (the 2016 Net Sales Milestone), provided that Executive is providing services to the Company as an employee or consultant on the date the 2016 Net Sales Milestone is achieved,
subject to any acceleration upon certain events as may be set forth in the Plan, the Restricted Stock Agreement, or Section 7 below.
4. One hundred twenty five thousand (125,000) shares of restricted stock shall vest and become non-forfeitable upon the
FDA approval of Auryxia (or, if applicable, an approved trade name utilized for Ferric Citrate related to the below-described trial) in the treatment of iron deficiency anemia in patients with
* |
Confidential material redacted and filed separately with the Commission. |
3
stages 3 5 non-dialysis dependent CKD resulting from the phase 3 clinical study initiated in September 2014 (the Approval Milestone), provided that Executive is
providing services to the Company as an employee or consultant on the date the Approval Milestone is achieved, and subject to any acceleration upon certain events as may be set forth in the Plan, the Restricted Stock Agreement, or Section 7
below.
The above-referenced milestones shall be referred to collectively as the Performance Milestones. The determination of
whether any Performance Milestone has been achieved (and whether the lapsing forfeiture right applicable to the restricted stock subject to such Performance Milestone shall lapse) shall be made by the Compensation Committee in its sole discretion,
upon written certification. Should any Performance Milestone remain unmet as of the end of the last day of the time period in which such Performance Milestone must be achieved, then the restricted stock subject to such Performance Milestone shall be
forfeited to the Company without consideration. The parties acknowledge and agree that the above-described grants of restricted stock are in addition to, and not in lieu of, the Companys prior equity grants to Executive, which grants shall
remain subject to their respective applicable governing plan document(s) and equity agreement(s).
During the Employment Period, Executive
may be eligible for additional stock-based awards under the Companys long-term incentive plans, as determined by the Compensation Committee from time to time. Nothing herein requires the Board or the Compensation Committee to make additional
equity grants in any year.
(c) Welfare Benefit Plans. During the Employment Period, Executive and Executives eligible
dependents shall be eligible for participation in, and shall receive all benefits under, the welfare benefit plans, practices, policies and programs provided by the Company (including, without limitation, medical, prescription drug, dental,
disability, and employee life insurance plans and programs) (Welfare Plans) to the extent available to other Peer Executives.
(d) Expenses. During the Employment Period, Executive shall be entitled to receive prompt reimbursement for all reasonable expenses
incurred by Executive in the course of performing his duties and responsibilities under this Agreement, including without limitation reasonable expenses relating to Executives travel to/from the Companys offices in New York, New York on
an as-needed basis, in accordance with the policies, practices and procedures of the Company with respect to travel, entertainment and other business expenses.
(e) Vacation. During the Employment Period, Executive shall be entitled to four (4) weeks of paid vacation per calendar year,
otherwise subject to and in accordance with the Companys vacation and paid time off policies.
6. Termination of Employment.
(a) Death. Executives employment shall terminate automatically upon Executives death during the Employment Period.
4
(b) Disability. If the Company determines in good faith that Executive has become Disabled
(as defined below) during the Employment Period, it may give to Executive written notice of its intention to terminate Executives employment. In such event, Executives employment with the Company shall terminate effective on the 30th day
after receipt of such written notice by Executive (the Disability Effective Date), provided that, within the 30 days after such receipt, Executive shall not have returned to full-time performance of Executives duties. For
purposes of this Agreement, Executive shall be Disabled if either of the following conditions is met, as determined by the Board in good faith:
(i) Executive is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment
that can be expected to result in death or can be expected to last for one or more periods totaling one hundred and twenty (120) days in any twelve (12) month period; or
(ii) Executive is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be
expected to last for one or more periods totaling one hundred and twenty (120) days in any twelve (12) month period, receiving income replacement benefits for a period of not less than three months under an accident and health plan
covering employees of the Company.
(c) Termination by the Company. The Company may terminate Executives employment during the
Employment Period with or without Cause. For purposes of this Agreement, a termination shall be considered to be for Cause if it occurs in conjunction with a determination by the Board that any of the following has occurred:
(i) Executives conviction of, pleading guilty to, or confession to a felony or any crime involving any act of dishonesty, fraud,
misappropriation or embezzlement;
(ii) Executives misconduct or gross negligence in connection with the performance of his duties
hereunder, including a violation of the Companys written policies or Code of Conduct and Ethics;
(iii) Executives engaging in
any fraudulent, disloyal or unprofessional conduct which is, or is likely to be, injurious to the Company, its financial condition, or its reputation;
(iv) Executives failure to perform his duties with the Company (other than any such failure resulting from Executives Disability);
(v) Executives failure to meet performance standards which may be agreed upon by Executive and the Company in writing from time to
time (with the understanding that failure to meet the performance criteria established with respect to an Annual Bonus alone shall not constitute Cause for purposes of this Agreement); or
(vi) Executives breach of the covenants set forth in Section 12 of this Agreement, or material breach of any other provisions of
this Agreement.
5
If the Company determines that it has grounds to terminate Executives employment for Cause
pursuant to the provisions of clauses (iv), (v), or (vi) of this subsection (c), then it shall first deliver to Executive a written notice setting forth with specificity the occurrence deemed to give rise to a right to terminate his employment
for Cause, and Executive shall have 30 days after the receipt of such written notice to cease such actions or otherwise correct any such failure or breach. If Executive does not cease such actions or otherwise correct such failure or breach within
such 30-day period, or having once received such written notice and ceased such actions or corrected such failure or breach, Executive at any time thereafter again so acts, fails, or breaches, the Company may terminate his employment for Cause
immediately. The Company may terminate Executives employment without Cause, or for Cause pursuant to the provisions of clauses (i), (ii), or (iii) of this subsection (c), immediately.
(d) Termination by Executive. Executives employment may be terminated by Executive with or without Good Reason. Executives
termination without Good Reason shall require 30 days prior written notice to the Company. Executives termination for Good Reason must occur within a period of 90 days after the occurrence of an event of Good Reason. For purposes of this
Agreement, Good Reason shall mean any of the following, without Executives consent:
(i) a material diminution in
Executives Base Salary, which for purposes of this Agreement shall mean a reduction of more than 15% in the aggregate;
(ii) a
material diminution in Executives title, position, authority, duties, or responsibilities;
(iii) a material change in the
geographic location of Executives principal place of business, which for purposes of this Agreement shall mean a location more than 35 miles from the Companys offices in Boston, Massachusetts at which Executive was principally employed
except for required travel on the Companys business; or
(iv) any other action or inaction that constitutes a material breach by the
Company of this Agreement.
A termination by Executive shall not constitute termination for Good Reason unless Executive shall first have
delivered to the Company a written notice setting forth with specificity the occurrence deemed to give rise to a right to terminate for Good Reason (which notice must be given no later than 60 days after the initial occurrence of such event), and
there shall have passed a reasonable time (not less than 30 days) within which the Company may take action to correct, rescind or otherwise substantially reverse the occurrence supporting termination for Good Reason as identified by Executive. Good
Reason shall not include Executives death or Disability. The parties intend, believe and take the position that a resignation by Executive for Good Reason as defined above effectively constitutes an involuntary separation from service within
the meaning of Section 409A of the Code and Treas. Reg. §1.409A-1(n)(2).
(e) Notice of Termination. Any termination by
the Company or Executive shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 18(d) of this Agreement. For purposes of this Agreement, a Notice of
6
Termination means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable
detail the facts and circumstances claimed to provide a basis for termination of Executives employment under the provision so indicated, and (iii) if the Date of Termination (as defined below) is other than the date of receipt of such
notice, specifies the termination date. The failure by the Company or Executive to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause or Good Reason shall not waive any right of the Company or
Executive hereunder or preclude the Company or Executive from asserting such fact or circumstance in enforcing its rights hereunder.
(f)
Date of Termination. Date of Termination means (i) if Executives employment is terminated other than by reason of death or Disability, the date of receipt of the Notice of Termination or any later date specified
therein, or (ii) if Executives employment is terminated by reason of death or Disability, the Date of Termination shall be the date of death of Executive or the Disability Effective Date, as the case may be.
7. Obligations of the Company upon Termination.
(a) Termination by Executive for Good Reason; Termination by the Company without Cause. If, during the Employment Period, the Company
shall terminate Executives employment without Cause, or Executive shall terminate his employment for Good Reason, then and, with respect to the payments and benefits described in clause (iii), (iv), (v), (vi), (vii) and (viii) below,
only if Executive shall have executed and not revoked a release of claims in a form satisfactory to the Company:
(i) the Company shall
pay to Executive in a lump sum in cash within 60 days after the Date of Termination, the exact payment date to be determined by the Company (or such later date as may be required pursuant to Section 17 hereof), the sum of
(1) Executives Base Salary through the Date of Termination to the extent not theretofore paid, (2) the Annual Bonus, pro-rated as necessary, earned by Executive for the fiscal year immediately prior to the year in which the Date of
Termination occurs, if any, to the extent not theretofore paid, and (3) any accrued but unused vacation pay to the extent not theretofore paid (the sum of the amounts described in clauses (1), (2) and (3) shall be hereinafter referred
to as the Accrued Obligations); and
(ii) to the extent not theretofore paid or provided, the Company shall timely pay or
provide to Executive any other amounts or benefits required to be paid or provided or which Executive is entitled to receive under any plan, program, policy or practice or contract or agreement of the Company and its affiliated companies (such other
amounts and benefits shall be hereinafter referred to as the Other Benefits); and
(iii) the Company shall pay to Executive
twelve (12) months of severance pay based on Executives Base Salary as of the Date of Termination (the Severance Pay). The foregoing Severance Pay shall be paid in equal installments over the severance period in accordance
with the Companys usual payroll schedule, commencing on the date that the release referred to above may no longer be revoked (or such later date as may be required pursuant to Section 17); and
7
(iv) the Company shall pay to Executive a severance bonus in an amount equal to a portion of the
Target Annual Bonus, pro-rated based on the period of Executives employment in the terminal year of employment through the Date of Termination; and
(v) for a period of up to twelve (12) months following Executives Date of Termination, Executive and where applicable,
Executives spouse and eligible dependents, shall continue to be eligible to receive health and medical coverage under the Companys health and medical plans in accordance with the terms of the applicable plan documents; provided,
that in order to receive such continued coverage at such rates, Executive shall be required to pay the applicable premiums to the plan provider, and the Company shall reimburse Executive, within sixty (60) days following the date such monthly
premium payment is due, an amount equal to the monthly COBRA (or, as applicable, other) premium payment, less tax withholdings (COBRA Benefits). Notwithstanding the above, if the Company determines in its sole discretion that it cannot
provide the foregoing COBRA benefits without potentially violating applicable law, the Company in lieu thereof shall provide to Executive a taxable lump sum payment in an amount equal to the monthly (or then remaining) COBRA premium that Executive
would be required to pay to continue his group health and medical coverage on the Date of Termination (which amount shall be based on the premium for the first month of COBRA coverage); and
(vi) any vested portion of stock options granted to Executive by the Company shall remain exercisable by Executive for a period of one
(1) year following the Date of Termination (or, if earlier, the normal expiration date of such stock options), and any unvested portion of stock options and any shares of restricted stock and other equity incentives outstanding (other than
shares of restricted stock subject to the Market Share Milestone or Approval Milestone, as described in subsections (vii) and (viii) below) as of the Date of Termination shall immediately lapse and be forfeited without consideration as of
the Date of Termination; and
(vii) any shares of restricted stock subject to the Market Share Milestone described in
Section 5(b)(ii) shall remain outstanding for a period of twelve (12) months following the Date of Termination, and to the extent that the Market Share Milestone is achieved during such twelve-month period, the shares of restricted stock
subject to the Market Share Milestone shall vest and become non-forfeitable pursuant to the terms set forth in Section 5(b)(ii), the Plan, and the applicable Restricted Stock Agreement; and
(viii) any shares of restricted stock subject to the Approval Milestone described in Section 5(b)(ii) shall remain outstanding for a
period of three (3) months following the Date of Termination, and to the extent that the Approval Milestone is achieved during such three-month period, the shares of restricted stock subject to the Approval Milestone shall vest and become
non-forfeitable pursuant to the terms set forth in Section 5(b)(ii), the Plan, and the applicable Restricted Stock Agreement.
(b)
Death or Disability. If Executives employment is terminated by reason of Executives death or Disability during the Employment Period, this Agreement shall terminate without further obligations to Executive or Executives
legal representatives under this
8
Agreement, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive or Executives estate or
beneficiaries, as applicable, in a lump sum in cash within 60 days after the Date of Termination. With respect to the provision of Other Benefits, the term Other Benefits as used in this Section 7(b) shall include without
limitation, and Executive or Executives estate and/or beneficiaries shall be entitled to receive, benefits under such plans, programs, practices and policies relating to death, disability or retirement benefits, if any, as are applicable to
Executive on the Date of Termination. In addition, in the event of such a termination, and provided that Executive or his estate or beneficiaries, if applicable, executes and does not revoke a release of claims in a form acceptable to the Company:
(i) any vested portion of stock options granted to Executive by the Company shall remain exercisable by Executive and/or his estate or
beneficiaries for a period of one (1) year following the Date of Termination (or, if earlier, the normal expiration date of such stock options), and any unvested portion of stock options and any shares of restricted stock and other equity
incentives outstanding as of the Date of Termination shall immediately lapse and be forfeited without consideration as of the Date of Termination; and
(ii) if Executives employment terminates due to death, the Compensation Committee of the Board shall determine the extent to which any
of the performance goals and objectives established pursuant to Section 5(b)(i) above were met as of the time Executives death. If, based on that determination, the Compensation Committee of the Board determines that a bonus is due, the
Company shall pay Executives estate an amount equal to such bonus, pro-rated for the portion of the fiscal year elapsed as of the time of Executives death.
(c) Termination by the Company for Cause; Resignation by Executive Other than for Good Reason. If Executives employment shall be
terminated for Cause during the Employment Period, or Executive shall resign other than for Good Reason during the Employment Period, this Agreement shall terminate without further obligations to Executive, other than for payment by the Company to
Executive of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive in a lump sum in cash within 60 days after the Date of Termination. In addition, in the event of such a
termination, any unvested equity awards shall lapse and be forfeited without consideration on the Date of Termination.
(d) Expiration
of Employment Period. If Executives employment shall be terminated by the Company or by Executive upon the normal expiration of the Employment Period as provided for in Section 3 hereof, this Agreement shall terminate without further
obligations to Executive, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive in a lump sum in cash within 60 days after the Date of Termination. In
addition, in the event of such a termination, and provided that Executive or his estate or beneficiaries, if applicable, executes and does not revoke a release of claims in a form acceptable to the Company, any vested portion of stock options shall
remain exercisable by Executive and/or his estate or beneficiaries for a period of one (1) year following the Date of Termination (or, if earlier, the normal expiration date of such stock options), and any unvested portions of stock options and
any shares of restricted and
9
other equity incentives (other than shares of restricted stock subject to the Market Share Milestone or Approval Milestone, as described in subsections (i) and (ii) below) outstanding
as of the Date of Termination shall immediately lapse and be forfeited without consideration as of the Date of Termination. In addition, in the event of such a termination, and provided that Executive or his estate or beneficiaries, if applicable,
executes a release of claims in a form acceptable to the Company, (i) any shares of restricted stock subject to the Market Share Milestone described in Section 5(b)(ii) shall remain outstanding for a period of twelve (12) months
following the Date of Termination, and to the extent that the Market Share Milestone is achieved during such twelve-month period, the shares of restricted stock subject to the Market Share Milestone shall vest and become non-forfeitable pursuant to
the terms set forth in Section 5(b)(ii), the Plan, and the applicable Restricted Stock Agreement; and (ii) any shares of restricted stock subject to the Approval Milestone described in Section 5(b)(ii) shall remain outstanding for a
period of three (3) months following the Date of Termination, and to the extent that the Approval Milestone is achieved during such three-month period, the shares of restricted stock subject to the Approval Milestone shall vest and become
non-forfeitable pursuant to the terms set forth in Section 5(b)(ii), the Plan, and the applicable Restricted Stock Agreement.
8.
Change in Control.
(a) Definition. For the purposes of this Agreement, a Change in Control shall mean:
(i) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the 1934 Act) of beneficial
ownership of any capital stock of the Company if, after such acquisition, such individual, entity or group beneficially owns (within the meaning of Rule 13d-3 promulgated under the 1934 Act) 30% or more of either (x) the then-outstanding shares
of common stock of the Company (the Outstanding Company Common Stock) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the Outstanding
Company Voting Securities); provided, however, that for purposes of this subsection (i), the following acquisitions shall not constitute a Change in Control: (A) any acquisition directly from the Company (excluding an
acquisition pursuant to the exercise, conversion or exchange of any security exercisable for, convertible into or exchangeable for common stock or voting securities of the Company, unless the individual, entity or group exercising, converting or
exchanging such security acquired such security directly from the Company or an underwriter or agent of the Company), (B) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation
controlled by the Company, or (C) any acquisition by any corporation pursuant to a Business Combination (as defined below) which complies with clauses (x) and (y) of subsection (iii) of this definition; or
(ii) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the Board of
Directors of a successor corporation to the Company), where the term Continuing Director means at any date a member of the Board (x) who was a member of the Board on the Start Date of this Agreement or (y) who was nominated or
elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who
were Continuing
10
Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (y) any individual whose initial assumption of office
occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or
(iii) the consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving the Company or a sale or other
disposition of all or substantially all of the assets of the Company (a Business Combination), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (x) all or substantially all
of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50%
of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business
Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Companys assets either directly or through one or more subsidiaries) (such resulting or
acquiring corporation is referred to herein as the Acquiring Corporation) in substantially the same proportions as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively,
immediately prior to such Business Combination and (y) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns,
directly or indirectly, 30% or more of the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of
directors (except to the extent that such ownership existed prior to the Business Combination).
(b) Severance Benefits. Upon the
occurrence of a Change in Control, if, within one (1) year after the effective date of the Change in Control, Executives employment is terminated by the Company or the successor corporation to the Company without Cause, or Executive
resigns for Good Reason (as defined above in section 6(d)), then in addition to payment of the Accrued Obligations and Other Benefits, and provided that Executive shall have executed and not revoked a general release of claims in a form satisfactory
to the Company: (i) Executive shall receive a cash payment equal to the sum of (A) 200% of Executives annual Base Salary as of the Date of Termination or, if higher, at the rate in effect immediately prior to a Change in Control, and
(B) 200% of the Annual Bonus earned by Executive for the fiscal year immediately prior to the year in which the Date of Termination occurs, if any, payable in a lump sum within sixty (60) days following the Date of Termination; and
(ii) Executive shall receive a cash payment equal to the total monthly premium payment (both the Companys portion and Executives portion of such premium) under the Companys group healthcare plan as in effect on the Date of
Termination multiplied by twenty-four (24), payable in a lump sum within sixty (60) days following the Date of Termination. The foregoing shall be in lieu of and not in addition to any amounts that Executive would otherwise be entitled to
receive under Section 7 hereof in the event of a termination without Cause or resignation for Good Reason.
11
(c) Equity Awards. Equity awards granted to Executive may be subject to modified treatment
(e.g., accelerated vesting, lapsing of restrictions, etc.) upon the occurrence of a Change in Control, pursuant to the terms and conditions of the Plan.
9. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit Executives continuing or future participation in
any employee benefit plan, program, policy or practice provided by the Company or its affiliated companies and for which Executive may qualify, except as specifically provided herein. Amounts that are vested benefits or which Executive is otherwise
entitled to receive under any plan, policy, practice or program of the Company or any of its affiliated companies at or subsequent to the Date of Termination shall be payable in accordance with such plan, policy, practice or program except as
explicitly modified by this Agreement.
10. No Mitigation. In no event shall Executive be obligated to seek other employment or take
any other action by way of mitigation of the severance amounts payable to Executive under any of the provisions of this Agreement and such amounts shall not be reduced whether or not Executive obtains other employment.
11. Mandatory Reduction of Payments in Certain Events.
(a) Anything in this Agreement to the contrary notwithstanding, in the event it shall be determined that any payment or distribution by the
Company to or for the benefit of Executive (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (a Payment) would be subject to the excise tax imposed by Section 4999 of the
Code (the Excise Tax), then, prior to the making of any Payment to Executive, a calculation shall be made comparing (i) the net benefit to Executive of the Payment after payment of the Excise Tax, to (ii) the net benefit to
Executive if the Payment had been limited to the extent necessary to avoid being subject to the Excise Tax. If the amount calculated under (i) above is less than the amount calculated under (ii) above, then the Payment shall be limited to
the extent necessary to avoid being subject to the Excise Tax (the Reduced Amount). The reduction of the Payments due hereunder, if applicable, shall be made in such a manner as to maximize the economic present value of all Payments
actually made to Executive, determined by the Determination Firm (as defined in Section 11(b) below) as of the date of the Change in Control using the discount rate required by Section 280G(d)(4) of the Code.
(b) The determination of whether an Excise Tax would be imposed, the amount of such Excise Tax, and the calculation of the amounts referred to
Section 12(a)(i) and (ii) above shall be made by an independent, nationally recognized accounting firm or compensation consulting firm mutually acceptable to the Company and Executive (the Determination Firm) which shall
provide detailed supporting calculations. Any determination by the Determination Firm shall be binding upon the Company and Executive. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial
determination by the Determination Firm hereunder, it is possible that Payments which Executive was entitled to, but did not receive pursuant to Section 11(a), could have been made without the imposition of the Excise Tax
(Underpayment). In such event, the Determination Firm shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for the benefit of Executive, but no later than
December 31 of the year after the year in which the Underpayment is determined to exist.
12
(c) In the event that the provisions of Code Section 280G and 4999 or any successor
provisions are repealed without succession, this Section 11 shall be of no further force or effect.
12. Restrictions on Conduct
of Executive.
(a) General. Executive and the Company understand and agree that the purpose of the provisions of this
Section 12 is to protect the legitimate business interests of the Company, as more fully described below, and is not intended to impair or infringe upon Executives right to work, earn a living, or acquire and possess property from the
fruits of his labor. Executive hereby acknowledges that Executive has received good and valuable consideration for the post-employment restrictions set forth in this Section 12 in the form of the compensation and benefits provided for herein.
Executive hereby further acknowledges that the post-employment restrictions set forth in this Section 12 are reasonable and that they do not, and shall not, unduly impair his ability to earn a living after the termination of this Agreement.
In addition, the parties acknowledge: (A) that Executives services under this Agreement require special expertise and talent
in the provision of Competitive Services and that Executive shall have substantial contacts with customers, suppliers, advertisers and vendors of the Company; (B) that pursuant to this Agreement, Executive shall be placed in a position of trust
and responsibility and he shall have access to a substantial amount of Confidential Information and Trade Secrets and that the Company is placing him in such position and giving him access to such information in reliance upon his agreement to comply
with the obligations set forth in this Section 12; (C) that due to his management duties, Executive shall be the repository of a substantial portion of the goodwill of the Company and would have an unfair advantage in competing with the
Company; (D) that due to Executives special experience and talent, the loss of Executives services to the Company under this Agreement cannot reasonably or adequately be compensated solely by damages in an action at law;
(E) that Executive is capable of competing with the Company; and (F) that Executive is capable of obtaining gainful, lucrative and desirable employment that does not violate the restrictions contained in this Agreement.
Therefore, subject to the limitations of reasonableness imposed by law, Executive shall be subject to the restrictions set forth in this
Section 12.
(b) Definitions. The following capitalized terms used in this Section 12 shall have the meanings assigned to
them below, which definitions shall apply to both the singular and the plural forms of such terms:
Competitive
Services means services involving the acquisition, development or commercialization of oral iron pharmaceutical products that are the same as or substantially similar to the oral iron pharmaceutical products offered or provided by the
Company or are in competition with the Companys products.
13
Confidential Information means all data and information relating to the
business of the Company that is disclosed to Executive or of which Executive becomes aware as a consequence of his employment and that has value to the Company and is not generally disclosed to those not employed or otherwise engaged by the Company.
Confidential Information shall include, but is not limited to, financial plans and data concerning the Company; management planning information; business plans; operational methods; market studies; marketing plans or strategies; product
development techniques or plans; customer lists; details of customer contracts; current and anticipated customer requirements; past, current and planned research and development; business acquisition plans; and new personnel acquisition plans.
Confidential Information shall not include information that has become generally available to the public by the act of one who has the right to disclose such information without violating any right or privilege of the Company. This
definition shall not limit any definition of confidential information or any equivalent term under state or federal law.
End Date means the last day of Executives employment with the Company for any reason whatsoever.
Person means any individual or any corporation, partnership, joint venture, limited liability company, association or other
entity or enterprise.
Principal or Representative means a principal, owner, partner, shareholder, joint venturer,
investor, member, trustee, director, officer, manager, employee, agent, representative or consultant.
Protected
Customers means any Person to whom the Company sold its products or services or solicited to sell its products or services during the Employment Period and (a) with whom Executive dealt on behalf of the Company; (b) whose
dealings with the Company were coordinated or supervised by Executive; or (c) about whom Executive obtained Trade Secrets or Confidential Information in the ordinary course of business as a result of his employment.
Protected Employees and Contractors means employees and independent contractors of the Company who were employed or engaged
by the Company at any time within six (6) months prior to the End Date.
Protected Providers means any service
provider, vendor or supplier with whom the Company conducted business or solicited to conduct business during the twelve (12) months prior to the End Date.
Restricted Period means the Employment Period and the one (1) year period following the End Date.
Restricted Territory means countries where Keryx has the right to market Zerenex, including, but not limited to, North
America, European Union, Eastern Europe, Central and Latin America.
Restrictive Covenants means the restrictive
covenants contained in Section 12(c) hereof.
14
Trade Secret means all information, without regard to form, including, but not
limited to, technical or nontechnical data, a formula, a pattern, a compilation, a program, a device, a method, a technique, a drawing, a process, financial data, financial plans, product plans, distribution lists or a list of actual or potential
customers, advertisers or suppliers which is not commonly known by or available to the public and which information: (A) derives economic value, actual or potential, from not being generally known to, and not being readily ascertainable by
proper means by, other persons who can obtain economic value from its disclosure or use; and (B) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. This definition shall not limit any definition of
trade secret or any equivalent term under state or federal law.
(c) Restrictive Covenants.
(i) Restriction on Disclosure and Use of Confidential Information and Trade Secrets. Executive understands and agrees that the
Confidential Information and Trade Secrets constitute valuable assets of the Company, and may not be converted to Executives own use. Accordingly, Executive hereby agrees that throughout the Employment Period and at all times after the End
Date, for so long as the information at issue remains either Confidential Information or a Trade Secret, Executive shall not, directly or indirectly, reveal, divulge, or disclose to any Person not expressly authorized by the Company any Confidential
Information or Trade Secrets and shall not, directly or indirectly, use or make use of any Confidential Information or Trade Secrets in connection with any business activity other than that of the Company.
Anything herein to the contrary notwithstanding, Executive shall not be restricted from disclosing or using Confidential Information or Trade
Secrets that are required to be disclosed by law, court order or other valid legal process; provided, however, that in the event disclosure is required by law, Executive shall provide the Company with prompt, written notice of such
requirement so that the Company may seek an appropriate protective order prior to any such required disclosure by Executive.
(ii)
Non-Solicitation of Protected Employees and Contractors. Executive understands and agrees that the relationship between the Company and each of its Protected Employees and Contractors constitutes a valuable asset of the Company and may not be
converted to Executives own use. Accordingly, Executive hereby agrees that, during the Restricted Period, Executive shall not, directly or indirectly, on Executives own behalf or as a Principal or Representative of any Person or
otherwise, solicit or induce any Protected Employee or Contractor to terminate his or her relationship with the Company or to enter into an employment, consulting or similar relationship with any other Person.
(iii) Non-Solicitation of Protected Customers. Executive understands and agrees that the relationship between the Company and each of
its Protected Customers constitutes a valuable asset of the Company and may not be converted to Executives own use. Accordingly, Executive hereby agrees that, during the Restricted Period, Executive shall not, directly or indirectly, on
Executives own behalf or as a Principal or Representative of any Person, solicit, divert, take away or attempt to solicit, divert or take away a Protected Customer for the purpose of providing or selling Competitive Services.
15
(iv) Non-Interference with Protected Providers. Executive understands and agrees that the
relationship between the Company and each of its Protected Providers constitutes a valuable asset of the Company and may not be converted to Executives own use. Executive hereby agrees that, during the Restricted Period, Executive shall not,
directly or indirectly, solicit or induce or attempt to solicit or induce any Protected Provider to cease, reduce or alter its relationship with the Company.
(v) Non-Competition with the Company. In consideration of the compensation and benefits being paid and to be paid by the Company to
Executive hereunder and the equity awards granted by the Company, Executive hereby agrees that, during the Restricted Period, Executive shall not, directly or indirectly, engage in or provide Competitive Services within the Restricted Territory,
whether on his own behalf or as a Principal or Representative of any other Person, in a capacity that involves the exercise of any job duties or responsibilities the same as or similar to the job duties and responsibilities executed by Executive on
behalf of the Company; provided, however, that the foregoing shall not be deemed to prohibit the ownership by Executive of not more than five percent (5%) of any class of securities of any corporation having a class of securities
registered pursuant to the Exchange Act, which investment does not exceed 3% of Executives net worth.
(d) Enforcement of
Restrictive Covenants.
(i) Rights and Remedies Upon Breach. In the event Executive breaches, or threatens to commit a breach
of, any of the provisions of the Restrictive Covenants, the Company shall have the right and remedy to enjoin, preliminarily and permanently, without the necessity of posting bond, Executive from violating or threatening to violate the Restrictive
Covenants and to have the Restrictive Covenants specifically enforced by any court of competent jurisdiction, it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Company and that
money damages would not provide an adequate remedy to the Company. Executive further understands and agrees that the Company shall be entitled to require Executive to pay the reasonable costs and attorneys fees incurred by the Company in
enforcing the terms of the Restrictive Covenants. The foregoing rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company at law or in equity.
(ii) Severability of Covenants. The parties hereunder agree that the Restrictive Covenants shall be considered and construed as
separate and independent covenants. Should any part or provision of any Restrictive Covenant be held invalid, void or unenforceable in any court of competent jurisdiction, such invalidity, voidness or unenforceability shall not render invalid, void
or unenforceable any other part or provision of this Agreement.
(iii) Reformation. The parties hereunder agree that it is their
intention that the Restrictive Covenants be enforced in accordance with their terms to the maximum extent possible under applicable law. The parties further agree that, in the event any court of competent jurisdiction shall find that any provision
hereof is not enforceable in accordance with its terms, the court shall reform the Restrictive Covenants such that they shall be enforceable to the maximum extent permissible at law.
16
13. Invention Assignment. Executive agrees that he shall promptly and fully disclose in
writing to the Company all inventions, designs, concepts, discoveries, developments, improvements, and innovations, whether or not they merit patent, trademark or copyright protection, conceived of, designed or reduced to practice by Executive,
either solely or in concert with others, at any time during his employment, which (i) relate in any manner, whether at the time of conception, design or reduction to practice, to the Companys business or its actual or demonstrably
anticipated research or development; (ii) result from any work performed by Executive on behalf of the Company; or (iii) result from the use of the Companys equipment, supplies, facilities, Confidential Information or Trade Secrets
(collectively referred to as Inventions).
Executive acknowledges and agrees that he shall keep and maintain adequate written
records of all such Inventions at all stages thereof in the form of notes, sketches, drawings, photographs, printouts, and/or reports relating thereto. These records are and shall remain the property of, and be available to, the Company or its
designee(s) at all times. Executive further acknowledges that all such Inventions shall be the exclusive property of the Company. As such, Executive hereby assigns his entire right, title, and interest in and to all such Inventions to the Company or
its designee(s). Executive will, at the Companys request and expense, execute specific transfers, assignments, documents or other instruments and take such further action as may be considered necessary by the Company at any time during or
subsequent to Executives employment to obtain and defend any intellectual property rights and vest complete title and ownership to such Inventions to the Company or its designee(s).
14. Return of Materials. Executive agrees that he shall not retain or destroy, and shall immediately return to the Company on or prior
to his last day of employment, or at any other time the Company requests such return, any and all property of the Company that is in his possession or subject to his control, including, but not limited to, keys, credit and identification cards,
equipment, client files and information, and all Confidential Information and Trade Secrets. Executive shall not make, distribute or retain copies of any such information or property. Executive agrees that he shall reimburse the Company for all of
its costs, including reasonable attorneys fees, of recovering the above materials and otherwise enforcing compliance with this provision if he does not return the materials in compliance with this provision.
15. Successors and Assigns.
(a) This Agreement is personal to Executive and shall not be assignable by Executive. This Agreement shall inure to the benefit of and be
enforceable by Executives legal representatives.
(b) The Company may assign this Agreement without the consent of Executive. This
Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.
16. Cooperation. Both
during and after his employment, Executive shall provide Executives reasonable cooperation in connection with any action or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executives
employment
17
hereunder. The Company shall reimburse Executive for any reasonable out-of-pocket expenses incurred in connection with Executives performance of obligations under this Section 16 at
the request of the Company. If Executive is entitled to be paid or reimbursed for any expenses under this Section 16, the amount reimbursable in any one (1) calendar year shall not affect the amount reimbursable in any other calendar year,
and the reimbursement of an eligible expense must be made no later than December 31 of the year after the year in which the expense was incurred. Executives obligations under this Section 16.
17. Code Section 409A.
(a) General. This Agreement shall be interpreted and administered in a manner so that any amount or benefit payable hereunder shall be
paid or provided in a manner that is either exempt from or compliant with the requirements Section 409A of the Code and applicable Internal Revenue Service guidance and Treasury Regulations issued thereunder (and any applicable transition
relief under Section 409A of the Code). Nevertheless, the tax treatment of the benefits provided under the Agreement is not warranted or guaranteed. Neither the Company nor its directors, officers, employees or advisers shall be held liable for
any taxes, interest, penalties or other monetary amounts owed by Executive as a result of the application of Section 409A of the Code.
(b) Definitional Restrictions. Notwithstanding anything in this Agreement to the contrary, to the extent that any amount or benefit that
would constitute non-exempt deferred compensation for purposes of Section 409A of the Code would otherwise be payable or distributable hereunder, or a different form of payment would be effected, by reason of a Change in Control or
Executives Disability or termination of employment, such amount or benefit shall not be payable or distributable to Executive, and/or such different form of payment shall not be effected, by reason of such circumstance unless (i) the
circumstances giving rise to such Change in Control, Disability or termination of employment, as the case may be, meet any description or definition of change in control event, disability or separation from
service, as the case may be, in Section 409A of the Code and applicable regulations (without giving effect to any elective provisions that may be available under such definition), or (ii) the payment or distribution of such amount or
benefit would be exempt from the application of Section 409A of the Code by reason of the short-term deferral exemption or otherwise. This provision does not prohibit the vesting of any amount upon a Change in Control, Disability or
termination of employment, however defined. If this provision prevents the payment or distribution of any amount or benefit, such payment or distribution shall be made on the date, if any, on which an event occurs that constitutes a
Section 409A-compliant change in control event, disability or separation from service, as the case may be, or such later date as may be required by subsection (c) below. If this provision prevents the
application of a different form of payment of any amount or benefit, such payment shall be made in the same form as would have applied absent such designated event or circumstance.
(c) Six-Month Delay in Certain Circumstances. Notwithstanding anything in this Agreement to the contrary, if any amount or benefit that
would constitute non-exempt deferred compensation for purposes of Section 409A of the Code would otherwise be payable or distributable under this Agreement by reason of Executives separation from service during a period in
which he is a Specified Employee (as defined below), then, subject to any permissible acceleration of payment by the Company under Treas. Reg. Section 1.409A-3(j)(4)(ii) (domestic relations order), (j)(4)(iii) (conflicts of interest), or
(j)(4)(vi) (payment of employment taxes):
18
(i) the amount of such non-exempt deferred compensation that would otherwise be payable during
the six-month period immediately following Executives separation from service shall be accumulated through and paid or provided on the first day of the seventh month following Executives separation from service (or, if Executive dies
during such period, within 30 days after Executives death) (in either case, the Required Delay Period); and
(ii) the
normal payment or distribution schedule for any remaining payments or distributions shall resume at the end of the Required Delay Period.
For purposes of this Agreement, the term Specified Employee has the meaning given such term in Code Section 409A and the
final regulations thereunder: provided, however, that the Companys Specified Employees and its application of the six-month delay rule of Code Section 409A(a)(2)(B)(i) shall be determined in accordance with rules adopted by
the Board or a committee thereof, which shall be applied consistently with respect to all nonqualified deferred compensation arrangements of the Company, including this Agreement.
18. Miscellaneous.
(a)
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without reference to principles of conflict of laws.
(b) Captions. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect.
(c) Amendments. This Agreement may not be amended or modified otherwise than-by a written agreement executed by the parties hereto or
their respective successors and legal representatives.
(d) Notices. All notices and other communications hereunder shall be in
writing and shall be given by hand delivery to the other party, email, or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows:
|
|
|
If to Executive: |
|
Gregory P. Madison 10 Deerfield Drive
Milton, MA 02186
Keryx Biopharmaceuticals, Inc. 750 Lexington Ave.
20th Floor New York, NY 10022
Attention: CEO Attention: Chairman of the Board |
19
or to such other address as either party shall have furnished to the other in writing in accordance herewith.
Notice and communications shall be effective when actually received by the addressee.
(e) Severability. The invalidity or
unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.
(f) Withholding. The Company may withhold from any amounts payable under this Agreement such Federal, state, local or foreign taxes as
shall be required to be withheld pursuant to any applicable law or regulation.
(g) Waivers. Executives or the Companys
failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right Executive or the Company may have hereunder, shall not be deemed to be a waiver of such provision or right or any other provision or
right of this Agreement.
(h) Entire Agreement. This Agreement contains the entire agreement between the Company and Executive with
respect to the subject matter hereof and, from and after the Effective Date, this Agreement shall supersede any other agreement between the parties with respect to the subject matter hereof.
(i) Arbitration. In the event that a dispute arises between the parties regarding the formation, interpretation and/or the terms and
conditions of this Agreement and/or if there arises any other claim or legal dispute between the parties with respect to Executives employment or the termination thereof (the Dispute), the complaining party shall submit the Dispute
in writing to the other party for resolution. If the Dispute is not resolved between the parties within thirty (30) days of the date the Dispute is submitted in writing to the other party, the complaining party must make a demand for final and
binding arbitration in New York, New York before an arbitrator pursuant to the Employment Arbitration Rules of the American Arbitration Association in effect at the time of the Dispute (the AAA Rules) if the complaining party wishes to
pursue the Dispute (Demand for Arbitration). Provided, however, that the foregoing shall not preclude (x) the Company from immediately seeking injunctive or other equitable relief in a court of competent jurisdiction
in connection with Executives breach or threatened breach of the Restrictive Covenants or the provisions set forth in Sections 13 or 14 of this Agreement or (y) Executive from immediately seeking in a court of competent jurisdiction
injunctive or other equitable relief or specific performance of his right to be paid during the pendency of the Dispute. The parties expressly understand that by agreeing to this arbitration provision, they are agreeing to waive any rights to a
civil action and/or jury trial regarding any Disputes between them. The parties shall share all costs, filing fees, and administrative fees for the arbitration equally as they come due; the parties shall be responsible for their own attorneys
fees, witness fees, and travel costs. Provided, however, that in the event a Dispute arises following a Change in Control, then the Company or the successor corporation to the Company shall pay to Executive, within thirty
(30) days after any such fees or expenses are incurred and substantiated to the Company or the successor corporation to the Company, all costs, reasonable attorneys fees, legal fees, filing fees, administrative fees for the arbitration,
and expenses incurred by Executive as a result of or in connection with any Dispute, including all such fees
20
and expenses, if any, incurred in contesting or disputing the termination of Executives employment with the Company or the successor corporation to the Company or in seeking to obtain or
enforce any right or benefit provided by this Agreement (other than any such fees or expenses incurred in connection with any such claim which is determined by arbitration, in accordance with this section, to be frivolous) or in connection with any
tax audit or proceeding to the extent attributable to the application of Section 409A of the Code, to any payment or benefit provided by the Agreement. The arbitrator shall have the authority to rule on any and all issues properly presented in
the Demand for Arbitration and/or pursuant to the AAA Rules and may award any and all relief provided under applicable law. The arbitrators award may be enforced, vacated, modified or corrected as set forth in the Federal Arbitration Act, 9
U.S.C § 1 et seq. This Agreement shall be governed by the Federal Arbitration Act, 9 U.S.C § 1 et seq., as amended, and the applicable rules of the American Arbitration Association set forth in this Agreement. This Agreement shall be
binding upon, and shall inure to the benefit of Executive, the Company and their respective permitted successors and assigns.
(j)
Timing of Release. Whenever in this Agreement a payment or benefit is conditioned on Executives execution of a release of claims, the Company shall provide such release to Executive promptly following the Date of Termination, and such
release must be executed and all revocation periods shall have expired in accordance with terms set forth in the release, but in no case later than sixty (60) days after the Date of Termination; failing which such payment or benefit shall be
forfeited. If such payment or benefit constitutes non-exempt deferred compensation, then, subject to Section 17(c) above, such payment or benefit (including any installment payments) that would have otherwise been payable during
such 60-day period shall be accumulated and paid on the 60th day after the Date of Termination provided such release shall have been executed and such revocation periods shall have expired. If such payment or benefit is exempt from Section 409A
of the Code, the Company may elect to make or commence payment at any time during such 60-day period.
(k) Counterparts; Scanned
Signatures. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become a binding agreement when one or more counterparts have been signed by each party and delivered
to the other party. A counterpart executed and delivered by PDF or facsimile shall be sufficient for the Agreement to become effective.
[Signature Page Follows]
21
IN WITNESS WHEREOF, Executive has hereunto set Executives hand and, pursuant to the
authorization from the Board, the Company has caused these presents to be executed in its name on its behalf, all as of the day and year first above written.
|
/s/ Gregory P. Madison |
Gregory P. Madison |
|
KERYX BIOPHARMACEUTICALS, INC. |
|
/s/ Ron Bentsur |
Ron Bentsur |
24
Exhibit 10.2
EMPLOYMENT AGREEMENT
BETWEEN
BRIAN R. ADAMS
AND
KERYX
BIOPHARMACEUTICALS, INC.
EMPLOYMENT AGREEMENT
|
|
|
|
|
|
|
|
|
1. |
|
Effective Date |
|
|
1 |
|
|
|
|
2. |
|
Employment |
|
|
1 |
|
|
|
|
3. |
|
Employment Period |
|
|
1 |
|
|
|
|
4. |
|
Extent of Service |
|
|
2 |
|
|
|
|
5. |
|
Compensation and Benefits |
|
|
2 |
|
|
|
|
|
|
|
(a) |
|
Base Salary |
|
|
2 |
|
|
|
|
|
|
|
(b) |
|
Incentive, Savings and Retirement Plans |
|
|
2 |
|
|
|
|
|
|
|
(c) |
|
Welfare Benefit Plans |
|
|
3 |
|
|
|
|
|
|
|
(d) |
|
Expenses |
|
|
3 |
|
|
|
|
|
|
|
(d) |
|
Vacation |
|
|
3 |
|
|
|
|
6. |
|
Termination of Employment |
|
|
4 |
|
|
|
|
|
|
|
(a) |
|
Death |
|
|
4 |
|
|
|
|
|
|
|
(b) |
|
Disability |
|
|
4 |
|
|
|
|
|
|
|
(c) |
|
Termination by the Company |
|
|
4 |
|
|
|
|
|
|
|
(d) |
|
Termination by Executive |
|
|
5 |
|
|
|
|
|
|
|
(e) |
|
Notice of Termination |
|
|
6 |
|
|
|
|
|
|
|
(f) |
|
Date of Termination |
|
|
6 |
|
|
|
|
7. |
|
Obligations of the Company upon Termination |
|
|
6 |
|
|
|
|
|
|
|
(a) |
|
Termination by Executive for Good Reason; Termination by the Company without Cause |
|
|
6 |
|
|
|
|
|
|
|
(b) |
|
Death or Disability |
|
|
7 |
|
|
|
|
|
|
|
(c) |
|
Termination by the Company for Cause; Resignation by Executive Other than for Good Reason |
|
|
8 |
|
|
|
|
|
|
|
(d) |
|
Expiration of Employment Period |
|
|
8 |
|
|
|
|
|
|
|
(e) |
|
Termination of the Agreement by the Company prior to the Start Date without Cause |
|
|
9 |
|
|
|
|
8. |
|
Change in Control |
|
|
9 |
|
|
|
|
|
|
|
(a) |
|
Definition |
|
|
9 |
|
|
|
|
|
|
|
(b) |
|
Severance Benefits |
|
|
10 |
|
|
|
|
9. |
|
Non-exclusivity of Rights |
|
|
11 |
|
|
|
|
10. |
|
No Mitigation |
|
|
11 |
|
|
|
|
|
|
|
|
|
|
11. |
|
Mandatory Reduction of Payments in Certain Events |
|
|
11 |
|
|
|
|
12. |
|
Restrictions on Conduct of Executive |
|
|
12 |
|
|
|
|
|
|
|
(a) |
|
General |
|
|
12 |
|
|
|
|
|
|
|
(b) |
|
Definitions |
|
|
12 |
|
|
|
|
|
|
|
(c) |
|
Restrictive Covenants |
|
|
14 |
|
|
|
|
|
|
|
(d) |
|
Enforcement of Restrictive Covenants |
|
|
15 |
|
|
|
|
13. |
|
Invention Assignment |
|
|
16 |
|
|
|
|
14. |
|
Return of Materials |
|
|
17 |
|
|
|
|
15. |
|
Successors and Assigns |
|
|
17 |
|
|
|
|
16. |
|
Cooperation |
|
|
17 |
|
|
|
|
17. |
|
Code Section 409A |
|
|
17 |
|
|
|
|
|
|
|
(a) |
|
General |
|
|
17 |
|
|
|
|
|
|
|
(b) |
|
Definitional Restrictions |
|
|
18 |
|
|
|
|
|
|
|
(c) |
|
Six-Month Delay in Certain Circumstances |
|
|
18 |
|
|
|
|
18. |
|
Miscellaneous |
|
|
19 |
|
|
|
|
|
|
|
(a) |
|
Governing Law |
|
|
19 |
|
|
|
|
|
|
|
(b) |
|
Captions |
|
|
19 |
|
|
|
|
|
|
|
(c) |
|
Amendments |
|
|
19 |
|
|
|
|
|
|
|
(d) |
|
Notices |
|
|
19 |
|
|
|
|
|
|
|
(e) |
|
Severability |
|
|
19 |
|
|
|
|
|
|
|
(f) |
|
Withholding |
|
|
19 |
|
|
|
|
|
|
|
(g) |
|
Waivers |
|
|
20 |
|
|
|
|
|
|
|
(h) |
|
Entire Agreement |
|
|
20 |
|
|
|
|
|
|
|
(i) |
|
Arbitration |
|
|
20 |
|
|
|
|
|
|
|
(j) |
|
Timing of Release |
|
|
20 |
|
|
|
|
|
|
|
(k) |
|
Counterparts; Scanned Signatures |
|
|
21 |
|
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this Agreement) is made and entered into this 8th
day of April, 2014 by and between Keryx Biopharmaceuticals, Inc., a Delaware corporation (the Company), and Brian R. Adams (Executive), to be effective as of the Effective Date, as defined in Section 1.
BACKGROUND
The Company
desires to engage Executive as General Counsel of the Company in accordance with the terms of this Agreement. Executive is willing to serve as such in accordance with the terms and conditions of this Agreement.
NOW THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Effective
Date. The effective date of this Agreement (the Effective Date) shall be the date first written above.
2.
Employment. Executive shall be employed as General Counsel of the Company commencing by no later than April 14, 2014 (the date on which Executive actually commences employment with the Company shall be the Start Date);
provided, however, that if Executive does not commence employment by April 14, 2014 for any reason, then this Agreement shall become null and void and neither Executive nor the Company shall have any obligations hereunder other than as
expressly set forth in Section 7(e) hereof. In his capacity as General Counsel, Executive shall have the duties, responsibilities and authority commensurate with such position as shall be assigned to him by the Chief Operating Officer (the
COO), the Chief Executive Officer (the CEO) and the Board of Directors of the Company (the Board), including but not limited to, building and managing a fully-integrated legal function at the Company, including
post-marketing compliance; and other corporate efforts, as requested and agreed to with the COO. In his capacity as General Counsel, Executive will report directly to the COO. The principal location of the Executives employment shall be at the
Companys offices in Boston, Massachusetts. The Executive understands and agrees that he may be required to travel from time to time for business reasons, including travel to/from the Companys offices in New York, New York.
3. Employment Period. Unless earlier terminated herein in accordance with Section 6 hereof, Executives employment shall be
for a term beginning on the Start Date and ending on March 15, 2017 (the Employment Period). The Employment Period may be extended upon the mutual, written agreement of the parties In the case of any such extension, the terms and
conditions of this Agreement shall continue to govern unless otherwise agreed to in writing by the parties.
1
4. Extent of Service. During the Employment Period, Executive agrees to devote his full
business time, attention, energy and best efforts to the business and affairs of the Company and to use Executives reasonable best efforts to perform faithfully and efficiently the responsibilities assigned to Executive hereunder. During the
Employment Period it shall not be a violation of this Agreement for Executive to (A) manage personal investments, or (B) devote time to charitable and community activities or, with the approval of the COO, industry or professional
activities including service on the board of directors of another corporation, so long as such activities do not interfere or conflict with the performance of Executives responsibilities as an employee of the Company in accordance with this
Agreement.
5. Compensation and Benefits.
(a) Base Salary. During the Employment Period, the Company will pay to Executive a base salary at the rate of U.S. $305,000 per year
(Base Salary), less normal withholdings, payable in approximately equal bi-weekly or other installments as are or become customary under the Companys payroll practices for its employees from time to time. The Compensation Committee
of the Board shall review Executives Base Salary annually and, in its sole discretion, may increase Executives Base Salary from year to year. Such adjusted salary then shall become Executives Base Salary for purposes of this
Agreement. The annual review of Executives Base Salary by the Board will consider, among other things, Executives own performance and the Companys performance.
(b) Incentive, Savings and Retirement Plans. During the Employment Period, Executive shall be entitled to participate in all incentive,
savings and retirement plans, practices, policies and programs available to other senior executive officers of the Company (Peer Executives), and on the same basis as such Peer Executives. Without limiting the foregoing, the following
shall apply:
(i) Discretionary Annual Bonus. For each year during the Employment Period, Executive may be eligible
to receive a discretionary annual bonus, not to exceed 40% of his Base Salary (the Annual Bonus). The Compensation Committee, in its sole discretion, will establish performance goals and objectives from year to year on which the Annual
Bonus will be based, and the Compensation Committee likewise reserves the sole discretion to modify such goals and objectives, or the final amount of the Annual Bonus, based upon events occurring during the related year or its assessment of the
Companys or the Executives performance in general. The Compensation Committee will provide the Executive with such goals and objectives and any modifications it may make. Unless otherwise provided herein, no Annual Bonus shall be deemed
to have been earned by Executive for any year in which Executive is not actively employed by the Company on the last day of the fiscal year to which the bonus relates. The Company shall pay the Annual Bonus no later than two and a half months after
the end of the fiscal year to which the applicable bonus relates.
(ii) Equity Grants. On the Start Date, the
Company shall grant to Executive under the Companys 2013 Incentive Plan (the Plan):
2
|
1. |
40,000 restricted shares of Company common stock (the Restricted Stock). The Restricted Stock will vest over three years with the first one-third vesting on the first anniversary of the Start Date and
thereafter the remaining shares shall vest in equal quarterly installments through the third anniversary of the Start Date, conditioned upon Executives continuing employment, and subject to other terms and conditions set forth in the award
certificate memorializing the Restricted Stock and the Plan. The vesting of the Restricted Stock shall accelerate in full upon the occurrence of a Change-in-Control, as such term is defined in this Agreement. |
|
2. |
60,000 stock options (the Stock Options). The Stock Options will vest over three years with the first one-third vesting on the first anniversary of the Start Date and thereafter the remaining shares shall
vest in equal quarterly installments through the third anniversary of the Start Date, conditioned upon Executives continuing employment, and subject to other terms and conditions set forth in the award certificate memorializing the Stock
Options and the Plan. The vesting of the Stock Options shall accelerate in full upon the occurrence of a Change-in-Control, as such term is defined in this Agreement. |
During the Employment Period, Executive may be eligible for additional stock-based awards under the Companys incentive plans, as
determined by the Compensation Committee from time to time. Nothing herein requires the Board or the Compensation Committee to make additional grants of options or other awards in any year.
(c) Welfare Benefit Plans. During the Employment Period, Executive and Executives eligible dependents shall be eligible for
participation in, and shall receive all benefits under, the welfare benefit plans, practices, policies and programs provided by the Company (including, without limitation, medical, prescription drug, dental, disability, and employee life insurance
plans and programs) (Welfare Plans) to the extent available to other Peer Executives.
(d) Expenses. During the
Employment Period, Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by Executive in the course of performing his duties and responsibilities under this Agreement, in accordance with the policies,
practices and procedures of the Company with respect to travel, entertainment and other business expenses, including but not limited to professional fees associated with maintaining your legal credentials (e.g. registration fees, bar association
fees and CLE costs).
(e) Vacation. During the Employment Period, Executive will be entitled to four weeks of paid vacation per
calendar year, subject to and in accordance with the Companys vacation policies. In accordance with Company policy, vacation days cannot be accrued and any vacation days not used in any calendar year will be forefeited.
3
6. Termination of Employment.
(a) Death. Executives employment shall terminate automatically upon Executives death during the Employment Period.
(b) Disability. If the Company determines in good faith that Executive has become Disabled (as defined below) during the Employment
Period, it may give to Executive written notice of its intention to terminate Executives employment. In such event, Executives employment with the Company shall terminate effective on the 30th day after receipt of such written notice by
Executive (the Disability Effective Date), provided that, within the 30 days after such receipt, Executive shall not have returned to full-time performance of Executives duties. For purposes of this Agreement, Executive shall be
Disabled if either of the following conditions is met, as determined by the Board in good faith:
(i) Executive is unable
to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for one or more periods totaling one hundred and twenty
(120) days in any twelve (12) month period; or
(ii) Executive is, by reason of any medically determinable
physical or mental impairment that can be expected to result in death or can be expected to last for one or more periods totaling one hundred and twenty (120) days in any twelve (12) month period, receiving income replacement benefits for
a period of not less than three months under an accident and health plan covering employees of the Company.
(c) Termination by the
Company. The Company may terminate Executives employment during the Employment Period with or without Cause. For purposes of this Agreement, a termination shall be considered to be for Cause if it occurs in conjunction with a
determination by the Board that any of the following has occurred:
(i) Executives conviction of, pleading guilty to,
or confession to a felony or any crime involving any act of dishonesty, fraud, misappropriation or embezzlement;
(ii)
Executives misconduct or gross negligence in connection with the performance of his duties hereunder, including a violation of the Companys written policies or Code of Conduct and Ethics;
4
(iii) Executives engaging in any fraudulent, disloyal or unprofessional
conduct which is, or is likely to be, injurious to the Company, its financial condition, or its reputation;
(iv)
Executives failure to perform his duties with the Company (other than any such failure resulting from Executives Disability);
(v) Executives failure to meet performance standards which may be agreed upon by Executive and the Company in writing
from time to time (with the understanding that failure to meet the performance criteria established with respect to an Annual Bonus alone shall not constitute Cause for purposes of this Agreement); or
(vi) Executives breach of the covenants set forth in Section 12 of this Agreement, or material breach of any other
provisions of this Agreement.
If the Company determines that it has grounds to terminate Executives employment for Cause pursuant
to the provisions of clauses (iv), (v), or (vi) of this subsection (c), then it will first deliver to Executive a written notice setting forth with specificity the occurrence deemed to give rise to a right to terminate his employment for Cause,
and Executive will have 30 days after the receipt of such written notice to cease such actions or otherwise correct any such failure or breach. If Executive does not cease such actions or otherwise correct such failure or breach within such 30-day
period, or having once received such written notice and ceased such actions or corrected such failure or breach, Executive at any time thereafter again so acts, fails, or breaches, the Company may terminate his employment for Cause immediately. The
Company may terminate Executives employment without Cause, or for Cause pursuant to the provisions of clauses (i), (ii), or (iii) of this subsection (c), immediately.
(d) Termination by Executive. Executives employment may be terminated by Executive with or without Good Reason. Executives
termination without Good Reason shall require 30 days prior written notice to the Company. Executives termination for Good Reason must occur within a period of 90 days after the occurrence of an event of Good Reason. For purposes of this
Agreement, Good Reason shall mean any of the following, without Executives consent:
(i) a material
diminution in Executives Base Salary, which for purposes of this Agreement shall mean a reduction of more than 15% in the aggregate;
(ii) a material diminution in Executives title, position, authority, duties, or responsibilities;
(iii) a material change in the geographic location of the Executives principal place of business, which for purposes of
this Agreement shall mean a location more than thirty-five (35) miles from the Companys offices in Boston, Massachusetts at which the Executive was principally employed except for required travel on the Companys business; or
5
(iv) any other action or inaction that constitutes a material breach by the
Company of this Agreement.
A termination by Executive shall not constitute termination for Good Reason unless Executive shall first have
delivered to the Company a written notice setting forth with specificity the occurrence deemed to give rise to a right to terminate for Good Reason (which notice must be given no later than 60 days after the initial occurrence of such event), and
there shall have passed a reasonable time (not less than 30 days) within which the Company may take action to correct, rescind or otherwise substantially reverse the occurrence supporting termination for Good Reason as identified by Executive. Good
Reason shall not include Executives death or Disability. The parties intend, believe and take the position that a resignation by the Executive for Good Reason as defined above effectively constitutes an involuntary separation from service
within the meaning of Section 409A of the Code and Treas. Reg. §1.409A-1(n)(2).
(e) Notice of Termination. Any
termination by the Company or Executive shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 18(d) of this Agreement. For purposes of this Agreement, a Notice of Termination means
a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of
Executives employment under the provision so indicated, and (iii) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the termination date. The failure by the Company or Executive to
set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause or Good Reason shall not waive any right of the Company or Executive hereunder or preclude the Company or Executive from asserting such fact or
circumstance in enforcing its rights hereunder.
(f) Date of Termination. Date of Termination means (i) if
Executives employment is terminated other than by reason of death or Disability, the date of receipt of the Notice of Termination or any later date specified therein, or (ii) if Executives employment is terminated by reason of death
or Disability, the Date of Termination shall be the date of death of Executive or the Disability Effective Date, as the case may be.
7.
Obligations of the Company upon Termination.
(a) Termination by Executive for Good Reason; Termination by the Company without
Cause. If, during the Employment Period, the Company shall terminate Executives employment without Cause, or Executive shall terminate his employment for Good Reason, then and, with respect to the payments and benefits described in clause
(ii), (iv), and (v) below, only if Executive shall have executed and not revoked a release of claims in a form satisfactory to the Company:
6
(i) the Company shall pay to Executive in a lump sum in cash within 60 days after the Date of
Termination, the exact payment date to be determined by the Company (or such later date as may be required pursuant to Section 17 hereof), the sum of (1) Executives Base Salary through the Date of Termination to the extent not
theretofore paid, (2) the Annual Bonus earned by the Executive for the fiscal year immediately prior to the year in which the Date of Termination occurs, if any, to the extent not theretofore paid, and (3) any accrued but unused vacation
pay to the extent not theretofore paid (the sum of the amounts described in clauses (1), (2) and (3) shall be hereinafter referred to as the Accrued Obligations); and
(ii) the Company shall pay to Executive twelve (12) months of severance pay based on Executives Base Salary as of the Date of
Termination (the Severance Pay). The foregoing Severance Pay shall be paid in equal installments over the severance period in accordance with the Companys usual payroll schedule, commencing on the date that the release referred to
above may no longer be revoked (or such later date as may be required pursuant to Section 17). In addition the Executive shall receive a cash payment equal to the total monthly premium payment (both the Companys portion and the
Executives portion of such premium) under the Companys group healthcare plan as in effect on the Date of Termination multiplied by twelve (12), payable in a lump sum within sixty (60) days following the Date of Termination, and
(iii) to the extent not theretofore paid or provided, the Company shall timely pay or provide to Executive any other amounts or benefits
required to be paid or provided or which Executive is entitled to receive under any plan, program, policy or practice or contract or agreement of the Company and its affiliated companies (such other amounts and benefits shall be hereinafter referred
to as the Other Benefits), and
(iv) any vested portion of stock options granted to Executive by the Company shall remain
exercisable by the Executive for a period of six (6) months following the Date of Termination (or, if earlier, the normal expiration date of such stock options), and any unvested portions of stock options granted to Executive by the Company
shall lapse and be forfeited without consideration as of the Date of Termination.
(b) Death or Disability. If Executives
employment is terminated by reason of Executives death or Disability during the Employment Period, this Agreement shall terminate without further obligations to Executive or Executives legal representatives under this Agreement, other
than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive or Executives estate or beneficiaries, as applicable, in a lump sum in cash within 60 days after the
Date of Termination. With respect to the provision of Other Benefits, the term Other Benefits as used in this Section 7(b) shall include without limitation, and Executive or Executives estate and/or beneficiaries shall be
entitled to receive, benefits under such plans, programs, practices and policies relating to death, disability or retirement benefits, if any, as are applicable to Executive on the Date of Termination. In addition, in the event of such a
termination, and provided that Executive or his estate or beneficiaries, if applicable, executes and does not revoke a release of claims in a form acceptable to the Company:
7
(i) any vested portion of stock options granted to Executive by the Company shall remain
exercisable by the Executive and/or his estate or beneficiaries for a period of six (6) monthsear following the Date of Termination (or, if earlier, the normal expiration date of such stock options), and any unvested portion of stock options
granted to Executive by the Company shall lapse and be forfeited without consideration as of the Date of Termination; and
(ii) if
Executives employment terminates due to death, the Compensation Committee of the Board shall determine the extent to which any of the performance goals and objectives established pursuant to Section 5(b)(i) above were met as of the time
Executives death. If, based on that determination, the Compensation Committte of the Board determines that a bonus is due, the Company shall pay Executives estate an amount equal to such bonus, pro-rated for the portion of the fiscal
year elapsed as of the time of Executives death.
(c) Termination by the Company for Cause; Resignation by Executive Other than
for Good Reason. If Executives employment shall be terminated for Cause during the Employment Period, or Executive shall resign other than for Good Reason during the Employment Period, this Agreement shall terminate without further
obligations to Executive, other than for payment of Accrued Obligations minus the Annual Bonus earned by the Executive for the fiscal year immediately prior to the year in which the Date of Termination occurs, if any, to the extent not theretofore
paid, and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive in a lump sum in cash within 60 days after the Date of Termination. In addition, in the event of such a termination, any unvested equity
awards shall lapse and be forfeited without consideration on the Date of Termination.
(d) Expiration of Employment Period. If
Executives employment shall be terminated by the Company or by the Executive upon the normal expiration of the Employment Period as provided for in Section 3 hereof, this Agreement shall terminate without further obligations to Executive,
other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive in a lump sum in cash within 60 days after the Date of Termination. In addition, in the event of such
a termination, and provided that Executive or his estate or beneficiaries, if applicable, executes and does not revoke a release of claims in a form acceptable to the Company, any vested portion of stock options granted to Executive by the Company
shall remain exercisable by the Executive and/or his estate or beneficiaries for a period of six (6) months following the Date of Termination (or, if earlier, the normal expiration date of such stock options), and any unvested portions of stock
options granted to Executive by the Company shall lapse and be forfeited without consideration as of the Date of Termination.
8
(e) Termination of the Agreement by the Company prior to the Start Date without Cause. If,
during the time period between the Effective Date and the Start Date, the Company shall terminate this Agreement without Cause, and only if Executive shall have executed and not revoked a release of claims in a form satisfactory to the Company, then
the Company shall pay to Executive twelve (12) months of severance pay based on Executives anticipated Base Salary as of the Start Date. The foregoing shall be paid in equal installments over a twelve (12) month period in accordance
with the Companys usual payroll schedule, commencing on the date that the release referred to above may no longer be revoked (or such later date as may be required pursuant to Section 17).
8. Change in Control.
(a) Definition. For the purposes of this Agreement, a Change in Control shall mean:
(i) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the 1934 Act)
of beneficial ownership of any capital stock of the Company if, after such acquisition, such individual, entity or group beneficially owns (within the meaning of Rule 13d-3 promulgated under the 1934 Act) 30% or more of either (x) the
then-outstanding shares of common stock of the Company (the Outstanding Company Common Stock) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors
(the Outstanding Company Voting Securities); provided, however, that for purposes of this subsection (i), the following acquisitions shall not constitute a Change in Control: (A) any acquisition directly from the
Company (excluding an acquisition pursuant to the exercise, conversion or exchange of any security exercisable for, convertible into or exchangeable for common stock or voting securities of the Company, unless the individual, entity or group
exercising, converting or exchanging such security acquired such security directly from the Company or an underwriter or agent of the Company), (B) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the
Company or any corporation controlled by the Company, or (C) any acquisition by any corporation pursuant to a Business Combination (as defined below) which complies with clauses (x) and (y) of subsection (iii) of this definition;
or
(ii) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if
applicable, the Board of Directors of a successor corporation to the Company), where the term Continuing Director means at any date a member of the Board (x) who was a member of the Board on the Start Date of this Agreement or
(y) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a
majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (y) any individual whose initial assumption of office occurred as
a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or
9
(iii) the consummation of a merger, consolidation, reorganization,
recapitalization or share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company (a Business Combination), unless, immediately following such Business Combination, each of
the following two conditions is satisfied: (x) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such
Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors,
respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Companys assets
either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the Acquiring Corporation) in substantially the same proportions as their ownership of the Outstanding Company Common
Stock and Outstanding Company Voting Securities, respectively, immediately prior to such Business Combination and (y) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by the
Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, 30% or more of the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such
corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination).
(b) Severance Benefits. Upon the occurrence of a Change in Control, if, within one year after the effective date of the Change in
Control, Executives employment is terminated by the Company or the successor corporation to the Company without Cause, or Executive resigns for Good Reason, then in addition to payment of the Accrued Obligations and Other Benefits, and
provided that Executive shall have executed and not revoked a general release of claims in a form satisfactory to the Company: (i) the Executive shall receive a cash payment equal to the sum of (A) 100% of the Executives annual Base
Salary as of the Date of Termination or, if higher, at the rate in effect immediately prior to a Change in Control, and (B) the Annual Bonus earned by the Executive for the fiscal year immediately prior to the year in which the Date of
Termination occurs, if any, payable in a lump sum within sixty (60) days following the Date of Termination; and (ii) the Executive shall receive a cash payment equal to the total monthly premium payment (both the Companys portion and
the Executives portion of such premium) under the Companys group healthcare plan as in effect on the Date of Termination multiplied by twelve (12), payable in a lump sum within sixty (60) days following the Date of Termination. The
foregoing shall be in lieu of and not in addition to any amounts that Executive would otherwise be entitled to receive under Section 7 hereof in the event of a termination without Cause or resignation for Good Reason.
10
9. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit
Executives continuing or future participation in any employee benefit plan, program, policy or practice provided by the Company or its affiliated companies and for which Executive may qualify, except as specifically provided herein. Amounts
that are vested benefits or which Executive is otherwise entitled to receive under any plan, policy, practice or program of the Company or any of its affiliated companies at or subsequent to the Date of Termination shall be payable in accordance
with such plan, policy, practice or program except as explicitly modified by this Agreement.
10. No Mitigation. In no event shall
Executive be obligated to seek other employment or take any other action by way of mitigation of the severance amounts payable to Executive under any of the provisions of this Agreement and such amounts shall not be reduced whether or not Executive
obtains other employment.
11. Mandatory Reduction of Payments in Certain Events.
(a) Anything in this Agreement to the contrary notwithstanding, in the event it shall be determined that any payment or distribution by the
Company to or for the benefit of Executive (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (a Payment) would be subject to the excise tax imposed by Section 4999 of the
Code (the Excise Tax), then, prior to the making of any Payment to Executive, a calculation shall be made comparing (i) the net benefit to Executive of the Payment after payment of the Excise Tax, to (ii) the net benefit to
Executive if the Payment had been limited to the extent necessary to avoid being subject to the Excise Tax. If the amount calculated under (i) above is less than the amount calculated under (ii) above, then the Payment shall be limited to
the extent necessary to avoid being subject to the Excise Tax (the Reduced Amount). The reduction of the Payments due hereunder, if applicable, shall be made in such a manner as to maximize the economic present value of all Payments
actually made to Executive, determined by the Determination Firm (as defined in Section 11(b) below) as of the date of the Change in Control using the discount rate required by Section 280G(d)(4) of the Code.
(b) The determination of whether an Excise Tax would be imposed, the amount of such Excise Tax, and the calculation of the amounts referred to
Section 12(a)(i) and (ii) above shall be made by an independent, nationally recognized accounting firm or compensation consulting firm mutually acceptable to the Company and Executive (the Determination Firm) which shall
provide detailed supporting calculations. Any determination by the Determination Firm shall be binding upon the Company and Executive. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial
determination by the Determination Firm hereunder, it is possible that Payments which Executive was entitled to, but did not receive pursuant to Section 11(a), could have been made without the imposition of the Excise Tax
(Underpayment). In such event, the Determination Firm shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for the benefit of Executive, but no later than
December 31 of the year after the year in which the Underpayment is determined to exist.
11
(c) In the event that the provisions of Code Section 280G and 4999 or any successor
provisions are repealed without succession, this Section 11 shall be of no further force or effect.
12. Restrictions on Conduct of
Executive.
(a) General. Executive and the Company understand and agree that the purpose of the provisions of this
Section 12 is to protect the legitimate business interests of the Company, as more fully described below, and is not intended to impair or infringe upon Executives right to work, earn a living, or acquire and possess property from the
fruits of his labor. Executive hereby acknowledges that Executive has received good and valuable consideration for the post-employment restrictions set forth in this Section 12 in the form of the compensation and benefits provided for herein.
Executive hereby further acknowledges that the post-employment restrictions set forth in this Section 12 are reasonable and that they do not, and will not, unduly impair his ability to earn a living after the termination of this Agreement.
In addition, the parties acknowledge: (A) that Executives services under this Agreement require special expertise and talent in the
provision of Competitive Services and that Executive will have substantial contacts with customers, suppliers, advertisers and vendors of the Company; (B) that pursuant to this Agreement, Executive will be placed in a position of trust and
responsibility and he will have access to a substantial amount of Confidential Information and Trade Secrets and that the Company is placing him in such position and giving him access to such information in reliance upon his agreement to comply with
the obligations set forth in this Section 12; (C) that due to his management duties, Executive will be the repository of a substantial portion of the goodwill of the Company and would have an unfair advantage in competing with the Company;
(D) that due to Executives special experience and talent, the loss of Executives services to the Company under this Agreement cannot reasonably or adequately be compensated solely by damages in an action at law; (E) that
Executive is capable of competing with the Company; and (F) that Executive is capable of obtaining gainful, lucrative and desirable employment that does not violate the restrictions contained in this Agreement.
Therefore, subject to the limitations of reasonableness imposed by law, Executive shall be subject to the restrictions set forth in this
Section 12.
(b) Definitions. The following capitalized terms used in this Section 12 shall have the meanings assigned to
them below, which definitions shall apply to both the singular and the plural forms of such terms:
12
Competitive Services means services involving the acquisition, development or
commercialization of oral iron pharmaceutical products that are the same as or substantially similar to the oral iron pharmaceutical products offered or provided by the Company or are in competition with the Companys products.
Confidential Information means all data and information relating to the business of the Company that is disclosed to
Executive or of which Executive becomes aware as a consequence of his employment and that has value to the Company and is not generally disclosed to those not employed or otherwise engaged by the Company. Confidential Information shall
include, but is not limited to, financial plans and data concerning the Company; management planning information; business plans; operational methods; market studies; marketing plans or strategies; product development techniques or plans; customer
lists; details of customer contracts; current and anticipated customer requirements; past, current and planned research and development; business acquisition plans; and new personnel acquisition plans. Confidential Information shall not
include information that has become generally available to the public by the act of one who has the right to disclose such information without violating any right or privilege of the Company. This definition shall not limit any definition of
confidential information or any equivalent term under state or federal law.
End Date means the last day of
Executives employment with the Company for any reason whatsoever.
Person means any individual or any
corporation, partnership, joint venture, limited liability company, association or other entity or enterprise.
Principal or
Representative means a principal, owner, partner, shareholder, joint venturer, investor, member, trustee, director, officer, manager, employee, agent, representative or consultant.
Protected Customers means any Person to whom the Company sold its products or services or solicited to sell its products or
services during the Employment Period and (a) with whom Executive dealt on behalf of the Company; (b) whose dealings with the Company were coordinated or supervised by Executive; or (c) about whom Executive obtained Trade Secrets or
Confidential Information in the ordinary course of business as a result of his employment.
Protected Employees and
Contractors means employees and independent contractors of the Company who were employed or engaged by the Company at any time within six (6) months prior to the End Date.
Protected Providers means any service provider, vendor or supplier with whom the Company conducted business or solicited to
conduct business during the twelve (12) months prior to the End Date.
13
Restricted Period means the Employment Period and the one (1) year period
following the End Date.
Restricted Territory means countries where Keryx has the right to market Zerenex, including,
but not limited to, North America, European Union, Eastern Europe, Central and Latin America.
Restrictive Covenants
means the restrictive covenants contained in Section 12(c) hereof.
Trade Secret means all information, without
regard to form, including, but not limited to, technical or nontechnical data, a formula, a pattern, a compilation, a program, a device, a method, a technique, a drawing, a process, financial data, financial plans, product plans, distribution lists
or a list of actual or potential customers, advertisers or suppliers which is not commonly known by or available to the public and which information: (A) derives economic value, actual or potential, from not being generally known to, and not
being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use; and (B) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. This definition shall
not limit any definition of trade secret or any equivalent term under state or federal law.
(c) Restrictive Covenants.
(i) Restriction on Disclosure and Use of Confidential Information and Trade Secrets. Executive understands and
agrees that the Confidential Information and Trade Secrets constitute valuable assets of the Company, and may not be converted to Executives own use. Accordingly, Executive hereby agrees that throughout the Employment Period and at all times
after the End Date, for so long as the information at issue remains either Confidential Information or a Trade Secret, Executive will not, directly or indirectly, reveal, divulge, or disclose to any Person not expressly authorized by the Company any
Confidential Information or Trade Secrets and will not, directly or indirectly, use or make use of any Confidential Information or Trade Secrets in connection with any business activity other than that of the Company.
Anything herein to the contrary notwithstanding, Executive shall not be restricted from disclosing or using Confidential
Information or Trade Secrets that are required to be disclosed by law, court order or other valid legal process; provided, however, that in the event disclosure is required by law, Executive shall provide the Company with prompt,
written notice of such requirement so that the Company may seek an appropriate protective order prior to any such required disclosure by Executive.
(ii) Non-Solicitation of Protected Employees and Contractors. Executive understands and agrees that the relationship
between the Company and each of its Protected Employees and Contrators constitutes a valuable asset of the
14
Company and may not be converted to Executives own use. Accordingly, Executive hereby agrees that, during the Restricted Period, Executive shall not, directly or indirectly, on
Executives own behalf or as a Principal or Representative of any Person or otherwise, solicit or induce any Protected Employee or Contractor to terminate his or her relationship with the Company or to enter into an employment, consulting or
similar relationship with any other Person.
(iii) Non-Solicitation of Protected Customers. Executive understands
and agrees that the relationship between the Company and each of its Protected Customers constitutes a valuable asset of the Company and may not be converted to Executives own use. Accordingly, Executive hereby agrees that, during the
Restricted Period, Executive shall not, directly or indirectly, on Executives own behalf or as a Principal or Representative of any Person, solicit, divert, take away or attempt to solicit, divert or take away a Protected Customer for the
purpose of providing or selling Competitive Services.
(iv) Non-Interference with Protected Providers. Executive
understands and agrees that the relationship between the Company and each of its Protected Providers constitutes a valuable asset of the Company and may not be converted to Executives own use. Executive hereby agrees that, during the
Restricted Period, Executive shall not, directly or indirectly, solicit or induce or attempt to solicit or induce any Protected Provider to cease, reduce or alter its relationship with the Company.
(v) Non-Competition with the Company. In consideration of the compensation and benefits being paid and to be paid by the
Company to Executive hereunder and the equity awards granted by the Company, Executive hereby agrees that, during the Restricted Period, Executive will not, directly or indirectly, engage in or provide Competitive Services within the Restricted
Territory, whether on his own behalf or as a Principal or Representative of any other Person, in a capacity that involves the exercise of any job duties or responsibilities the same as or similar to the job duties and responsibilities executed by
Executive on behalf of the Company; provided, however, that the foregoing shall not be deemed to prohibit the ownership by Executive of not more than five percent (5%) of any class of securities of any corporation having a class
of securities registered pursuant to the Exchange Act, which investment does not exceed 3% of Executives net worth.
(d)
Enforcement of Restrictive Covenants.
(i) Rights and Remedies Upon Breach. In the event Executive breaches,
or threatens to commit a breach of, any of the provisions of the Restrictive Covenants, the Company shall have the right and remedy to enjoin, preliminarily and permanently, without the necessity of posting bond, Executive from violating or
threatening to violate the Restrictive Covenants and to have the
15
Restrictive Covenants specifically enforced by any court of competent jurisdiction, it being agreed that any breach or threatened breach of the Restrictive Covenants could cause irreparable
injury to the Company and that money damages may not provide an adequate remedy to the Company. The foregoing rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company at law or in
equity.
(ii) Severability of Covenants. The parties hereunder agree that the Restrictive Covenants shall be
considered and construed as separate and independent covenants. Should any part or provision of any Restrictive Covenant be held invalid, void or unenforceable in any court of competent jurisdiction, such invalidity, voidness or unenforceability
shall not render invalid, void or unenforceable any other part or provision of this Agreement.
(iii) Reformation.
The parties hereunder agree that it is their intention that the Restrictive Covenants be enforced in accordance with their terms to the maximum extent possible under applicable law. The parties further agree that, in the event any court of competent
jurisdiction shall find that any provision hereof is not enforceable in accordance with its terms, the court shall reform the Restrictive Covenants such that they shall be enforceable to the maximum extent permissible at law.
13. Invention Assignment. Executive agrees that he will promptly and fully disclose in writing to the Company all inventions, designs,
concepts, discoveries, developments, improvements, and innovations, whether or not they merit patent, trademark or copyright protection, conceived of, designed or reduced to practice by Executive, either solely or in concert with others, at any time
during his employment, which (i) relate in any manner, whether at the time of conception, design or reduction to practice, to the Companys business or its actual or demonstrably anticipated research or development; (ii) result from
any work performed by Executive on behalf of the Company; or (iii) result from the use of the Companys equipment, supplies, facilities, Confidential Information or Trade Secrets (collectively referred to as Inventions).
Executive acknowledges and agrees that he will keep and maintain adequate written records of all such Inventions at all stages thereof in the
form of notes, sketches, drawings, photographs, printouts, and/or reports relating thereto. These records are and shall remain the property of, and be available to, the Company or its designee(s) at all times. Executive further acknowledges that all
such Inventions shall be the exclusive property of the Company. As such, Executive hereby assigns his entire right, title, and interest in and to all such Inventions to the Company or its designee(s). Executive will, at the Companys request
and expense, execute specific transfers, assignments, documents or other instruments and take such further action as may be considered necessary by the Company at any time during or subsequent to Executives employment to obtain and defend any
intellectual property rights and vest complete title and ownership to such Inventions to the Company or its designee(s).
16
14. Return of Materials. Executive agrees that he will not retain or destroy, and will
immediately return to the Company on or prior to his last day of employment, or at any other time the Company requests such return, any and all property of the Company that is in his possession or subject to his control, including, but not limited
to, keys, credit and identification cards, equipment, client files and information, and all Confidential Information and Trade Secrets. Executive will not make, distribute or retain copies of any such information or property. Executive agrees that
he will reimburse the Company for all of its costs, including reasonable attorneys fees, of recovering the above materials and otherwise enforcing compliance with this provision if he does not return the materials in compliance with this
provision.
15. Successors and Assigns.
(a) This Agreement is personal to Executive and shall not be assignable by Executive. This Agreement shall inure to the benefit of and be
enforceable by Executives legal representatives.
(b) The Company may assign this Agreement without the consent of Executive. This
Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.
16. Cooperation. Both
during and after his employment, Executive shall provide Executives reasonable cooperation in connection with any action or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executives
employment hereunder. The Company shall reimburse Executive for any reasonable out-of-pocket expenses incurred in connection with Executives performance of obligations under this Section 16 at the request of the Company. If Executive is
entitled to be paid or reimbursed for any expenses under this Section 16, the amount reimbursable in any one calendar year shall not affect the amount reimbursable in any other calendar year, and the reimbursement of an eligible expense must be
made no later than December 31 of the year after the year in which the expense was incurred. Executives obligations under this Section 16.
17. Code Section 409A.
(a) General. This Agreement shall be interpreted and administered in a manner so that any amount or benefit payable hereunder shall be
paid or provided in a manner that is either exempt from or compliant with the requirements Section 409A of the Code and applicable Internal Revenue Service guidance and Treasury Regulations issued thereunder (and any applicable transition
relief under Section 409A of the Code). Nevertheless, the tax treatment of the benefits provided under the Agreement is not warranted or guaranteed. Neither the Company nor its directors, officers, employees or advisers shall be held liable for
any taxes, interest, penalties or other monetary amounts owed by Executive as a result of the application of Section 409A of the Code.
17
(b) Definitional Restrictions. Notwithstanding anything in this Agreement to the contrary,
to the extent that any amount or benefit that would constitute non-exempt deferred compensation for purposes of Section 409A of the Code would otherwise be payable or distributable hereunder, or a different form of payment would be
effected, by reason of a Change in Control or the Executives Disability or termination of employment, such amount or benefit will not be payable or distributable to the Executive, and/or such different form of payment will not be effected, by
reason of such circumstance unless (i) the circumstances giving rise to such Change in Control, Disability or termination of employment, as the case may be, meet any description or definition of change in control event,
disability or separation from service, as the case may be, in Section 409A of the Code and applicable regulations (without giving effect to any elective provisions that may be available under such definition), or
(ii) the payment or distribution of such amount or benefit would be exempt from the application of Section 409A of the Code by reason of the short-term deferral exemption or otherwise. This provision does not prohibit the vesting of
any amount upon a Change in Control, Disability or termination of employment, however defined. If this provision prevents the payment or distribution of any amount or benefit, such payment or distribution shall be made on the date, if any, on which
an event occurs that constitutes a Section 409A-compliant change in control event, disability or separation from service, as the case may be, or such later date as may be required by subsection
(c) below. If this provision prevents the application of a different form of payment of any amount or benefit, such payment shall be made in the same form as would have applied absent such designated event or circumstance.
(c) Six-Month Delay in Certain Circumstances. Notwithstanding anything in this Agreement to the contrary, if any amount or benefit that
would constitute non-exempt deferred compensation for purposes of Section 409A of the Code would otherwise be payable or distributable under this Agreement by reason of Executives separation from service during a period in
which he is a Specified Employee (as defined below), then, subject to any permissible acceleration of payment by the Company under Treas. Reg. Section 1.409A-3(j)(4)(ii) (domestic relations order), (j)(4)(iii) (conflicts of interest), or
(j)(4)(vi) (payment of employment taxes):
(i) the amount of such non-exempt deferred compensation that would otherwise be
payable during the six-month period immediately following Executives separation from service will be accumulated through and paid or provided on the first day of the seventh month following Executives separation from service (or, if
Executive dies during such period, within 30 days after Executives death) (in either case, the Required Delay Period); and
(ii) the normal payment or distribution schedule for any remaining payments or distributions will resume at the end of the
Required Delay Period.
18
For purposes of this Agreement, the term Specified Employee has the meaning given
such term in Code Section 409A and the final regulations thereunder: provided, however, that the Companys Specified Employees and its application of the six-month delay rule of Code Section 409A(a)(2)(B)(i) shall be determined
in accordance with rules adopted by the Board or a committee thereof, which shall be applied consistently with respect to all nonqualified deferred compensation arrangements of the Company, including this Agreement.
18. Miscellaneous.
(a)
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without reference to principles of conflict of laws.
(b) Captions. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect.
(c) Amendments. This Agreement may not be amended or modified otherwise than-by a written agreement executed by the parties hereto or
their respective successors and legal representatives.
(d) Notices. All notices and other communications hereunder shall be in
writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows:
|
|
|
If to Executive: |
|
Brian R. Adams |
|
|
54 Douglas Road |
|
|
Needham, MA 02492 |
|
|
If to the Company: |
|
Keryx Biopharmaceuticals, Inc. |
|
|
750 Lexington Ave. |
|
|
20th Floor |
|
|
New York, NY 10022 |
|
|
Attention: CEO |
or to such other address as either party shall have furnished to the other in writing in accordance herewith. Notice and
communications shall be effective when actually received by the addressee.
(e) Severability. The invalidity or unenforceability of
any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.
(f)
Withholding. The Company may withhold from any amounts payable under this Agreement such Federal, state, local or foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation.
19
(g) Waivers. Executives or the Companys failure to insist upon strict
compliance with any provision of this Agreement or the failure to assert any right Executive or the Company may have hereunder, shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement.
(h) Entire Agreement. This Agreement contains the entire agreement between the Company and Executive with respect to the subject matter
hereof and, from and after the Effective Date, this Agreement shall supersede any other agreement between the parties with respect to the subject matter hereof.
(i) Arbitration. In the event that a dispute arises between the parties regarding the formation, interpretation and/or the terms and
conditions of this Agreement and/or if there arises any other claim or legal dispute between the parties with respect to Executives employment or the termination thereof (the Dispute), the complaining party shall submit the Dispute
in writing to the other party for resolution. If the Dispute is not resolved between the parties within thirty (30) days of the date the Dispute is submitted in writing to the other party, the complaining party must make a demand for final and
binding arbitration in New York, New York before an arbitrator pursuant to the Employment Arbitration Rules of the American Arbitration Association in effect at the time of the Dispute (the AAA Rules) if the complaining party wishes to
pursue the Dispute (Demand for Arbitration). Provided, however, that the foregoing shall not preclude the Company from immediately seeking injunctive or other equitable relief in a court of competent jurisdiction in connection
with Executives breach or threatened breach of the Restrictive Covenants or the provisions set forth in Sections 13 or 14 of this Agreement. The parties expressly understand that by agreeing to this arbitration provision, they are agreeing to
waive any rights to a civil action and/or jury trial regarding any Disputes between them. The parties shall share all costs, filing fees, and administrative fees for the arbitration equally as they come due; the parties shall be responsible for
their own attorneys fees, witness fees, and travel costs. The arbitrator shall have the authority to rule on any and all issues properly presented in the Demand for Arbitration and/or pursuant to the AAA Rules and may award any and all relief
provided under applicable law. The arbitrators award may be enforced, vacated, modified or corrected as set forth in the Federal Arbitration Act, 9 U.S.C § 1 et seq. This Agreement shall be governed by the Federal Arbitration Act, 9 U.S.C
§ 1 et seq., as amended, and the applicable rules of the American Arbitration Association set forth in this Agreement. This Agreement shall be binding upon, and shall inure to the benefit of Executive, the Company and their respective permitted
successors and assigns.
(j) Timing of Release. Whenever in this Agreement a payment or benefit is conditioned on the
Executives execution of a release of claims, the Company shall provide such release to the Executive promptly following the Date of Termination, and such release must be executed and all revocation periods shall have expired in accordance with
terms set forth in the release, but in no case later than sixty (60) days after the Date of Termination; failing which such payment or benefit shall be forfeited. If such payment or benefit constitutes non-exempt deferred
compensation, then, subject to Section 17(c) above, such payment or benefit (including any installment payments) that would have otherwise been payable during such 60-day period shall be accumulated
20
and paid on the 60th day after the Date of Termination provided such release shall have been executed and such revocation periods shall have expired. If such payment or benefit is exempt from
Section 409A of the Code, the Company may elect to make or commence payment at any time during such 60-day period.
(k)
Counterparts; Scanned Signatures. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become a binding agreement when one or more counterparts have been signed by
each party and delivered to the other party. A counterpart executed and delivered by PDF or facsimile shall be sufficient for the Agreement to become effective.
IN WITNESS WHEREOF, Executive has hereunto set Executives hand and, pursuant to the authorization from the Board, the Company has caused
these presents to be executed in its name on its behalf, all as of the day and year first above written.
|
/s/ Brian R. Adams |
Brian R. Adams |
|
KERYX BIOPHARMACEUTICALS, INC. |
|
/s/ Ron Benstur |
Ron Bentsur |
CEO |
21
Exhibit 10.3
EMPLOYMENT AGREEMENT
BETWEEN
JOHN F. NEYLAN
M.D.
AND
KERYX BIOPHARMACEUTICALS, INC.
EMPLOYMENT AGREEMENT
|
|
|
|
|
|
|
1. Effective Date |
|
|
1 |
|
|
|
2. Employment |
|
|
1 |
|
|
|
3. Employment Period |
|
|
1 |
|
|
|
4. Extent of Service |
|
|
2 |
|
|
|
5. Compensation and Benefits |
|
|
2 |
|
|
|
|
(a) |
|
Base Salary |
|
|
2 |
|
|
|
|
(b) |
|
Incentive, Savings and Retirement Plans |
|
|
2 |
|
|
|
|
(c) |
|
Welfare Benefit Plans |
|
|
3 |
|
|
|
|
(d) |
|
Expenses |
|
|
3 |
|
|
|
|
(d) |
|
Vacation |
|
|
3 |
|
|
|
6. Termination of Employment |
|
|
4 |
|
|
|
|
(a) |
|
Death |
|
|
4 |
|
|
|
|
(b) |
|
Disability |
|
|
4 |
|
|
|
|
(c) |
|
Termination by the Company |
|
|
4 |
|
|
|
|
(d) |
|
Termination by Executive |
|
|
5 |
|
|
|
|
(e) |
|
Notice of Termination |
|
|
6 |
|
|
|
|
(f) |
|
Date of Termination |
|
|
6 |
|
|
|
7. Obligations of the Company upon Termination |
|
|
6 |
|
|
|
|
(a) |
|
Termination by Executive for Good Reason; Termination by the Company without Cause |
|
|
6 |
|
|
|
|
(b) |
|
Death or Disability |
|
|
7 |
|
|
|
|
(c) |
|
Termination by the Company for Cause; Resignation by Executive Other than for Good Reason |
|
|
8 |
|
|
|
|
(d) |
|
Expiration of Employment Period |
|
|
8 |
|
|
|
|
(e) |
|
Termination of the Agreement by the Company prior to the Start Date without Cause |
|
|
9 |
|
|
|
8. Change in Control |
|
|
9 |
|
|
|
|
(a) |
|
Definition |
|
|
9 |
|
|
|
|
(b) |
|
Severance Benefits |
|
|
10 |
|
|
|
9. Non-exclusivity of Rights |
|
|
10 |
|
|
|
10. No Mitigation |
|
|
11 |
|
|
|
|
|
|
|
|
11. Mandatory Reduction of Payments in Certain Events |
|
|
11 |
|
|
|
12. Restrictions on Conduct of Executive |
|
|
12 |
|
|
|
|
(a) |
|
General |
|
|
12 |
|
|
|
|
(b) |
|
Definitions |
|
|
12 |
|
|
|
|
(c) |
|
Restrictive Covenants |
|
|
14 |
|
|
|
|
(d) |
|
Enforcement of Restrictive Covenants |
|
|
15 |
|
|
|
13. Invention Assignment |
|
|
16 |
|
|
|
14. Return of Materials |
|
|
16 |
|
|
|
15. Successors and Assigns |
|
|
17 |
|
|
|
16. Cooperation |
|
|
17 |
|
|
|
17. Code Section 409A |
|
|
17 |
|
|
|
|
(a) |
|
General |
|
|
17 |
|
|
|
|
(b) |
|
Definitional Restrictions |
|
|
17 |
|
|
|
|
(c) |
|
Six-Month Delay in Certain Circumstances |
|
|
18 |
|
|
|
18. Miscellaneous |
|
|
18 |
|
|
|
|
(a) |
|
Governing Law |
|
|
18 |
|
|
|
|
(b) |
|
Captions |
|
|
19 |
|
|
|
|
(c) |
|
Amendments |
|
|
19 |
|
|
|
|
(d) |
|
Notices |
|
|
19 |
|
|
|
|
(e) |
|
Severability |
|
|
19 |
|
|
|
|
(f) |
|
Withholding |
|
|
19 |
|
|
|
|
(g) |
|
Waivers |
|
|
19 |
|
|
|
|
(h) |
|
Entire Agreement |
|
|
19 |
|
|
|
|
(i) |
|
Arbitration |
|
|
19 |
|
|
|
|
(j) |
|
Timing of Release |
|
|
20 |
|
|
|
|
(k) |
|
Counterparts; Scanned Signatures |
|
|
20 |
|
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this Agreement) is made and entered into this 22nd
day of April, 2015 by and between Keryx Biopharmaceuticals, Inc., a Delaware corporation (the Company), and John F. Neylan M.D. (Executive), to be effective as of the Effective Date, as defined in Section 1.
BACKGROUND
The Company
desires to engage Executive as Chief Medical Officer of the Company in accordance with the terms of this Agreement. Executive is willing to serve as such in accordance with the terms and conditions of this Agreement.
NOW THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Effective
Date. The effective date of this Agreement (the Effective Date) shall be the date first written above.
2.
Employment. Executive shall be employed as Chief Medical Officer of the Company commencing by no later than April 22, 2015 (the date on which Executive actually commences employment with the Company shall be the Start Date);
provided, however, that if Executive does not commence employment by April 27, 2015 for any reason, then this Agreement shall become null and void and neither Executive nor the Company shall have any obligations hereunder other than as
expressly set forth in Section 7(e) hereof. In his capacity as Chief Medical Officer, Executive shall have the duties, responsibilities and authority commensurate with such position as shall be assigned to him by the Chief Executive Officer
(the CEO) and the Board of Directors of the Company (the Board), including but not limited to, managing fully-integrated medical, clinical and pharmacovigilance functions at the Company and other corporate efforts, as
requested and agreed to with the CEO. In his capacity as Chief Medical Officer, Executive will report directly to the CEO. The principal location of the Executives employment shall be at the Companys offices in Boston, Massachusetts. The
Executive understands and agrees that he may be required to travel from time to time for business reasons, including travel to/from the Companys offices in New York, New York.
3. Employment Period. Unless earlier terminated herein in accordance with Section 6 hereof, Executives employment shall be
for a term beginning on the Start Date and ending on April 30, 2018 (the Employment Period). The Employment Period may be extended upon the mutual, written agreement of the parties In the case of any such extension, the terms and
conditions of this Agreement shall continue to govern unless otherwise agreed to in writing by the parties.
1
4. Extent of Service. During the Employment Period, Executive agrees to devote his full
business time, attention, energy and best efforts to the business and affairs of the Company and to use Executives reasonable best efforts to perform faithfully and efficiently the responsibilities assigned to Executive hereunder. During the
Employment Period it shall not be a violation of this Agreement for Executive to (A) manage personal investments, or (B) devote time to charitable and community activities or, with the approval of the CEO, industry or professional
activities including service on the board of directors of another corporation, so long as such activities do not interfere or conflict with the performance of Executives responsibilities as an employee of the Company in accordance with this
Agreement.
5. Compensation and Benefits.
(a) Base Salary. During the Employment Period, the Company will pay to Executive a base salary at the rate of U.S. $400,000 per year
(Base Salary), less normal withholdings, payable in approximately equal bi-weekly or other installments as are or become customary under the Companys payroll practices for its employees from time to time. The Compensation Committee
of the Board shall review Executives Base Salary annually and, in its sole discretion, may increase Executives Base Salary from year to year. Such adjusted salary then shall become Executives Base Salary for purposes of this
Agreement. The annual review of Executives Base Salary by the Board will consider, among other things, Executives own performance and the Companys performance.
(b) Incentive, Savings and Retirement Plans. During the Employment Period, Executive shall be entitled to participate in all incentive,
savings and retirement plans, practices, policies and programs available to other senior executive officers of the Company (Peer Executives), and on the same basis as such Peer Executives. Without limiting the foregoing, the following
shall apply:
(i) Discretionary Annual Bonus. For each year during the Employment Period, Executive may be eligible
to receive a discretionary annual bonus, not to exceed 40% of his Base Salary (the Annual Bonus). The Compensation Committee, in its sole discretion, will establish performance goals and objectives from year to year on which the Annual
Bonus will be based, and the Compensation Committee likewise reserves the sole discretion to modify such goals and objectives, or the final amount of the Annual Bonus, based upon events occurring during the related year or its assessment of the
Companys or the Executives performance in general. The Compensation Committee will provide the Executive with such goals and objectives and any modifications it may make. Unless otherwise provided herein, no Annual Bonus shall be deemed
to have been earned by Executive for any year in which Executive is not actively employed by the Company on the last day of the fiscal year to which the bonus relates. The Company shall pay the Annual Bonus no later than two and a half months after
the end of the fiscal year to which the applicable bonus relates.
(ii) Equity Grants. On the Start Date, the
Company shall grant to Executive under the Companys 2013 Incentive Plan (the Plan):
2
|
1. |
45,000 restricted shares of Company common stock (the Restricted Stock). The Restricted Stock will vest over three years with the first one-third vesting on the first anniversary of the Start Date and
thereafter the remaining shares shall vest in equal quarterly installments through the third anniversary of the Start Date, conditioned upon Executives continuing employment, and subject to other terms and conditions set forth in the award
certificate memorializing the Restricted Stock and the Plan. The vesting of the Restricted Stock shall accelerate in full upon the occurrence of a Change-in-Control, as such term is defined in this Agreement. |
|
2. |
90,000 stock options (the Stock Options). The Stock Options will vest over three years with the first one-third vesting on the first anniversary of the Start Date and thereafter the remaining shares shall
vest in equal quarterly installments through the third anniversary of the Start Date, conditioned upon Executives continuing employment, and subject to other terms and conditions set forth in the award certificate memorializing the Stock
Options and the Plan. The vesting of the Stock Options shall accelerate in full upon the occurrence of a Change-in-Control, as such term is defined in this Agreement. |
During the Employment Period, Executive may be eligible for additional stock-based awards under the Companys incentive plans, as
determined by the Compensation Committee from time to time. Nothing herein requires the Board or the Compensation Committee to make additional grants of options or other awards in any year.
(c) Welfare Benefit Plans. During the Employment Period, Executive and Executives eligible dependents shall be eligible for
participation in, and shall receive all benefits under, the welfare benefit plans, practices, policies and programs provided by the Company (including, without limitation, medical, prescription drug, dental, disability, and employee life insurance
plans and programs) (Welfare Plans) to the extent available to other Peer Executives.
(d) Expenses. During the
Employment Period, Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by Executive in the course of performing his duties and responsibilities under this Agreement, in accordance with the policies,
practices and procedures of the Company with respect to travel, entertainment and other business expenses, including but not limited to professional fees associated with maintaining your medical credentials.
(e) Vacation. During the Employment Period, Executive will be entitled to four weeks of paid vacation per calendar year, subject to and
in accordance with the Companys vacation policies. In accordance with Company policy, vacation days cannot be accrued and any vacation days not used in any calendar year will be forefeited.
3
6. Termination of Employment.
(a) Death. Executives employment shall terminate automatically upon Executives death during the Employment Period.
(b) Disability. If the Company determines in good faith that Executive has become Disabled (as defined below) during the Employment
Period, it may give to Executive written notice of its intention to terminate Executives employment. In such event, Executives employment with the Company shall terminate effective on the 30th day after receipt of such written notice by
Executive (the Disability Effective Date), provided that, within the 30 days after such receipt, Executive shall not have returned to full-time performance of Executives duties. For purposes of this Agreement, Executive shall be
Disabled if either of the following conditions is met, as determined by the Board in good faith:
(i) Executive is unable
to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for one or more periods totaling one hundred and twenty
(120) days in any twelve (12) month period; or
(ii) Executive is, by reason of any medically determinable
physical or mental impairment that can be expected to result in death or can be expected to last for one or more periods totaling one hundred and twenty (120) days in any twelve (12) month period, receiving income replacement benefits for
a period of not less than three months under an accident and health plan covering employees of the Company.
(c) Termination by the
Company. The Company may terminate Executives employment during the Employment Period with or without Cause. For purposes of this Agreement, a termination shall be considered to be for Cause if it occurs in conjunction with a
determination by the Board that any of the following has occurred:
(i) Executives conviction of, pleading guilty to,
or confession to a felony or any crime involving any act of dishonesty, fraud, misappropriation or embezzlement;
(ii)
Executives misconduct or gross negligence in connection with the performance of his duties hereunder, including a violation of the Companys written policies or Code of Conduct and Ethics;
4
(iii) Executives engaging in any fraudulent, disloyal or unprofessional
conduct which is, or is likely to be, injurious to the Company, its financial condition, or its reputation;
(iv)
Executives failure to perform his duties with the Company (other than any such failure resulting from Executives Disability);
(v) Executives failure to meet performance standards which may be agreed upon by Executive and the Company in writing
from time to time (with the understanding that failure to meet the performance criteria established with respect to an Annual Bonus alone shall not constitute Cause for purposes of this Agreement); or
(vi) Executives breach of the covenants set forth in Section 12 of this Agreement, or material breach of any other
provisions of this Agreement.
If the Company determines that it has grounds to terminate Executives employment for Cause pursuant
to the provisions of clauses (iv), (v), or (vi) of this subsection (c), then it will first deliver to Executive a written notice setting forth with specificity the occurrence deemed to give rise to a right to terminate his employment for Cause,
and Executive will have 30 days after the receipt of such written notice to cease such actions or otherwise correct any such failure or breach. If Executive does not cease such actions or otherwise correct such failure or breach within such 30-day
period, or having once received such written notice and ceased such actions or corrected such failure or breach, Executive at any time thereafter again so acts, fails, or breaches, the Company may terminate his employment for Cause immediately. The
Company may terminate Executives employment without Cause, or for Cause pursuant to the provisions of clauses (i), (ii), or (iii) of this subsection (c), immediately.
(d) Termination by Executive. Executives employment may be terminated by Executive with or without Good Reason. Executives
termination without Good Reason shall require 30 days prior written notice to the Company. Executives termination for Good Reason must occur within a period of 90 days after the occurrence of an event of Good Reason. For purposes of this
Agreement, Good Reason shall mean any of the following, without Executives consent:
(i) a material
diminution in Executives Base Salary, which for purposes of this Agreement shall mean a reduction of more than 15% in the aggregate;
(ii) a material diminution in Executives title, position, authority, duties, or responsibilities;
(iii) a material change in the geographic location of the Executives principal place of business, which for purposes of
this Agreement shall mean a location more than thirty-five (35) miles from the Companys offices in Boston, Massachusetts at which the Executive was principally employed except for required travel on the Companys business; or
5
(iv) any other action or inaction that constitutes a material breach by the
Company of this Agreement.
A termination by Executive shall not constitute termination for Good Reason unless Executive shall first have
delivered to the Company a written notice setting forth with specificity the occurrence deemed to give rise to a right to terminate for Good Reason (which notice must be given no later than 60 days after the initial occurrence of such event), and
there shall have passed a reasonable time (not less than 30 days) within which the Company may take action to correct, rescind or otherwise substantially reverse the occurrence supporting termination for Good Reason as identified by Executive. Good
Reason shall not include Executives death or Disability. The parties intend, believe and take the position that a resignation by the Executive for Good Reason as defined above effectively constitutes an involuntary separation from service
within the meaning of Section 409A of the Code and Treas. Reg. §1.409A-1(n)(2).
(e) Notice of Termination. Any
termination by the Company or Executive shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 18(d) of this Agreement. For purposes of this Agreement, a Notice of Termination means
a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of
Executives employment under the provision so indicated, and (iii) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the termination date. The failure by the Company or Executive to
set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause or Good Reason shall not waive any right of the Company or Executive hereunder or preclude the Company or Executive from asserting such fact or
circumstance in enforcing its rights hereunder.
(f) Date of Termination. Date of Termination means (i) if
Executives employment is terminated other than by reason of death or Disability, the date of receipt of the Notice of Termination or any later date specified therein, or (ii) if Executives employment is terminated by reason of death
or Disability, the Date of Termination shall be the date of death of Executive or the Disability Effective Date, as the case may be.
7.
Obligations of the Company upon Termination.
(a) Termination by Executive for Good Reason; Termination by the Company without
Cause. If, during the Employment Period, the Company shall terminate Executives employment without Cause, or Executive shall terminate his employment for Good Reason, then and, with respect to the payments and benefits described in clause
(ii), (iv), and (v) below, only if Executive shall have executed and not revoked a release of claims in a form satisfactory to the Company:
6
(i) the Company shall pay to Executive in a lump sum in cash within 60 days after the Date of
Termination, the exact payment date to be determined by the Company (or such later date as may be required pursuant to Section 17 hereof), the sum of (1) Executives Base Salary through the Date of Termination to the extent not
theretofore paid, (2) the Annual Bonus earned by the Executive for the fiscal year immediately prior to the year in which the Date of Termination occurs, if any, to the extent not theretofore paid, and (3) any accrued but unused vacation
pay to the extent not theretofore paid (the sum of the amounts described in clauses (1), (2) and (3) shall be hereinafter referred to as the Accrued Obligations); and
(ii) the Company shall pay to Executive twelve (12) months of severance pay based on Executives Base Salary as of the Date of
Termination (the Severance Pay). The foregoing Severance Pay shall be paid in equal installments over the severance period in accordance with the Companys usual payroll schedule, commencing on the date that the release referred to
above may no longer be revoked (or such later date as may be required pursuant to Section 17). In addition the Executive shall receive a cash payment equal to the total monthly premium payment (both the Companys portion and the
Executives portion of such premium) under the Companys group healthcare plan as in effect on the Date of Termination multiplied by twelve (12), payable in a lump sum within sixty (60) days following the Date of Termination, and
(iii) to the extent not theretofore paid or provided, the Company shall timely pay or provide to Executive any other amounts or benefits
required to be paid or provided or which Executive is entitled to receive under any plan, program, policy or practice or contract or agreement of the Company and its affiliated companies (such other amounts and benefits shall be hereinafter referred
to as the Other Benefits), and
(iv) any vested portion of stock options granted to Executive by the Company shall remain
exercisable by the Executive for a period of six (6) months following the Date of Termination (or, if earlier, the normal expiration date of such stock options), and any unvested portions of stock options granted to Executive by the Company
shall lapse and be forfeited without consideration as of the Date of Termination.
(b) Death or Disability. If Executives
employment is terminated by reason of Executives death or Disability during the Employment Period, this Agreement shall terminate without further obligations to Executive or Executives legal representatives under this Agreement, other
than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive or Executives estate or beneficiaries, as applicable, in a lump sum in cash within 60 days after the
Date of Termination. With respect to the provision of Other Benefits, the term Other Benefits as used in this Section 7(b) shall include without limitation, and Executive or Executives estate and/or beneficiaries shall be
entitled to receive, benefits under such plans, programs, practices and policies relating to death, disability or retirement benefits, if any, as are applicable to Executive on the Date of Termination. In addition, in the event of such a
termination, and provided that Executive or his estate or beneficiaries, if applicable, executes and does not revoke a release of claims in a form acceptable to the Company:
7
(i) any vested portion of stock options granted to Executive by the Company shall remain
exercisable by the Executive and/or his estate or beneficiaries for a period of six (6) months following the Date of Termination (or, if earlier, the normal expiration date of such stock options), and any unvested portion of stock options
granted to Executive by the Company shall lapse and be forfeited without consideration as of the Date of Termination; and
(ii) if
Executives employment terminates due to death, the Compensation Committee of the Board shall determine the extent to which any of the performance goals and objectives established pursuant to Section 5(b)(i) above were met as of the time
Executives death. If, based on that determination, the Compensation Committte of the Board determines that a bonus is due, the Company shall pay Executives estate an amount equal to such bonus, pro-rated for the portion of the fiscal
year elapsed as of the time of Executives death.
(c) Termination by the Company for Cause; Resignation by Executive Other than
for Good Reason. If Executives employment shall be terminated for Cause during the Employment Period, or Executive shall resign other than for Good Reason during the Employment Period, this Agreement shall terminate without further
obligations to Executive, other than for payment of Accrued Obligations minus the Annual Bonus earned by the Executive for the fiscal year immediately prior to the year in which the Date of Termination occurs, if any, to the extent not theretofore
paid, and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive in a lump sum in cash within 60 days after the Date of Termination. In addition, in the event of such a termination, any unvested equity
awards shall lapse and be forfeited without consideration on the Date of Termination.
(d) Expiration of Employment Period. If
Executives employment shall be terminated by the Company or by the Executive upon the normal expiration of the Employment Period as provided for in Section 3 hereof, this Agreement shall terminate without further obligations to Executive,
other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive in a lump sum in cash within 60 days after the Date of Termination. In addition, in the event of such
a termination, and provided that Executive or his estate or beneficiaries, if applicable, executes and does not revoke a release of claims in a form acceptable to the Company, any vested portion of stock options granted to Executive by the Company
shall remain exercisable by the Executive and/or his estate or beneficiaries for a period of six (6) months following the Date of Termination (or, if earlier, the normal expiration date of such stock options), and any unvested portions of stock
options granted to Executive by the Company shall lapse and be forfeited without consideration as of the Date of Termination.
8
8. Change in Control.
(a) Definition. For the purposes of this Agreement, a Change in Control shall mean:
(i) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the 1934 Act)
of beneficial ownership of any capital stock of the Company if, after such acquisition, such individual, entity or group beneficially owns (within the meaning of Rule 13d-3 promulgated under the 1934 Act) 30% or more of either (x) the
then-outstanding shares of common stock of the Company (the Outstanding Company Common Stock) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors
(the Outstanding Company Voting Securities); provided, however, that for purposes of this subsection (i), the following acquisitions shall not constitute a Change in Control: (A) any acquisition directly from the
Company (excluding an acquisition pursuant to the exercise, conversion or exchange of any security exercisable for, convertible into or exchangeable for common stock or voting securities of the Company, unless the individual, entity or group
exercising, converting or exchanging such security acquired such security directly from the Company or an underwriter or agent of the Company), (B) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the
Company or any corporation controlled by the Company, or (C) any acquisition by any corporation pursuant to a Business Combination (as defined below) which complies with clauses (x) and (y) of subsection (iii) of this definition;
or
(ii) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if
applicable, the Board of Directors of a successor corporation to the Company), where the term Continuing Director means at any date a member of the Board (x) who was a member of the Board on the Start Date of this Agreement or
(y) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a
majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (y) any individual whose initial assumption of office occurred as
a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or
(iii) the consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving the Company or
a sale or other disposition of all or substantially all of the assets of the Company (a Business Combination), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (x) all or
substantially all of the individuals and entities who were the beneficial owners of
9
the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the
then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination
(which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Companys assets either directly or through one or more subsidiaries) (such resulting or acquiring
corporation is referred to herein as the Acquiring Corporation) in substantially the same proportions as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, immediately prior
to such Business Combination and (y) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or
indirectly, 30% or more of the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors
(except to the extent that such ownership existed prior to the Business Combination).
(b) Severance Benefits. Upon the occurrence
of a Change in Control, if, within one year after the effective date of the Change in Control, Executives employment is terminated by the Company or the successor corporation to the Company without Cause, or Executive resigns for Good Reason,
then in addition to payment of the Accrued Obligations and Other Benefits, and provided that Executive shall have executed and not revoked a general release of claims in a form satisfactory to the Company: (i) the Executive shall receive a cash
payment equal to the sum of (A) 100% of the Executives annual Base Salary as of the Date of Termination or, if higher, at the rate in effect immediately prior to a Change in Control, and (B) the Annual Bonus earned by the Executive
for the fiscal year immediately prior to the year in which the Date of Termination occurs, if any, payable in a lump sum within sixty (60) days following the Date of Termination; and (ii) the Executive shall receive a cash payment equal to
the total monthly premium payment (both the Companys portion and the Executives portion of such premium) under the Companys group healthcare plan as in effect on the Date of Termination multiplied by twelve (12), payable in a lump
sum within sixty (60) days following the Date of Termination. The foregoing shall be in lieu of and not in addition to any amounts that Executive would otherwise be entitled to receive under Section 7 hereof in the event of a termination
without Cause or resignation for Good Reason.
9. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit
Executives continuing or future participation in any employee benefit plan, program, policy or practice provided by the Company or its affiliated companies and for which Executive may qualify, except as specifically provided herein. Amounts
that are vested benefits or which Executive is otherwise entitled to receive under any plan, policy, practice or program of the Company or any of its affiliated companies at or subsequent to the Date of Termination shall be payable in accordance
with such plan, policy, practice or program except as explicitly modified by this Agreement.
10
10. No Mitigation. In no event shall Executive be obligated to seek other employment or
take any other action by way of mitigation of the severance amounts payable to Executive under any of the provisions of this Agreement and such amounts shall not be reduced whether or not Executive obtains other employment.
11. Mandatory Reduction of Payments in Certain Events.
(a) Anything in this Agreement to the contrary notwithstanding, in the event it shall be determined that any payment or distribution by the
Company to or for the benefit of Executive (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (a Payment) would be subject to the excise tax imposed by Section 4999 of the
Code (the Excise Tax), then, prior to the making of any Payment to Executive, a calculation shall be made comparing (i) the net benefit to Executive of the Payment after payment of the Excise Tax, to (ii) the net benefit to
Executive if the Payment had been limited to the extent necessary to avoid being subject to the Excise Tax. If the amount calculated under (i) above is less than the amount calculated under (ii) above, then the Payment shall be limited to
the extent necessary to avoid being subject to the Excise Tax (the Reduced Amount). The reduction of the Payments due hereunder, if applicable, shall be made in such a manner as to maximize the economic present value of all Payments
actually made to Executive, determined by the Determination Firm (as defined in Section 11(b) below) as of the date of the Change in Control using the discount rate required by Section 280G(d)(4) of the Code.
(b) The determination of whether an Excise Tax would be imposed, the amount of such Excise Tax, and the calculation of the amounts referred to
Section 12(a)(i) and (ii) above shall be made by an independent, nationally recognized accounting firm or compensation consulting firm mutually acceptable to the Company and Executive (the Determination Firm) which shall
provide detailed supporting calculations. Any determination by the Determination Firm shall be binding upon the Company and Executive. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial
determination by the Determination Firm hereunder, it is possible that Payments which Executive was entitled to, but did not receive pursuant to Section 11(a), could have been made without the imposition of the Excise Tax
(Underpayment). In such event, the Determination Firm shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for the benefit of Executive, but no later than
December 31 of the year after the year in which the Underpayment is determined to exist.
(c) In the event that the provisions of Code
Section 280G and 4999 or any successor provisions are repealed without succession, this Section 11 shall be of no further force or effect.
11
12. Restrictions on Conduct of Executive.
(a) General. Executive and the Company understand and agree that the purpose of the provisions of this Section 12 is to protect the
legitimate business interests of the Company, as more fully described below, and is not intended to impair or infringe upon Executives right to work, earn a living, or acquire and possess property from the fruits of his labor. Executive hereby
acknowledges that Executive has received good and valuable consideration for the post-employment restrictions set forth in this Section 12 in the form of the compensation and benefits provided for herein. Executive hereby further acknowledges
that the post-employment restrictions set forth in this Section 12 are reasonable and that they do not, and will not, unduly impair his ability to earn a living after the termination of this Agreement.
In addition, the parties acknowledge: (A) that Executives services under this Agreement require special expertise and talent in the
provision of Competitive Services and that Executive will have substantial contacts with customers, suppliers, advertisers and vendors of the Company; (B) that pursuant to this Agreement, Executive will be placed in a position of trust and
responsibility and he will have access to a substantial amount of Confidential Information and Trade Secrets and that the Company is placing him in such position and giving him access to such information in reliance upon his agreement to comply with
the obligations set forth in this Section 12; (C) that due to his management duties, Executive will be the repository of a substantial portion of the goodwill of the Company and would have an unfair advantage in competing with the Company;
(D) that due to Executives special experience and talent, the loss of Executives services to the Company under this Agreement cannot reasonably or adequately be compensated solely by damages in an action at law; (E) that
Executive is capable of competing with the Company; and (F) that Executive is capable of obtaining gainful, lucrative and desirable employment that does not violate the restrictions contained in this Agreement.
Therefore, subject to the limitations of reasonableness imposed by law, Executive shall be subject to the restrictions set forth in this
Section 12.
(b) Definitions. The following capitalized terms used in this Section 12 shall have the meanings assigned to
them below, which definitions shall apply to both the singular and the plural forms of such terms:
Competitive
Services means services involving the acquisition, development or commercialization of oral iron pharmaceutical products that are the same as or substantially similar to the oral iron pharmaceutical products offered or provided by the
Company or are in competition with the Companys products.
Confidential Information means all data and
information relating to the business of the Company that is disclosed to Executive or of which Executive becomes aware as a consequence of his employment and that has value to the Company and is not generally disclosed to those not employed or
otherwise engaged by the Company.
12
Confidential Information shall include, but is not limited to, financial plans and data concerning the Company; management planning information; business plans; operational methods;
market studies; marketing plans or strategies; product development techniques or plans; customer lists; details of customer contracts; current and anticipated customer requirements; past, current and planned research and development; business
acquisition plans; and new personnel acquisition plans. Confidential Information shall not include information that has become generally available to the public by the act of one who has the right to disclose such information without
violating any right or privilege of the Company. This definition shall not limit any definition of confidential information or any equivalent term under state or federal law.
End Date means the last day of Executives employment with the Company for any reason whatsoever.
Person means any individual or any corporation, partnership, joint venture, limited liability company, association or other
entity or enterprise.
Principal or Representative means a principal, owner, partner, shareholder, joint venturer,
investor, member, trustee, director, officer, manager, employee, agent, representative or consultant.
Protected
Customers means any Person to whom the Company sold its products or services or solicited to sell its products or services during the Employment Period and (a) with whom Executive dealt on behalf of the Company; (b) whose
dealings with the Company were coordinated or supervised by Executive; or (c) about whom Executive obtained Trade Secrets or Confidential Information in the ordinary course of business as a result of his employment.
Protected Employees and Contractors means employees and independent contractors of the Company who were employed or engaged
by the Company at any time within six (6) months prior to the End Date.
Protected Providers means any service
provider, vendor or supplier with whom the Company conducted business or solicited to conduct business during the twelve (12) months prior to the End Date.
Restricted Period means the Employment Period and the one (1) year period following the End Date.
Restricted Territory means countries where Keryx has the right to market Zerenex, including, but not limited to, North
America, European Union, Eastern Europe, Central and Latin America.
Restrictive Covenants means the restrictive
covenants contained in Section 12(c) hereof.
13
Trade Secret means all information, without regard to form, including, but not
limited to, technical or nontechnical data, a formula, a pattern, a compilation, a program, a device, a method, a technique, a drawing, a process, financial data, financial plans, product plans, distribution lists or a list of actual or potential
customers, advertisers or suppliers which is not commonly known by or available to the public and which information: (A) derives economic value, actual or potential, from not being generally known to, and not being readily ascertainable by
proper means by, other persons who can obtain economic value from its disclosure or use; and (B) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. This definition shall not limit any definition of
trade secret or any equivalent term under state or federal law.
(c) Restrictive Covenants.
(i) Restriction on Disclosure and Use of Confidential Information and Trade Secrets. Executive understands and agrees
that the Confidential Information and Trade Secrets constitute valuable assets of the Company, and may not be converted to Executives own use. Accordingly, Executive hereby agrees that throughout the Employment Period and at all times after
the End Date, for so long as the information at issue remains either Confidential Information or a Trade Secret, Executive will not, directly or indirectly, reveal, divulge, or disclose to any Person not expressly authorized by the Company any
Confidential Information or Trade Secrets and will not, directly or indirectly, use or make use of any Confidential Information or Trade Secrets in connection with any business activity other than that of the Company.
Anything herein to the contrary notwithstanding, Executive shall not be restricted from disclosing or using Confidential
Information or Trade Secrets that are required to be disclosed by law, court order or other valid legal process; provided, however, that in the event disclosure is required by law, Executive shall provide the Company with prompt,
written notice of such requirement so that the Company may seek an appropriate protective order prior to any such required disclosure by Executive.
(ii) Non-Solicitation of Protected Employees and Contractors. Executive understands and agrees that the relationship
between the Company and each of its Protected Employees and Contrators constitutes a valuable asset of the Company and may not be converted to Executives own use. Accordingly, Executive hereby agrees that, during the Restricted Period,
Executive shall not, directly or indirectly, on Executives own behalf or as a Principal or Representative of any Person or otherwise, solicit or induce any Protected Employee or Contractor to terminate his or her relationship with the Company
or to enter into an employment, consulting or similar relationship with any other Person.
14
(iii) Non-Solicitation of Protected Customers. Executive understands and
agrees that the relationship between the Company and each of its Protected Customers constitutes a valuable asset of the Company and may not be converted to Executives own use. Accordingly, Executive hereby agrees that, during the Restricted
Period, Executive shall not, directly or indirectly, on Executives own behalf or as a Principal or Representative of any Person, solicit, divert, take away or attempt to solicit, divert or take away a Protected Customer for the purpose of
providing or selling Competitive Services.
(iv) Non-Interference with Protected Providers. Executive understands
and agrees that the relationship between the Company and each of its Protected Providers constitutes a valuable asset of the Company and may not be converted to Executives own use. Executive hereby agrees that, during the Restricted Period,
Executive shall not, directly or indirectly, solicit or induce or attempt to solicit or induce any Protected Provider to cease, reduce or alter its relationship with the Company.
(v) Non-Competition with the Company. In consideration of the compensation and benefits being paid and to be paid by the
Company to Executive hereunder and the equity awards granted by the Company, Executive hereby agrees that, during the Restricted Period, Executive will not, directly or indirectly, engage in or provide Competitive Services within the Restricted
Territory, whether on his own behalf or as a Principal or Representative of any other Person, in a capacity that involves the exercise of any job duties or responsibilities the same as or similar to the job duties and responsibilities executed by
Executive on behalf of the Company; provided, however, that the foregoing shall not be deemed to prohibit the ownership by Executive of not more than five percent (5%) of any class of securities of any corporation having a class
of securities registered pursuant to the Exchange Act, which investment does not exceed 3% of Executives net worth.
(d)
Enforcement of Restrictive Covenants.
(i) Rights and Remedies Upon Breach. In the event Executive breaches,
or threatens to commit a breach of, any of the provisions of the Restrictive Covenants, the Company shall have the right and remedy to enjoin, preliminarily and permanently, without the necessity of posting bond, Executive from violating or
threatening to violate the Restrictive Covenants and to have the Restrictive Covenants specifically enforced by any court of competent jurisdiction, it being agreed that any breach or threatened breach of the Restrictive Covenants could cause
irreparable injury to the Company and that money damages may not provide an adequate remedy to the Company. The foregoing rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company at law
or in equity.
(ii) Severability of Covenants. The parties hereunder agree that the Restrictive Covenants shall be
considered and construed as separate and independent covenants. Should any part or provision of any Restrictive Covenant be held invalid, void or unenforceable in any court of competent jurisdiction, such invalidity, voidness or unenforceability
shall not render invalid, void or unenforceable any other part or provision of this Agreement.
15
(iii) Reformation. The parties hereunder agree that it is their intention
that the Restrictive Covenants be enforced in accordance with their terms to the maximum extent possible under applicable law. The parties further agree that, in the event any court of competent jurisdiction shall find that any provision hereof is
not enforceable in accordance with its terms, the court shall reform the Restrictive Covenants such that they shall be enforceable to the maximum extent permissible at law.
13. Invention Assignment. Executive agrees that he will promptly and fully disclose in writing to the Company all inventions, designs,
concepts, discoveries, developments, improvements, and innovations, whether or not they merit patent, trademark or copyright protection, conceived of, designed or reduced to practice by Executive, either solely or in concert with others, at any time
during his employment, which (i) relate in any manner, whether at the time of conception, design or reduction to practice, to the Companys business or its actual or demonstrably anticipated research or development; (ii) result from
any work performed by Executive on behalf of the Company; or (iii) result from the use of the Companys equipment, supplies, facilities, Confidential Information or Trade Secrets (collectively referred to as Inventions).
Executive acknowledges and agrees that he will keep and maintain adequate written records of all such Inventions at all stages thereof in the
form of notes, sketches, drawings, photographs, printouts, and/or reports relating thereto. These records are and shall remain the property of, and be available to, the Company or its designee(s) at all times. Executive further acknowledges that all
such Inventions shall be the exclusive property of the Company. As such, Executive hereby assigns his entire right, title, and interest in and to all such Inventions to the Company or its designee(s). Executive will, at the Companys request
and expense, execute specific transfers, assignments, documents or other instruments and take such further action as may be considered necessary by the Company at any time during or subsequent to Executives employment to obtain and defend any
intellectual property rights and vest complete title and ownership to such Inventions to the Company or its designee(s).
14. Return of
Materials. Executive agrees that he will not retain or destroy, and will immediately return to the Company on or prior to his last day of employment, or at any other time the Company requests such return, any and all property of the Company that
is in his possession or subject to his control, including, but not limited to, keys, credit and identification cards, equipment, client files and information, and all Confidential Information and Trade Secrets. Executive will not make, distribute or
retain copies of any such information or property. Executive agrees that he will reimburse the Company for all of its costs, including reasonable attorneys fees, of recovering the above materials and otherwise enforcing compliance with this
provision if he does not return the materials in compliance with this provision.
16
15. Successors and Assigns.
(a) This Agreement is personal to Executive and shall not be assignable by Executive. This Agreement shall inure to the benefit of and be
enforceable by Executives legal representatives.
(b) The Company may assign this Agreement without the consent of Executive. This
Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.
16. Cooperation. Both
during and after his employment, Executive shall provide Executives reasonable cooperation in connection with any action or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executives
employment hereunder. The Company shall reimburse Executive for any reasonable out-of-pocket expenses incurred in connection with Executives performance of obligations under this Section 16 at the request of the Company. If Executive is
entitled to be paid or reimbursed for any expenses under this Section 16, the amount reimbursable in any one calendar year shall not affect the amount reimbursable in any other calendar year, and the reimbursement of an eligible expense must be
made no later than December 31 of the year after the year in which the expense was incurred. Executives obligations under this Section 16.
17. Code Section 409A.
(a) General. This Agreement shall be interpreted and administered in a manner so that any amount or benefit payable hereunder shall be
paid or provided in a manner that is either exempt from or compliant with the requirements Section 409A of the Code and applicable Internal Revenue Service guidance and Treasury Regulations issued thereunder (and any applicable transition
relief under Section 409A of the Code). Nevertheless, the tax treatment of the benefits provided under the Agreement is not warranted or guaranteed. Neither the Company nor its directors, officers, employees or advisers shall be held liable for
any taxes, interest, penalties or other monetary amounts owed by Executive as a result of the application of Section 409A of the Code.
(b) Definitional Restrictions. Notwithstanding anything in this Agreement to the contrary, to the extent that any amount or benefit that
would constitute non-exempt deferred compensation for purposes of Section 409A of the Code would otherwise be payable or distributable hereunder, or a different form of payment would be effected, by reason of a Change in Control or
the Executives Disability or termination of employment, such amount or benefit will not be payable or distributable to the Executive, and/or such different form of payment will not be effected, by reason of such circumstance unless
(i) the circumstances giving rise to such Change in Control, Disability or termination of employment, as the case may be, meet any description or definition of change in control event, disability or separation from
service, as the case may be, in Section 409A of the Code and applicable regulations (without giving
17
effect to any elective provisions that may be available under such definition), or (ii) the payment or distribution of such amount or benefit would be exempt from the application of
Section 409A of the Code by reason of the short-term deferral exemption or otherwise. This provision does not prohibit the vesting of any amount upon a Change in Control, Disability or termination of employment, however defined. If this
provision prevents the payment or distribution of any amount or benefit, such payment or distribution shall be made on the date, if any, on which an event occurs that constitutes a Section 409A-compliant change in control event,
disability or separation from service, as the case may be, or such later date as may be required by subsection (c) below. If this provision prevents the application of a different form of payment of any amount or
benefit, such payment shall be made in the same form as would have applied absent such designated event or circumstance.
(c) Six-Month
Delay in Certain Circumstances. Notwithstanding anything in this Agreement to the contrary, if any amount or benefit that would constitute non-exempt deferred compensation for purposes of Section 409A of the Code would otherwise
be payable or distributable under this Agreement by reason of Executives separation from service during a period in which he is a Specified Employee (as defined below), then, subject to any permissible acceleration of payment by the Company
under Treas. Reg. Section 1.409A-3(j)(4)(ii) (domestic relations order), (j)(4)(iii) (conflicts of interest), or (j)(4)(vi) (payment of employment taxes):
(i) the amount of such non-exempt deferred compensation that would otherwise be payable during the six-month period immediately
following Executives separation from service will be accumulated through and paid or provided on the first day of the seventh month following Executives separation from service (or, if Executive dies during such period, within 30 days
after Executives death) (in either case, the Required Delay Period); and
(ii) the normal payment or
distribution schedule for any remaining payments or distributions will resume at the end of the Required Delay Period.
For purposes of
this Agreement, the term Specified Employee has the meaning given such term in Code Section 409A and the final regulations thereunder: provided, however, that the Companys Specified Employees and its application of the
six-month delay rule of Code Section 409A(a)(2)(B)(i) shall be determined in accordance with rules adopted by the Board or a committee thereof, which shall be applied consistently with respect to all nonqualified deferred compensation
arrangements of the Company, including this Agreement.
18. Miscellaneous.
(a) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts,
without reference to principles of conflict of laws.
18
(b) Captions. The captions of this Agreement are not part of the provisions hereof and
shall have no force or effect.
(c) Amendments. This Agreement may not be amended or modified otherwise than-by a written agreement
executed by the parties hereto or their respective successors and legal representatives.
(d) Notices. All notices and other
communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows:
|
|
|
If to Executive: |
|
John F. Neylan M.D. |
|
|
22 Westgate Road |
|
|
Wellesley MA 02481 |
|
|
If to the Company: |
|
Keryx Biopharmaceuticals, Inc. |
|
|
One Marina Park Drive |
|
|
Boston, MA 02110 |
|
|
Attention: General Counsel |
or to such other address as either party shall have furnished to the other in writing in accordance herewith. Notice and
communications shall be effective when actually received by the addressee.
(e) Severability. The invalidity or unenforceability of
any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.
(f)
Withholding. The Company may withhold from any amounts payable under this Agreement such Federal, state, local or foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation.
(g) Waivers. Executives or the Companys failure to insist upon strict compliance with any provision of this Agreement or the
failure to assert any right Executive or the Company may have hereunder, shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement.
(h) Entire Agreement. This Agreement contains the entire agreement between the Company and Executive with respect to the subject matter
hereof and, from and after the Effective Date, this Agreement shall supersede any other agreement between the parties with respect to the subject matter hereof.
(i) Arbitration. In the event that a dispute arises between the parties regarding the formation, interpretation and/or the terms and
conditions of this Agreement and/or if there arises any other claim or legal dispute between the parties with respect to Executives employment or the termination thereof (the Dispute), the complaining
19
party shall submit the Dispute in writing to the other party for resolution. If the Dispute is not resolved between the parties within thirty (30) days of the date the Dispute is submitted
in writing to the other party, the complaining party must make a demand for final and binding arbitration in New York, New York before an arbitrator pursuant to the Employment Arbitration Rules of the American Arbitration Association in effect at
the time of the Dispute (the AAA Rules) if the complaining party wishes to pursue the Dispute (Demand for Arbitration). Provided, however, that the foregoing shall not preclude the Company from immediately seeking
injunctive or other equitable relief in a court of competent jurisdiction in connection with Executives breach or threatened breach of the Restrictive Covenants or the provisions set forth in Sections 13 or 14 of this Agreement. The parties
expressly understand that by agreeing to this arbitration provision, they are agreeing to waive any rights to a civil action and/or jury trial regarding any Disputes between them. The parties shall share all costs, filing fees, and administrative
fees for the arbitration equally as they come due; the parties shall be responsible for their own attorneys fees, witness fees, and travel costs. The arbitrator shall have the authority to rule on any and all issues properly presented in the
Demand for Arbitration and/or pursuant to the AAA Rules and may award any and all relief provided under applicable law. The arbitrators award may be enforced, vacated, modified or corrected as set forth in the Federal Arbitration Act, 9 U.S.C
§ 1 et seq. This Agreement shall be governed by the Federal Arbitration Act, 9 U.S.C § 1 et seq., as amended, and the applicable rules of the American Arbitration Association set forth in this Agreement. This Agreement shall be binding
upon, and shall inure to the benefit of Executive, the Company and their respective permitted successors and assigns.
(j) Timing of
Release. Whenever in this Agreement a payment or benefit is conditioned on the Executives execution of a release of claims, the Company shall provide such release to the Executive promptly following the Date of Termination, and such
release must be executed and all revocation periods shall have expired in accordance with terms set forth in the release, but in no case later than sixty (60) days after the Date of Termination; failing which such payment or benefit shall be
forfeited. If such payment or benefit constitutes non-exempt deferred compensation, then, subject to Section 17(c) above, such payment or benefit (including any installment payments) that would have otherwise been payable during
such 60-day period shall be accumulated and paid on the 60th day after the Date of Termination provided such release shall have been executed and such revocation periods shall have expired. If such payment or benefit is exempt from Section 409A
of the Code, the Company may elect to make or commence payment at any time during such 60-day period.
(k) Counterparts; Scanned
Signatures. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become a binding agreement when one or more counterparts have been signed by each party and delivered
to the other party. A counterpart executed and delivered by PDF or facsimile shall be sufficient for the Agreement to become effective.
20
IN WITNESS WHEREOF, Executive has hereunto set Executives hand and, pursuant to the
authorization from the Board, the Company has caused these presents to be executed in its name on its behalf, all as of the day and year first above written.
|
/s/ John F. Neylan M.D. |
John F. Neylan M.D. |
|
KERYX BIOPHARMACEUTICALS, INC. |
|
/s/ Greg Madison |
Greg Madison |
President & COO |
21
Exhibit 10.4
THIRD AMENDMENT to the EMPLOYMENT AGREEMENT Between RON
BENTSUR and KERYX BIOPHARMACEUTICALS, INC.
This THIRD amendment (the Third Amendment) to the EMPLOYMENT AGREEMENT dated September 14, 2009 between RON BENTSUR and KERYX
BIOPHARMACEUTICALS, INC., as amended (the Employment Agreement), is made, entered into and effective this 30th day of April, 2015, by and between Keryx Biopharmaceuticals, Inc., a Delaware corporation (the Company), and Ron
Bentsur (Executive). Capitalized terms used herein and not otherwise defined in the Third Amendment shall have the meaning ascribed to them in the Employment Agreement.
WHEREAS, on the 14th day of September, 2009, the Company and Executive entered into the
Employment Agreement effective as of May 20, 2009, which is the date on which Executive was appointed as Chief Executive Officer of the Company; and
WHEREAS, on the 13th day of January, 2012, the Company and Executive entered into a first
amendment to the Employment Agreement (the First Amendment) effective as of such date; and
WHEREAS, on the 11th day of June, 2013, the Company and Executive entered into a second amendment to the Employment Agreement (the Second Amendment) effective as of such date;
WHEREAS, the Company desires to make certain additional modifications to the terms of the Employment Agreement, in accordance with the terms
of this Amendment.
NOW THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein, and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Section 7(c) of the Employment Agreement (Cause; Resignation Other than for Good Reason) shall be amended by
deleting the third sentence of such Section 7(c) in its entirety and replacing such deleted third sentence with the following sentence:
In addition: (i) in the event that Executives employment is terminated for Cause during the Employment Period, any portion of the
Stock Option outstanding as of the Date of Termination, whether vested or unvested, and any outstanding Earned Milestone Awards, shall lapse and be forfeited without consideration on the Date of Termination, and any Unearned Milestone Opportunity
shall expire without consideration on the Date of Termination; and (ii) in the event that Executive resigns other than for Good Reason, the vested and unvested portions of the Stock Option, any outstanding Earned Milestone Awards, and the
Milestone-Based Incentive Awards shall be treated the same as if there occurred an Expiration of the Employment Period pursuant to Section 7(d) (i.e., the same terms and conditions described in Section 7(d) shall apply
to the vested and unvested portions of the Stock Option, to any outstanding Earned Milestone Awards, and to the Milestone-Based Incentive Awards).
2. Except as modified in this Amendment, the Employment Agreement and all terms, covenants and
conditions thereof shall remain in full force and effect.
IN WITNESS WHEREOF, Executive has hereunto set Executives hand and,
pursuant to the authorization from the Board, the Company has caused these presents to be executed in its name on its behalf, all as of the day and year first above written.
|
|
|
/s/ Ron Bentsur |
Ron Bentsur |
|
KERYX BIOPHARMACEUTICALS, INC. |
|
|
By: |
|
/s/ Gregory P. Madison |
2
Exhibit 31.1
CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
I, Gregory P.
Madison, certify that:
1. |
I have reviewed this quarterly report on Form 10-Q of Keryx Biopharmaceuticals, Inc.; |
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; |
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; |
4. |
The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c) |
Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and |
|
d) |
Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. |
The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the
registrants board of directors (or persons performing the equivalent functions): |
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record,
process, summarize and report financial information; and |
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
|
|
|
|
|
|
|
Date: May 4, 2015 |
|
|
|
|
|
/s/ Gregory P. Madison |
|
|
|
|
|
|
Gregory P. Madison Chief Executive
Officer Principal Executive Officer |
Exhibit 31.2
CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
I, James F.
Oliviero, certify that:
1. |
I have reviewed this quarterly report on Form 10-Q of Keryx Biopharmaceuticals, Inc.; |
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; |
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; |
4. |
The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c) |
Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and |
|
d) |
Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. |
The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the
registrants board of directors (or persons performing the equivalent functions): |
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record,
process, summarize and report financial information; and |
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
|
|
|
|
|
|
|
Date: May 4, 2015 |
|
|
|
|
|
/s/ James F. Oliviero |
|
|
|
|
|
|
James F. Oliviero, CFA Chief Financial
Officer Principal Financial and Accounting Officer |
Exhibit 32.1
STATEMENT OF CHIEF EXECUTIVE OFFICER OF
KERYX BIOPHARMACEUTICALS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Keryx Biopharmaceuticals, Inc. (the Company) on Form 10-Q for the period ended
March 31, 2015 as filed with the Securities and Exchange Commission (the Report), I, Gregory P. Madison, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, that, based on my knowledge:
1) The Report fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and
2) The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
|
|
|
|
|
|
|
Date: May 4, 2015 |
|
|
|
|
|
/s/ Gregory P. Madison |
|
|
|
|
|
|
Gregory P. Madison Chief Executive Officer
Principal Executive Officer |
Exhibit 32.2
STATEMENT OF CHIEF FINANCIAL OFFICER OF
KERYX BIOPHARMACEUTICALS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Keryx Biopharmaceuticals, Inc. (the Company) on Form 10-Q for the period ended
March 31, 2015 as filed with the Securities and Exchange Commission (the Report), I, James F. Oliviero, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, that, based on my knowledge:
1) The Report fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and
2) The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
|
|
|
|
|
|
|
Date: May 4, 2015 |
|
|
|
|
|
/s/ James F. Oliviero |
|
|
|
|
|
|
James F. Oliviero, CFA Chief Financial
Officer Principal Financial and Accounting Officer |
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024